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Summary
Amyotrophic lateral sclerosis (ALS) is the most common type of motor neuron 
disease affecting both upper and lower motor neurons. About 10% of ALS 
cases run in families with known genetic background, and mutations in the 
Fused in Sarcoma (FUS) gene are responsible for about 5% of the fALS 
cases (ALS-FUS). Despite normal FUS is a predominantly nuclear protein, 
mutant FUS is found to accumulate and aggregate in the cytoplasm of 
affected neurons and glial cells in ALS-FUS. It is generally believed that 
mutations are the primary cause of FUS protein mislocalisation, and additional 
stresses are required to trigger the formation of insoluble FUS aggregates 
(FUSopathy). However, no clear consensus has been achieved on many 
important questions. For instance, what are the consequences of FUS protein 
mutation for its nuclear function and how do they contribute to ALS-FUS 
development? What is the nature of the stress that promotes the massive 
protein accumulation and inclusion formation in the cytoplasm? This thesis 
attempts to address these questions using novel cellular models with targeted 
modifications of the FUS gene. It is demonstrated that the presence of 
endogenous mutant FUS protein in the nucleus causes hyper-assembly of 
structurally and functionally abnormal paraspeckles - nuclear bodies
assembled on the long non-coding RNA called Nuclear Paraspeckle Assembly 
Transcript 1 (NEAT1). Dysfunctional paraspeckles together with accumulation 
of NEAT1 outside paraspeckles might contribute to the disease severity. 
Stresses capable of triggering cytoplasmic FUS aggregates are also 
investigated, and as a result, antiviral immune response has emerged as a 
potent stress promoting formation of persistent cytoplasmic FUS-positive 
assemblies. In addition, type I interferon expressed during antiviral response 
is found to cause FUS protein accumulation by increasing FUS mRNA 
stability. I propose a multi-step model where antiviral immune response serves 
as the "second hit" provoking FUSopathy. This thesis offers novel insights into 
the cellular and molecular events leading to the initiation and progression of 
ALS-FUS, which should help inform the development of therapeutic strategies 
in the future.
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1Chapter 1. General Introduction
2
31.1. Amyotrophic Lateral Sclerosis (ALS)
1.1.1. Motor neuron diseases and ALS
1.1.1.1. Clinical features of ALS
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron 
disease, primarily affecting the upper and/or lower motor neurons in the motor 
cortex, brainstem and spinal cord. The degeneration of the lower motor 
neurons results in the denervation of muscles causing fasciculation, cramps, 
muscle wasting, and weakness. The degeneration of the upper motor neurons 
affects fine motor control of the lower motor neuron system, causing spastic 
paresis (Volk et al. 2018). The symptoms typically begin focally from one 
motor unit and gradually propagates to adjacent ones (Taylor et al. 2016). 
ALS commonly affects people in their mid-adulthood (Hardiman et al. 2017). 
Male to female ratios with ALS are 2.5 and 1.4 before and after the age of 50, 
respectively (Manjaly et al. 2010). Death occurs, in most cases, typically within 
5 years since the disease onset, mainly due to the respiratory failure, although 
there are exceptions with patients surviving longer (Taylor et al. 2016). The 
incidence of ALS varies across the continents, with 1.89 and 0.83 per 100,000 
in North Europe and East Asia respectively, suggesting a possible link 
between ancestry, environment and ALS incidence (Marin et al. 2017).
Up to 50% of ALS patients show various degrees of cognitive impairment, with 
14% meeting definite diagnosis of Frontotemporal lobar degeneration (FTLD) 
(Phukan et al. 2012). FTLD is a neurodegenerative disorder characterised by 
progressive decline of behavioural, language and cognitive function, is the 
second common cause of dementia among people under the age of 65. 
Importantly, FTLD and ALS share striking overlaps on clinical, genetic and 
neuropathological levels. Mutations in chromosome 9 open reading frame 72 
(C9orf72), fused in sarcoma (FUS) and TAR DNA binding protein (TARDBP)
together with some other rare genes have been found to be associated with 
both ALS and FTLD (Sreedharan et al. 2008, Van Langenhove et al. 2010, 
DeJesus-Hernandez et al. 2011, Karch et al. 2018). In addition, development 
of ubiquitin-positive inclusions with TDP-43 (protein encoded by TARDBP
gene) as major component is the pathological hallmark of a subset of ALS and 
4FTLD brain (Neumann et al. 2006). Primary lateral sclerosis and progressive 
muscular atrophy, which affect only upper and lower motor neurons 
respectively, although initially categorised in an independent disease group, 
are now considered as ALS variants (Turner and Swash 2015). Taken 
together, diseases categorised under ALS is expanding with primary lateral 
sclerosis/progressive muscular atrophy and FTLD being the two extreme ends 
of this disease spectrum (Figure 1.1). 
Currently only two drugs, Riluzole and Edaravone, have been approved by the 
United States Food and Drug Administration (FDA), with very limited benefits 
on survival. Riluzole acts to ameliorate the glutamate excitotoxicity, one of the 
proposed pathomechanisms of ALS (Trotti et al. 1999), but it only extends life 
expectancy by 3 months (Riviere et al. 1998). Edaravone is a free-radical 
scavenger that acts against the oxidative stress (Nagase et al. 2016), and it 
may slow down the disease progression by 33% only in a selected subgroup 
of ALS patients (Writing Group 2017). As there are no medications that can 
reverse the disease, the contemporary treatment of ALS is to alleviate the 
related symptoms and to ameliorate the progressive degeneration.
Figure 1.1 Disease spectrum of ALS/FTLD.
ALS is currently considered to be a group of diseases with primary lateral sclerosis 
(PLS) and progressive muscular atrophy (PMA) and FTLD as two extreme ends of 
the disease spectrum. Genes associated with corresponding phenotypic groups 
along the spectrum are indicated. This figure is adapted from (Radford et al. 2015).
1.1.1.2. Histopathology of ALS/FTLD
Motor neuron loss and gliosis in affected brain areas (spinal cord, frontal and 
temporal cortex, hippocampus, cerebellum, etc.) are the major 
5neuropathological features of ALS and FTLD. Residual neurons and 
surrounding oligodendrocytes contain cytoplasmic and/or nuclear, 
morphologically variable (skein-like or Lewy body-like) inclusions that are 
positive for ubiquitin and composed of misfolded proteins (Forman et al.
2004). Ultrastructural observation revealed filamentous aggregates covered 
with electron dense granules within the inclusions (Lin and Dickson 2008).
In 2006, a ground-breaking discovery was made by Neumann and her 
colleagues that TDP-43, a highly abundant, ubiquitously expressed nuclear 
protein, is the major component of pathological inclusions found in ALS and 
FTLD patients (Neumann et al. 2006). Redistribution of TDP-43 and 
concomitant nuclear clearance are frequently observed in the neurons 
containing inclusions, suggesting a possible loss-of-function mechanism 
contributing to the disease pathogenesis. Biochemical analysis has revealed 
that this pathological TDP-43 component is present predominantly in the form 
of cleaved C-terminal fragments of ~25 kDa and ~35 kDa, together with a high 
molecular weight smear on western blots, and these protein species are 
abnormally ubiquitinated and hyper-phosphorylated. Slightly different TDP-43 
variants are detected among different ALS/FTLD subtypes, which might 
explain differences of inclusion distribution within brain regions and clinical 
manifestations among these subtypes (Neumann et al. 2006).
In addition to TDP-43, a whole range of other proteins encoded by disease-
associated genes usually become the prominent component of ubiquitin-
positive inclusions found in corresponding mutation carriers, such as SOD1, 
FUS, optineurin, ubiquilin-2, ataxin-2, C9orf72 (encoded by SOD1, FUS, 
OPTN, UBQLN, ATXN2, C9orf72 gene, respectively), among others (Blokhuis
et al. 2013). Importantly, these proteins can be found in pathological 
inclusions of non-mutation carriers, suggesting shared molecular mechanisms 
that might underlie both familial and sporadic ALS/FTLD (Blokhuis et al.
2013). Other protein components of neuronal inclusions are ribonucleoprotein 
(RNP) granule markers, such as T cell-restricted intracellular antigen 1 (TIA1), 
poly(A) binding protein cytoplasmic 1 (PABP1), eukaryotic translation initiation 
factor 4 gamma 1 (eIF4G) and non-POU domain containing octamer binding 
(NONO), most likely incorporated into protein aggregates by sequestration 
6mechanism (Dormann et al. 2010, Liu-Yesucevitz et al. 2010, Shelkovnikova
et al. 2014b). Such sequestration and subsequent clearance from the sites of 
function would inevitably result in downstream effects that might contribute to 
disease onset and/or progression.
There are also other types of inclusions found in degenerating neurons of 
ALS. Bunina bodies are small, round, eosinophilic inclusions that are negative 
for ubiquitin. Ultrastructurally, Bunina bodies appear to be amorphous 
electron-dense material surrounded by tubules and vesicles (Okamoto et al.
2008). Another type of inclusions are found at axonal hillock of affected 
neurons containing neurofilaments, usually located close to ubiquitin-positive 
inclusions (Blokhuis et al. 2013). Other non-specific pathological changes of 
ALS/FTLD are mitochondrial vacuolisation, fragmentation of Golgi apparatus 
and neuromuscular junction abnormalities (Jaarsma et al. 2000, Blokhuis et al.
2013, Sundaramoorthy et al. 2015).
1.1.2. ALS subtypes and genes associated with the disease
ALS is a genetically heterogeneous disorder with monogenic forms as well as 
complex genetic aetiology. In about 10% cases, the disease runs in the family 
(familial ALS, fALS) (Mitchell and Borasio 2007), and a monogenic cause can 
be identified in 70% of fALS (Renton et al. 2014, Volk et al. 2018). The 
remaining 90% cases appear to be sporadic (sALS), nevertheless mutations 
in genes implicated in fALS can also be found in 10% of sALS patients 
(Renton et al. 2014, Volk et al. 2018). Among over 30 genes reported to date, 
the most frequently identified genes are C9orf72 and SOD1, together 
accounting for nearly half of fALS cases (Volk et al. 2018) (Table 1.1).
Mutations in TDP-43 and FUS, although less prevalent than above genes, are 
found in about 10% of fALS cases, and have been studied extensively (Lagier-
Tourenne and Cleveland 2009) (Table 1.1). Therefore, I will focus on these 
four genes in the following sections.
1.1.2.1. C9orf72
A hexanucleotide (GGGGCC-) repeat expansion in the non-coding region 
between exons 1a and 1b of C9orf72 gene is the most frequent genetic cause 
7of fALS and FTLD in Europe and North America, corresponding to about 35% 
of fALS and 12% of  familial FTLD (DeJesus-Hernandez et al. 2011, Renton et 
al. 2011, Zou et al. 2017). Although the exact cut-off between normal and 
pathological repeat length is unclear, patients with an expanded allele usually 
have several hundred to thousand repeats, and healthy individuals usually 
have less than 20 repeats (DeJesus-Hernandez et al. 2011). Long 
hexanucleotide repeat of C9orf72 is inherited in an autosomal dominant 
manner, and also linked to other neurodegenerative disease including 
Parkinson’s disease, Huntington’s disease-like disorders and Alzheimer’s 
disease (Cooper-Knock et al. 2014).
Three mutually non-exclusive mechanisms that might explain disease 
pathogenesis have been suggested for ALS associated with C9orf72 mutation 
(ALS-C9 hereafter): i) haploinsufficiency of C9orf72 protein; ii) toxic gain of 
function from C9orf72 repeat RNA; and iii) toxic gain of function from dipeptide 
repeat proteins (DPRs) (Balendra and Isaacs 2018). Firstly, protein product of 
C9orf72, whose exact function is still under investigation, is found to be 
decreased in ALS/FTLD patient motor neurons (DeJesus-Hernandez et al.
2011, Belzil et al. 2013), suggesting a possible loss of function mechanism. 
Secondly, the toxic effect of hexanucleotide repeats may arise from its RNA 
and protein product. In this case, the expanded repeats are transcribed 
bidirectionally into RNA molecules before they accumulate and form sense 
and antisense RNA foci within the nuclei of neurons and glial cells, which 
sequester numerous RNA-binding proteins (RBPs) (Gendron et al. 2013, 
Mizielinska et al. 2013, Zu et al. 2013). Finally, these repeat sequences-
containing RNA can be translated into six different DPRs through repeat-
associated non-ATG translation, which further aggregate to form inclusions in 
affected neurons (Ash et al. 2013, Gendron et al. 2013, Mori et al. 2013a, Mori
et al. 2013b, Zu et al. 2013). These inclusions often contain more than one 
type of DPR and are positive for the ubiquitin-binding protein p62 but negative 
for TDP-43 (Mori et al. 2013a).
1.1.2.2. SOD1
Superoxide dismutase 1 (SOD1) gene is the first gene identified as an ALS-
causing gene and the second most frequently identified gene in ALS, 
8accounting for 15% and 2% of fALS and sALS cases, respectively (Rosen et 
al. 1993, Zou et al. 2017). Up to date, more than 160 different mutations have 
been identified, and most of them are missense mutations, although small 
deletions and truncation mutations are also detected. It is inherited in 
autosomal dominant or recessive manner (Andersen and Al-Chalabi 2011). 
SOD1 protein is a ubiquitously expressed enzyme that catalyses the reduction 
of superoxide anions to oxygen and hydrogen peroxide. Misfolding and 
aggregation of mutant SOD1 protein, rather than the loss of its enzymatic 
activity, is thought to be the central pathomechanism of ALS linked with SOD1
(Sibilla and Bertolotti 2017).
1.1.2.3. TARDBP
Although TDP-43 deposition in neuronal inclusions is a pathological hallmark 
of ALS and FTLD, TARDBP mutations have been identified in only 4% of fALS 
and 1% of sALS cases and rarely in FTLD (Zou et al. 2017). More than 60 
mutations have been identified, with the majority being missense mutations 
clustered within the prion-like domain of the protein (Lattante et al. 2013). 
TDP-43 is an RBP involved in many aspects of RNA biology, including 
splicing, miRNA biogenesis, RNA transport and translation (reviewed in 
(Buratti and Baralle 2012)). TDP-43 is a predominantly nuclear protein, which 
can also shuttle between the cytoplasm and the nucleus (Ayala et al. 2008), 
and mutant TDP-43 has been shown to mislocalise to the cytoplasm
(Barmada et al. 2010). Although the exact pathological mechanism of ALS 
caused by TDP-43 mutation is largely unknown, both gain-of-function in the 
cytoplasm and loss-of-function in the nucleus are believed to underlie ALS 
pathology caused by TDP-43 mutations. 
1.1.2.4. FUS
FUS gene was initially identified as a fusion oncogene causing human 
liposarcoma (Crozat et al. 1993, Rabbitts et al. 1993), and hence named as 
Fused in Sarcoma (FUS). FUS gene mutations have been found to be 
causative in a subset of fALS in 2009 (Kwiatkowski et al. 2009, Vance et al.
2009). Later on, FUS mutations have also been identified in sALS and FTLD 
(Corrado et al. 2010, Van Langenhove et al. 2010, Deng et al. 2014a). FUS 
mutations are responsible for about ~5% of fALS and 1% sALS cases, and are 
9very rare in FTLD (Zou et al. 2017, Volk et al. 2018). FUS mutations are 
inherited in an autosomal dominant manner in most cases, with a few 
exceptions, where autosomal recessive mode and de novo mutations were 
also reported (Kwiatkowski et al. 2009, Volk et al. 2018). Over 50 FUS gene 
mutations have been identified, and the majority are missense mutations but 
rare truncation/frameshift mutations have also been found (Deng et al. 2014a). 
Most of the mutations affect the nuclear localisation signal (NLS) of FUS 
protein on its C-terminus, therefore, mutant proteins exhibit impaired nuclear 
targeting leading to their cytoplasmic mislocalisation (Deng et al. 2014a). FUS 
mutations are frequently associated with early onset and rapid progressive 
ALS, with the youngest reported victim developed the disease at the age of 13 
(Suzuki et al. 2010b, Yan et al. 2010, Gromicho et al. 2017). Different 
mutations affect the nuclear targeting of FUS protein differently and the extent 
to which FUS mutants mislocalise to the cytoplasm correlates with the disease 
severity (Bosco et al. 2010, Dormann et al. 2010). For example, patients with 
FUS R495X mutation, which deletes the entire NLS, exhibit relatively severe 
disease phenotype compared with missense mutation carriers (Bosco et al.
2010).
Inclusions containing FUS protein in the spinal motor neurons are a 
pathological hallmark of ALS caused by FUS gene mutation (ALS-FUS
hereafter) (Kwiatkowski et al. 2009, Vance et al. 2009). FUS-positive 
inclusions can also be found in Tau-negative and TDP-negative FTLD cases, 
and these cases are subcategorised as FTLD-FUS (Neumann et al. 2009). 
Contrary to TDP-43, complete nuclear clearance of FUS is rarely observed in 
affected human spinal motor neurons (Kwiatkowski et al. 2009, Vance et al.
2009).
FUS is an abundant nuclear DNA/RNA binding protein playing important roles 
in multiple cellular processes such as cell proliferation, DNA repair and RNA 
metabolism (Deng et al. 2014a). Nuclear loss/gain of function and cytoplasmic 
gain of function by FUS have been implicated in the disease pathogenesis. 
This will be discussed further in section 1.1.4.
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1.1.2.5. Other genes implicated in ALS
During the past 10 years, thanks to the advances in next-generation 
sequencing technology, there has been an explosive increase in the number 
of ALS-causitive genes identified (Chia et al. 2018). A list of these genes and 
their functional implications in ALS is given in Table 1.1. Although mutations in 
the most of newly identified genes are rare, some genes are found mutated 
relatively frequently and therefore are studied more intensively, such as TBK1 
and MATR3.
TBK1 gene, which encodes TANK-binding kinase 1, a multiplayer in the
autophagic process and inflammatory signalling (Weidberg and Elazar 2011), 
has been found to be mutated in a number of fALS pedigrees (Freischmidt et 
al. 2015) and in several sALS patients (Cirulli et al. 2015). To date, more than 
50 mutations have been reported, representing 4% of fALS cases among 
Caucasians, although meta analysis showed lower prevalence (Cui et al.
2018). Remarkable similarity has been found between the neuropathology in 
ALS-TBK1 patients and ALS-C9 patients, both characterised by TDP-43-
positive perinuclear inclusions in affected neurons (Freischmidt et al. 2015). 
Optineurin and p62 are both substrates of TBK1 in autophagy, and are 
coincidentally also ALS-associated genes (Maruyama et al. 2010, Fecto et al.
2011). Therefore TBK1 mutations suggest the important mechanistic role of 
autophagy in ALS development.
MATR3 gene encodes an RNA/DNA-binding protein matrin 3 that interacts 
with TDP-43, and MATR3 mutations are found in about 1% of fALS and sALS 
cases (Johnson et al. 2014, Therrien et al. 2016). Nuclear accumuation and 
mild cytoplasmic distribution of Matrin 3 is observed in the spinal cord neurons 
of mutation carriers, yet no neuronal inclusions containing Martrin 3 are found 
in these patients (Johnson et al. 2014). Importantly, Matrin 3 is occasionally 
found in the pathological inclusions in ALS-C9 patients (Johnson et al. 2014), 
and recently, it was also identified in the cytoplamsic TDP-43-positive 
inclusions in the spinal motor neurons of sALS patients (Tada et al. 2018). 
Identification of MATR3 mutations further strengthens the role of dysregulated
RNA metabolism in ALS aetiology.
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Table 1.1 A summary of ALS-associated genes and their functions implicated in ALS
Gene Protein
Mode of 
inheritance
Prevalence  
fALS/sALS
Protein functions 
relevant to ALS 
Number of 
mutations
References
C9orf72 C9orf72 AD 35% / 8%
Intracellular 
transport, 
autophagy, protein 
degradation
Intronic 
GGGGCC 
repeat
(DeJesus-Hernandez et al.
2011, Renton et al. 2011)
SOD1
Cu/Zn 
superoxide 
dismutase
AD, AR 15% / 2% Neurotoxicity >150 (Rosen et al. 1993)
FUS FUS/TLS AD, AR 5% / 1% RNA metabolism >50
(Kwiatkowski et al. 2009, 
Vance et al. 2009, Van 
Langenhove et al. 2010)
TARDBP TDP-43 AD, AR 4% / 1% RNA metabolism >40
(Gitcho et al. 2008, Kabashi et 
al. 2008, Sreedharan et al.
2008)
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CCNF
G2/mitotic-
specific cyclin-
F
AD 4% / 2% Protein degradation 10 (Williams et al. 2016)
VCP
Valosin-
containing 
protein
AD 1% / 1% Protein degradation 7 (Johnson et al. 2010)
UBQLN2 Ubiquilin-2 XL <1% / <1% Protein degradation 5 (Deng et al. 2011)
VAPB
Synaptobrevin-
associated 
membrane 
protein B
AD N/A Protein degradation 3 (Nishimura et al. 2004)
TBK1
TANK-binding 
kinase 1
AD 3% / <1%
Autophagy, 
inflammation
>50
(Cirulli et al. 2015, Freischmidt
et al. 2015)
SQSTM1 p62 AD 1% / <1%
Autophagy, 
inflammation
12 (Fecto et al. 2011)
OPTN Optineurin AD, AR <1% / <1%
Autophagy, 
inflammation
11 (Maruyama et al. 2010)
13
GRN Granulin AD <1% / <1%
Autophagy, 
inflammation
4 (Schymick et al. 2007)
FIG4 Sac3 AD, AR <1% / <1% Autophagy 10 (Chow et al. 2009)
MATR3 Matrin 3 AD <1% / <1% RNA metabolism 15 (Johnson et al. 2014)
HNRNPA1 hnRNPA1 AD N/A RNA metabolism 3 (Kim et al. 2013)
HNRNPA2B1 hnRNPA2 AD N/A RNA metabolism 1 (Kim et al. 2013)
SETX Senataxin AD N/A RNA metabolism 4 (Chen et al. 2004)
ATXN2 Ataxin-2 AD N/A RNA metabolism
Intermediate-
length polyQ 
expansions
(Elden et al. 2010)
TAF15
TATA-Box 
Binding Protein 
Associated 
Factor 15
AR, AD 1% / 1% RNA metabolism 8 (Ticozzi et al. 2011)
EWSR1
Ewing sarcoma 
breakpoint 
region 1
AD 1% / 1% RNA metabolism 3 (Couthouis et al. 2012)
GLE1
Nucleoporin 
GLE1
AD <1% / <1% RNA metabolism 3 (Kaneb et al. 2015)
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NEK1
NIMA-related 
kinase 1
AD, AR 2% / 2%
Cytoskeletal 
organisation
4 (Kenna et al. 2016)
ANG Angiogenin AD N/A
Cytoskeleton 
organisation, 
angiogenesis
>20 (Greenway et al. 2006)
PRPH Peripherin AD <1% / <1%
Cytoskeleton 
organisation
10 (Gros-Louis et al. 2004)
PFN1 Profilin-1 AD <1% / <1%
Cytoskeleton 
organisation, axonal 
transport
8 (Wu et al. 2012)
TUBB4A α-tubulin AD <1% / <1%
Cytoskeleton 
organisation, axonal 
transport
7 (Smith et al. 2014)
NEFH
Neurofilament 
heavy 
polypeptide
AD N/A Axonal transport 5
(Tomkins et al. 1998, Al-
Chalabi et al. 1999)
KIF5A
Kinesin family 
member 5A
AD <1% / <1% Axonal transport 12 (Nicolas et al. 2018)
DCTN1 Dynactin AD N/A Axonal transport 10 (Puls et al. 2003)
15
CHMP2B
Charged 
multivesicular 
protein 2B
AD N/A Vesicular trafficking 3 (Parkinson et al. 2006)
ALS2 Alsin AR N/A Vesicular trafficking 5
(Hadano et al. 2001, Yang et
al. 2001)
SS18L1
SS18-like 
protein 1
AD N/A Dendritic outgrowth 4 (Chesi et al. 2013)
SPAST Spastin AD N/A Axonal growth 2 (Meyer et al. 2005)
CHCHD10
Coiled-coil-
helix-coiled-
coil-helix 
domain 
containing 10
AD <1% / <1%
Mitochondrial 
function
10 (Bannwarth et al. 2014)
SIGMAR1 Sig-1R AR <1% / <1%
Mitochondrial 
function
3 (Al-Saif et al. 2011)
DAO
D-amino acid 
oxidase
AD <1% / <1% Neurotoxicity 2 (Mitchell et al. 2010)
SPG11 Spatacsin AR <1% / <1% DNA damage 2 (Orlacchio et al. 2010)
AD autosomal-dominant, AR autosomal-recessive, XL X-linked, N/A not available
The top four most common genes are given in the order of frequency, and the rest are sorted by the primary functions relevant to ALS
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1.1.3. Molecular mechanisms underlying ALS pathogenesis
Since the identification of the first ALS-causing gene SOD1, whose mutant 
protein product is known to form abnormal aggregates in affected neurons, 
impaired protein homeostasis has been extensively studied as the central 
mechanism underlying ALS pathogenesis. After over two decades of study, 
along with the ever-growing number of ALS-causative genes being 
discovered, a plethora of cellular mechanisms involving almost every aspect
of neuronal biology has been suggested to be involved in ALS development 
and progression. Among them, perturbed proteostasis, dysregulation in RNA 
metabolism and altered axonal transport are believed to be the most 
prominent mechanisms, as evidenced by the convergence of the majority of 
disease-associated genes within these categories (Ling et al. 2013, Taylor et 
al. 2016) (Table 1.1). 
1.1.3.1. Protein quality control and proteostasis
Cells produce misfolded proteins throughout their lifespan due to various 
internal processing errors and environmental stresses, which, if not managed 
promptly, would lead to protein aggregation, toxicity, and cell death. Cells 
have evolved three main strategies to precisely maintain their proteostasis –
re-folding, degradation and sequestration. Among them, protein degradation is 
the most effective strategy to eliminate potentially deleterious species and 
recycle amino acids when the upstream correction has failed. There exist two 
major pathways for protein degradation in eukaryotic cells: the ubiquitin-
proteasome system (UPS) and autophagy (Chen et al. 2011, Webster et al.
2017). The protein quality control systems of eukaryotic cells are described in 
detail in Figure 1.2. The ability of cells to preserve the stability of proteome 
declines with age (Morimoto and Cuervo 2009), and this is more deleterious 
for the long-living, post-mitotic cells like neurons, which are not able to dilute 
the accumulated misfolded proteins via cell division (Son et al. 2012).  
Inclusions containing misfolded proteins in the degenerating neurons and 
surrounding glial cells are the most common pathological hallmark of ALS. 
These inclusions are mainly composed of ubiquitinated proteins (Neumann et 
al. 2006, Dormann et al. 2010), and very often contain proteasome- and 
autophagy- related proteins such as p62 and molecular chaperons (Basso et 
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al. 2009, King et al. 2011). Experimental inhibition of UPS or autophagy 
results in accumulation and aggregation of TDP-43 protein in cultured cells 
(Urushitani et al. 2010, Wang et al. 2010). Taken together, these findings 
suggest that impaired proteostasis is involved in the disease aetiology in ALS. 
Several ALS-associated proteins contribute to protein degradation pathways 
(see Table 1.1). For example, misfolded proteins marked with ubiquitins are 
brought to proteasome for degradation by ubiquilin-2 and p62 (Moscat and 
Diaz-Meco 2012), whereas valosin-containing protein (VCP) extracts 
misfolded proteins from the endoplasmic reticulum (ER) and targets them for 
degradation via the proteasome (Wojcik et al. 2006). p62 and optineurin serve 
as adaptor proteins for targeting substrates to autophagy, and TBK1 regulates 
autophagy by directly phosphorylating p62 and optineurin (Wild et al. 2011, 
Heo et al. 2015). Finally, TBK1, CHMP2B and FIG4 are required for 
autophagosome maturation (Pilli et al. 2012, Ling et al. 2013). ALS-causing 
mutations in some of these genes have been proven to affect protein 
clearance pathways to a different extent eventually leading to the 
accumulation of substrates for degradation (reviewed in (Webster et al.
2017)). 
Cytoplasmic aggregation coupled with nuclear clearance of TDP-43 is 
frequently observed in motor neurons of ALS patients. TDP-43 nuclear loss-
of-function is known to affect the expression of protein degradation pathway 
components, such as CHMP2B, FIG4, optineurin, VAPB, and VCP 
(Polymenidou et al. 2011). In addition, TDP-43 silencing is shown to result in 
decreased autophagosome numbers and impaired autophagosome delivery to 
lysosomes, due to the downregulation of Atg7 and dynactin 1 expression, 
respectively (Bose et al. 2011, Xia et al. 2016). Similarly, FUS is also shown to 
bind to the transcripts encoding optineurin, ubiquilin-2, VAPB and VCP (Ling
et al. 2013). 
In SOD1 mouse models, mutant SOD1 shows increased interaction with 
chaperones, which may result in a depletion of the chaperone pool and 
impaired protein folding (Tummala et al. 2005, Ganesan et al. 2008). 
Moreover, ALS-causing mutant SOD1 has been shown to interact with an ER 
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protein Derlin-1 which is essential for ER-associated degradation (ERAD), 
causing impaired ERAD response and cellular toxicity (Nishitoh et al. 2008).  
C9orf72 is also known to play important roles in autophagy (Farg et al. 2014). 
C9orf72 regulates autophagy by forming a complex with SMCR8-C9orf72 
complex subunit (SMCR8) and WD repeat domain 41 (WDR41) proteins 
(Sellier et al. 2016, Sullivan et al. 2016, Xiao et al. 2016). Depletion of C9orf72 
in primary cortical neurons results in impaired autophagy and TDP-43 and p62 
aggregation (Sellier et al. 2016). 
Protein misfolding and aggregation are considered to crucially contribute to
motor neuron degeneration, and clearance of these toxic species heavily 
relies on protein degradation pathways. However, once the balance of protein 
homeostasis is disrupted due to a primary mutation or many secondary 
factors, a feedforward loop is initiated, leading to a snowballing effect that 
would eventually cause inclusion formation and neuronal degeneration 
(Webster et al. 2017).
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Figure 1.2 Protein quality control systems of eukaryotic cells and ALS-
associated proteins.
Protein folding happens co-translationally, which continues in the cytoplasm and the 
ER lumen with the assistance of molecular chaperones. Misfolding can be corrected 
by chaperones during this process. However, chronic misfolding leads to the overload 
of chaperones therefore requires the UPS and autophagy pathways for the clearance 
of the misfolded proteins. Cytoplasmic misfolded proteins are ubiquitinated and 
targeted to the UPS, and when the system is overloaded, poly-ubiquitinated 
aggregates form, which, if not cleared by autophagy, may lead to cell death. Chronic 
misfolding in ER triggers unfolded protein response, which upregulates ER-
associated degradation (ERAD) and autophagy by altering gene expression. Failure 
to maintain the proteostasis can lead to aggregate formation. A large number of ALS-
associated proteins (indicated in red) are indirectly or directly involved in this network. 
This figure is adapted from (Webster et al. 2017).
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1.1.3.2. RNA metabolism
TDP-43 and FUS, whose dysregulation and aggregation accounts for the 
majority of ALS cases, are both ubiquitously expressed, abundant nuclear 
RBPs with important functions across many aspects of RNA biology. 
Remarkably, TDP-43 and FUS are known to bind to over 6,000 and 5,500 
RNA targets respectively in the human brain, which is about 30% of the total 
transcriptome, regulating every stage of RNA life cycle including transcription, 
splicing, stability, transport and beyond (reviewed in (Ling et al. 2013)). In 
addition, apart from FUS and TDRDBP, a number of other ALS-associated 
genes, including hnRNPA1, hnRNPA2B1, RGNEF, SETX, ANG, TAF15, 
EWSR1, TIA-1 and MATR3, encode RBPs that have important functions in 
RNA metabolism. Moreover, a variety of RBPs are found to be sequestered in 
the protein inclusions found in the central nervous system (CNS) of ALS and 
FTLD patients, which might result in downstream consequences due to the 
depletion of their functional pool.
i Transcription and splicing
TDP-43 and FUS play critical roles in the regulation of RNA transcription and 
pre-mRNA splicing, actively participating in splicing events in the mouse brain 
and in human neuronal cells (Polymenidou et al. 2011, Tollervey et al. 2011). 
Knockdown of TDP-43 or FUS in adult mouse brain changed the expression 
levels as well as splicing patterns of hundreds of mRNAs, with surprisingly 
little overlap with each other (Lagier-Tourenne et al. 2012). Transcripts 
downregulated both by TDP-43 and FUS knockdown tend to have 
exceptionally long introns and encode proteins essential for neuronal integrity 
(Lagier-Tourenne et al. 2012). In line with this experimental evidence, studies 
of post-mortem tissues of ALS patients revealed decreased number of Gemini 
of Cajal bodies (Gems), nuclear bodies responsible for the biogenesis of 
uridine-rich small nuclear RNA (U snRNA), a component of the splicing 
machinery, in spinal motor neurons (Ishihara et al. 2013, Tsuiji et al. 2013). 
Furthermore, recent studies using mouse models with endogenous TDP-43 or 
FUS mutations also suggest that splicing abnormalities are a major 
consequence of these mutations (Fratta et al. 2018, White et al. 2018). Very 
recently, Klim and his colleagues found that the expression level of stathmin 2 
21
(STMN2), a microtubule regulator that mediates motor neuron growth and 
repair, is extremely sensitive to TDP-43 knockdown in human motor neurons 
differentiated from induced pluripotent stem cells (iPSCs), and this change is 
due to altered splicing of STMN2 transcripts. Importantly, the same change 
was also found in the motor neurons derived from iPSCs generated from ALS 
patients carrying TDP-43 mutations, as well as in ALS patients’ post-mortem 
spinal cord samples (Klim et al. 2019). This study, for the first time, provides a
clear link between altered splicing pattern caused by TDP-43 depletion and 
motor neuron degeneration.
ii miRNA biogenesis and function
Mounting clinical and laboratory evidence points to altered miRNA system as 
a possible contributor to ALS pathogenesis. Global downregulation of miRNA 
levels has been observed in ALS motor neurons and serum (Cloutier et al.
2015, Emde et al. 2015), and it has been suggested as a common molecular 
feature in fALS and sALS (Emde et al. 2015). Loss of miRNA biogenesis by 
knocking out Dicer, an enzyme in a multi-protein complex that processes pre-
miRNA into mature miRNA, in motor neurons is sufficient to cause spinal 
motor neuron degeneration in mouse models (Haramati et al. 2010). 
Moreover, enhancing Dicer activity by enoxacin has shown beneficial effects
on neuromuscular function in two independent ALS mouse models (SOD1 and 
TDP-43) (Emde et al. 2015). 
TDP-43 and FUS are known to participate in miRNA biogenesis and function 
by associating with various protein complexes at several stages of miRNA life 
cycle. For example, TDP-43 associates with the Microprocessor (Ling et al.
2010), a complex that processes pri-miRNAs into pre-miRNAs, and Dicer 
complex (Kawahara and Mieda-Sato 2012); FUS binds to miRNA-induced 
silencing complex (miRISC) component Argonaute-2 as well as miRNAs and 
their target transcripts (Zhang et al. 2018b) (Figure 1.3). Consistently, reduced 
miRNA biogenesis was observed in iPSC-derived human motor neurons from 
TDP-43 or FUS mutation carriers (Zhang et al. 2013b, De Santis et al. 2017). 
FUS and TDP-43 are also components of the paraspeckle, a nuclear body 
whose role in ALS pathomechanisms has become increasingly appreciated.
Interestingly, paraspeckles have recently been suggested to have profound 
22
effect on miRNA biogenesis on a global scale through orchestrating efficient 
pri-miRNA processing by spatially organising multiple RBPs within the 
Microprocessor (Jiang et al. 2017). 
Key components of multi-protein complexes participating in the miRNA 
biogenesis and function also interact with the pathways involving stress 
response and stress granule (SG) assembly, one of the major mechanisms 
underlying ALS pathology. For example, Dicer and its co-factors play roles in 
the stress response (Emde and Hornstein 2014), and its loss-of-function 
results in impaired stress tolerance and shortened life span in C. elegans 
(Mori et al. 2012). In addition, various stress-signalling cascades are known to 
regulate Argonaute-2 activity by altering its stability, post-translational 
modifications and its recruitment into SGs (Leung et al. 2006, Shen et al.
2013).
Figure 1.3 miRNA biogenesis and ALS-associated proteins.
Generation of mature miRNA in mammalian cells involves the processing of pri-
miRNA to pre-miRNA by microprocessor complex in the nucleus as well as further 
cleavage by Dicer in the cytoplasm. Mature single-stranded miRNA forms miRNA-
induced silencing complex (RISC) with a member of Argonaute (Ago) protein families 
to repress translation of target mRNA. ALS-associated proteins TDP-43 and FUS 
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participate in miRNA biogenesis as components of key macromolecular complexes at 
multiple critical miRNA processing steps. This figure is modified from (Volonte et al.
2015).
iii Translation
TDP-43 is known to be associated with the translation machinery by 
interacting with the ribosomal protein receptor for activated C kinase 1 
(RACK1), and increased cytoplasmic TDP-43 level resulted in the global 
suppression of protein synthesis (Russo et al. 2017). Indeed, knockdown of 
TDP-43 homologue TBPH in D. melanogaster reduced the expression of 
Futsch, a neuronal microtubule associated protein, and resulted in altered 
neuromuscular junction organisation (Romano et al. 2016). Similarly, 
inclusions containing mutant FUS are enriched in proteins related to 
translation in the overexpression cellular models, and the presence of mutant 
FUS impaired global protein translation by ~ 30% in the fibroblasts derived 
from ALS-FUS patients (Kamelgarn et al. 2018). Reduced protein synthesis 
has detrimental effects on the neuronal function and survival (Holt and 
Schuman 2013). 
Apart from its roles in global translation, FUS also regulates local translation of 
specific mRNAs at the distal ends of neuronal axons. As a component of the 
adenomatous polyposis coli (APC)-RNP complex, which targets mRNAs to 
cell protrusions for expression, FUS promotes translation preferentially within 
the protrusions (Yasuda et al. 2013). In the cytoplasmic aggregates formed by 
mutant FUS, a small group of mRNA is translated, and this ectopic protein 
expression is suggested to cause local protein imbalance and synaptic 
dysfunction (Yasuda et al. 2013, Yasuda and Mili 2016).
iv Stability and degradation
TDP-43 also regulates the stability of mRNAs. TDP-43 is found to stabilise the 
neurofilament light chain (NFL) mRNA by directly binding to its 3’ UTR (Strong
et al. 2007, Volkening et al. 2009), and reduced NFL mRNA level has been 
reported in the motor neurons of sALS patients (Wong et al. 2000). Very 
recently, a profound instability of hundreds of mRNAs was reported in the 
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fibroblasts and iPSCs derived from sALS and ALS-C9, and this phenotype can 
be recapitulated by TDP-43 overexpression in control iPSCs. Destabilised 
transcripts encode ribosomal and mitochondrial components, and reduction of 
oxidative phosphorylation is detected in the CNS of ALS patients (Tank et al.
2018).  
Mutant FUS also contributes to the hyper-activation of nonsense-mediated 
mRNA decay (NMD) pathway by upregulating the pro-NMD factors while 
decreasing molecular brake of NMD (Kamelgarn et al. 2018). However, others 
demonstrated that enhancing NMD by overexpressing pro-NMD factor UPF1 
RNA helicase and ATPase (UPF1) can protect cells against FUS or TDP-43 
mediated toxicity (Barmada et al. 2015, Jackson et al. 2015). Therefore, 
increased NMD activity can be pathogenic, or alternatively, it can be a 
protective response of cells against protein overload.
1.1.3.3. Cytoskeletal defects and altered axonal transport
In humans, although axons of motor neurons can extend for more than a 
meter, therefore, active axonal transport is crucial for maintaining function and 
survival of neurons (Hirokawa 2006). Interestingly, it has been reported that in 
SOD1 mice models, retardation in axonal transport and dismantling of 
neuromuscular junction precedes the degeneration of neurons and the onset 
of first symptoms (Williamson and Cleveland 1999, Fischer et al. 2004, 
Bilsland et al. 2010). 
Interestingly, many novel ALS-associated genes encode proteins involved in 
the cytoskeletal maintenance and axonal transport (see Table 1.1). α-tubulin, 
profilin-1, neurofilament heavy chain and peripherin encoded by TUBA4A, 
PFN1, NEFH, and PRPH, respectively, are building blocks of the cellular 
scaffold and axonal transport machinery, and their mutations are shown to 
significantly compromise cytoskeletal organisation and axonal transport 
(reviewed in (Chia et al. 2018)). For example, ALS-causing mutations in 
TUBA4A have been shown to destabilise microtubule network in primary 
motor neurons by affecting tubulin dimerisation (Smith et al. 2014). 
TDP-43 is a component of RNP granules that undergo bidirectional, 
microtubule-dependent transport in neurons (Fallini et al. 2012), and ALS-
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associated TDP-43 mutants impair axonal trafficking of transport granules in 
D. melanogaster ALS models and in human motor neurons obtained from 
iPSCs carrying a TDP-43 mutation (Alami et al. 2014, Baldwin et al. 2016). As 
mutations investigated in this study are located in the prion-like domain of 
TDP-43, which are important for the assembly of RNA granules, it is 
speculated that abnormal assembly of transport granules could be the main 
cause of the transport defects. A more recent study reported that an ALS-
associated TDP-43 mutant has a compromised affinity to mRNA cargoes 
thereby causing impaired mRNA transport (Ishiguro et al. 2016). FUS is also a 
component of RNA transport granules (Fujii et al. 2005), and ALS-associated 
mutant FUS is shown to induce axonal defects in primary motor neurons 
(Groen et al. 2013). In addition, FUS is a binding partner of IGF2 mRNA-
binding protein 1 (IMP1), a protein involved in axonal transport, and IMP1 is 
found sequestered in the cytoplasmic inclusions containing mutant FUS 
(Kamelgarn et al. 2016). This sequestration could also lead to the defects in 
axonal transport.  
Mutant SOD1 is known to interact with the dynein-dynactin complex, the
essential machinery for intercellular transport, in motor neurons, and SOD1 
transgenic mice displayed significantly impaired axonal transport, which was 
correlated with disease progression (Ligon et al. 2005, Zhang et al. 2007). In 
line with this, depletion of mitochondria in axons due to the deficit in axonal 
transport is found in cultured motor neurons and murine models with SOD1 
mutation (De Vos et al. 2007, Vande Velde et al. 2011). Importantly, similar 
findings have also been reported in various model systems with TDP-43, FUS 
and C9orf72 mutations (Magrane et al. 2014, Baldwin et al. 2016, Chen et al.
2016). 
Together, these data strongly suggest that the defective cytoskeleton integrity 
and axonal transport are important mechanisms in ALS onset and/or 
progression. 
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1.1.4. FUS gene, protein and FUSopathy
1.1.4.1. FUS gene and protein
FUS gene is located on chromosome 16 in humans and contains 15 exons, 
encoding a protein of 526 amino acids (Deng et al. 2014a). FUS protein 
belongs to the FET protein family, which also includes Ewing Sarcoma (EWS) 
protein and TATA binding associated factor 15 (TAF15) (Tan and Manley 
2009). FUS protein has a Gln–Gly–Ser–Tyr (QGSY)-rich region, several
RNA/DNA recognition/binding domains such as RNA-recognition motif (RRM), 
Arg–Gly–Gly-rich motif (RGG) and zinc-finger motif (ZnF), a nuclear export 
signal and an NLS (Figure 1.4). QGSY-rich domain possesses prion-like 
properties that confer aggregation-prone nature to the protein. NLS is 
responsible for targeting FUS to the nucleus through interaction with the 
nuclear transport receptor transportin 1 (Iko et al. 2004, Dormann et al. 2010, 
Dormann et al. 2012). 
FUS is mainly localised in the nucleus under physiological conditions, but it 
can also shuttle between nucleus and cytoplasm (Zinszner et al. 1997). FUS 
plays important roles in DNA damage response and repair (Mastrocola et al.
2013, Wang et al. 2013, Rulten et al. 2014), which is supported by the finding 
that mouse embryonic fibroblasts derived from FUS knockout (KO) mice 
showed significant chromosomal instability and increased sensitivity to the 
radiation (Hicks et al. 2000, Kuroda et al. 2000). 
FUS is also known to regulate gene expression in the nucleus by binding to a 
variety of molecular targets including nuclear hormone receptors, gene-
specific transcription factors, transcription initiation factors and RNA 
polymerase II. It can also bind to the promoter region of some genes to 
regulate their expression (Deng et al. 2014a). 
Regulation of mRNA splicing and maturation is another well-known function of 
FUS. Importantly, FUS is shown to regulate alternative splicing of some 
transcripts whose protein products are involved in pathological aggregate 
formation in neurodegeneration. For example, knockout of FUS promotes 
inclusion of exons 2, 3 and 10 into tau transcripts, which would result in 
increased production of tau isoforms containing four amino acid repeats 
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(Orozco and Edbauer 2013). Such change in tau isoform composition is 
known to be associated to ALS-FUS and FTLD-FUS (Orozco et al. 2012). 
FUS is an essential structural component of a nuclear body paraspeckle, 
which is a highly organised nuclear RNP granule (Naganuma et al. 2012, 
Shelkovnikova et al. 2014b). Absence of FUS causes loss of paraspeckles, 
and compromised paraspeckle assembly is thought to be a pathogenic factor 
in FUSopathy (Shelkovnikova et al. 2014b) (discussed further in section 1.2). 
In addition, as a component of the Microprocessor complex (Gregory et al.
2004), FUS contributes to miRNA biogenesis facilitating co-transcriptional 
Drosha recruitment to specific pri-miRNA sites (Gregory et al. 2004, Morlando
et al. 2012).  
FUS gene expression is subject to autoregulation attributable to the 
suppressive effect of FUS protein on its own pre-mRNA splicing. FUS protein 
binds to the region of exon 7 and its flanking introns of FUS pre-mRNA and 
promotes exon 7 skipping. The transcripts lacking exon 7 are degraded 
through NMD, resulting in downregulation of FUS protein (Zhou et al. 2013).
Figure 1.4 Schematic illustration of FUS protein functional domains with gene 
mutations identified in patients with ALS.
The grey bar on the bottom represents the FUS transcript, which is shown to indicate 
the corresponding coding region for each protein domain. SYGQ: Ser–Tyr–Gly–Gln; 
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RGG: Arg–Gly–Gly-rich motifs; E: nuclear export signal; RRM: RNA-recognition motif; 
ZnF: zinc-finger motif; NLS: nuclear localisation signal. The figure was modified from 
(Deng et al. 2014a).
1.1.4.2. FUSopathy
Mutations in the FUS gene were identified in a subset of fALS cases in 2009, 
reported by two independent research groups (Kwiatkowski et al. 2009, Vance
et al. 2009). Up to date, more than 50 ALS-associated FUS mutations, mostly 
missense mutations, have been reported, and there are two regions in the 
FUS gene where mutations occur most frequently: exons 12-15 encoding ZnF, 
RGG2, RGG3 and NLS account for 2/3 of mutations, and exons 3-6 encoding 
QGSY-rich domain and RGG1 account for the rest 1/3 known mutations 
(Deng et al. 2014a) (Figure 1.4). Of note, mutations found in exons 12-15 are 
often found in fALS cases with high penetrance whereas those found in exons 
3-6 are mainly identified in sALS cases or in fALS with incomplete penetrance 
(Deng et al. 2014a).
Formation of FUS immunoreactive cytoplasmic or nuclear inclusions in 
affected neurons and glial cells is the pathological hallmark of ALS-FUS and 
FTLD associated with FUS protein dysregulation (collectively called 
FUSopathy). It is worth mentioning that extremely high degree of 
heterogeneity is an important feature of FUSopathy. Firstly, FUS-positive 
inclusions are different in terms of morphology, components, ultrastructure 
and regional distribution (Mackenzie et al. 2010a, Mackenzie et al. 2010b). 
For instance, FUS-containing inclusions found in FTLD are also positive for 
Transportin 1, whereas ALS-FUS inclusions are Transportin 1-negative 
(Troakes et al. 2013). Secondly, even within ALS-FUS or FTLD-FUS, 
pathological and clinical heterogeneity among different missense mutation 
carriers has been described. For example, in FUS p.P525L cases, round, 
basophilic neuronal cytoplasmic inclusions have been identified, whereas in 
FUS p.R521C cases, tangle-like neuronal and oligodendroglial cytoplasmic 
inclusions are typical. The former cases showed early onset, severe clinical 
manifestations while the latter mutation is found in late onset, slowly 
progressing cases (Mackenzie et al. 2011). Finally, it was also reported that 
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FUSopathy takes different forms even among individuals with the same 
mutation (Mackenzie et al. 2010b). Taken together, the complexity of 
molecular mechanisms leading to FUSopathy might exceed our estimation, 
where each mutant FUS protein interacts with a specific subset of molecules 
eventually resulting in neurodegeneration via different pathogenic pathways.
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1.2. RNP granules in ALS pathophysiology
1.2.1. RNP granules and their physiological functions
At any stage of the mRNA life cycle, mRNAs are often bound to a set of RBPs 
to form RNP particles. These RNP particles could further cluster and interact 
to form dynamic membraneless compartments called RNP granules, which is 
considered to be a conserved cellular mechanism to concentrate specific 
cellular components to increase efficiency of biological processes (Protter and 
Parker 2016). RNP granules include nucleolus, Cajal bodies and paraspeckles 
in the nucleus as well as SGs and processing bodies (P bodies) in the 
cytoplasm (Spector 2006), each of which serves as a distinct molecular hub 
for RNA storage and processing. 
Physiological functions of RNP granules cover a broad range of mRNA-related 
processes as well as many other cellular processes and pathways that are 
important for basal cellular metabolism and stress response alike. The 
nucleolus is the primary site for the ribosomal RNA transcription, maturation 
and initial assembly of ribosomes (Pederson 2011). Cajal bodies are the main 
sites for processing, assembly, modification and maturation of spliceosomal 
small nuclear ribonucleoproteins (snRNPs) and recycling of spliceosome 
components (Wang et al. 2016). Paraspeckles are relatively recently identified 
nuclear bodies whose structure and physiological roles are just beginning to 
emerge. SGs and P bodies are two conserved RNP granules that are 
essential for cytoplasmic mRNA metabolism under stress conditions. When 
mRNAs in the cytoplasm are not engaged in translation, they are recruited into 
either P bodies or into SGs. P bodies contain translation repressors and 
mRNA decay machinery, and SGs contain mRNAs stalled in translation 
initiation and various translation initiation factors (Anderson and Kedersha 
2009a). When they disassemble, stored mRNAs can return to translation. 
Excessive SG formation and/or their disrupted clearance are considered to be 
one of the central mechanisms underlying ALS/FTLD pathogenesis. A 
surprisingly strong association between paraspeckles and neurodegenerative 
diseases, and ALS in particular, will be discussed further in the following 
sections.
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1.2.2. Paraspeckles
1.2.2.1. Long non-coding RNA NEAT1
Nuclear Paraspeckle Assembly Transcript 1, initially named as Nuclear 
Enriched Abundant Transcript 1 (NEAT1), is one of the most abundant long 
non-coding RNAs (lncRNAs) in the mammalian nucleus (Hutchinson et al.
2007). It is transcribed from the familial tumour syndrome multiple endocrine 
neoplasia (MEN) type I gene on human chromosome 11 (Guru et al. 1997). 
Two NEAT1 isoforms – 3.7 kb NEAT1_1 and 23 kb NEAT1_2 are generated 
from the gene locus. The primary NEAT1 transcript synthesised by RNA 
polymerase II is cleaved and polyadenylated through a canonical RNA 
processing pathway to generate NEAT1_1. In contrast, the tRNA-like structure 
at the 3’-end of the primary transcript is recognised and cleaved by RNase P, 
giving rise to a much longer NEAT1_2 with a triple helix structure at its 3’-end, 
which stabilises the transcript (Sunwoo et al. 2009, Brown et al. 2012, Wilusz
et al. 2012) (Figure 1.5). Hereafter, NEAT1 refers to both NEAT1_1 and 
NEAT1_2.
In vitro, both NEAT1 isoforms are expressed in the majority of cultured cells 
except embryonic stem cells (Chen and Carmichael 2009). In vivo, while 
NEAT1_1 is ubiquitously expressed in the majority of adult organs and 
tissues, NEAT1_2 is only present in certain types of cells, such as epithelial 
cells in the digestive tract (Nakagawa et al. 2011). Both isoforms are hardly 
detectable in the developing mouse embryo, suggesting their limited function 
during mammalian embryogenesis (Nakagawa et al. 2011). 
Human and mouse postmitotic neurons cultured in vitro express a very low 
level of NEAT1_2, and NEAT1_2 is barely expressed in the adult nervous 
system (Nakagawa et al. 2011, Bluthgen et al. 2017, Shelkovnikova et al.
2018). Therefore, the bulk of NEAT1 gene expression in the nervous system 
is attributable to NEAT1_1. NEAT1 levels are low in the progenitors of 
neurons or oligodendrocytes, however, as they differentiate, NEAT1 becomes 
upregulated (Mercer et al. 2010).
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Figure 1.5 NEAT1 gene produces two NEAT1 isoforms.
A schematic illustration of NEAT1 gene and two transcript isoforms generated from it. 
NEAT1 primary transcript transcribed from NEAT1 locus gives rise to two isoforms 
through two distinct processing pathways: NEAT1_1 is generated through canonical 
cleavage and polyadenylation, whereas NEAT1_2 is generated by Rnase P 
cleavage. A triple helix structure at the 3’ end of NEAT1_2 stabilises the transcript. 
The triple helical structure is enlarged to show how two U-rich motifs (green) and A-
rich tract (purple) interact to form triple helix (Brown et al. 2012).
1.2.2.2. Paraspeckles
What makes lncRNA NEAT1 truly unique is that it has a nuclear body of its 
own – the paraspeckle. Paraspeckles are located in the interchromatin space, 
usually adjacent to the splicing speckles (Andersen et al. 2002, Fox et al.
2002). NET1_2 is an essential component of paraspeckles, and multiple 
copies of NEAT1_2 transcripts line up to build a scaffold for protein and RNA 
components (Clemson et al. 2009, Fox and Lamond 2010, Naganuma et al.
2012, Yamazaki and Hirose 2015) (Figure 1.6). Paraspeckle assembly is 
strictly dependent on RNA polymerase II transcription of NEAT1_2 and on the 
binding of paraspeckle proteins to NEAT1_2 (Mao et al. 2011). Although not 
essential, NEAT1_1 is also a component of paraspeckles and is hardly 
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present outside these structures (Naganuma et al. 2012). Nevertheless, since 
NEAT1_1 is highly expressed in the cell types devoid of paraspeckles 
(Nakagawa et al. 2011), it likely has a range of paraspeckle-independent 
functions.
More than 60 paraspeckle proteins have been identified, and the majority are 
RBPs (Naganuma et al. 2012). Some of them bind to NEAT1_2 to stabilise it 
(SFPQ, NONO, RBM14), and some maintain secondary structure of 
paraspeckles (FUS, DAZAP1), whereas others (CPSF6, NUDT21) regulate
the ratio of the two NEAT1 isoforms. Presence of prion-like domain is the 
common feature of paraspeckle proteins important for liquid-liquid phase 
separation (LLPS), a phenomenon when a mixture of molecules forms a 
network of multivalent weak interactions. These molecules concentrate and 
separate from the surrounding molecules to form a distinct phase (Protter and 
Parker 2016). Prion-like domains are important for paraspeckle formation
(Hennig et al. 2015, Yamazaki et al. 2018). For example, disruption of the 
prion-like domain of FUS or RBM14 is sufficient to disassemble paraspeckles 
(Shelkovnikova et al. 2014b, Hennig et al. 2015). 
Figure 1.6 Paraspeckles
A) NEAT1_2 and an essential paraspeckle protein NONO colocalise within the 
paraspeckles. The average size of paraspeckles is 0.5–1 µm in diameter. The scale 
bar is 5 μm. B) Structural organisation of paraspeckles. On the cross section, 
NEAT1_2 transcripts folded end-to-end are arranged in a circle to form the scaffold 
for other paraspeckle components. The middle region of NEAT1_2 transcripts and 
essential paraspeckle proteins comprise the stable “core”, while the 3’ and 5’-ends of 
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NEAT1_2, together with NEAT1_1 and other paraspeckle components, make up the 
more labile “shell”. This figure was adapted from (Lin et al. 2018).
Compared to the paraspeckle proteome, less is known about its RNA 
components. In addition to NEAT1_1, which is the second most abundant 
paraspeckle RNA following NEAT1_2, two classes of RNA species have also 
been reported to be enriched within paraspeckles, namely Adenosine-to-
Inosine (A-to-I hereafter) edited transcripts (Chen et al. 2008) and 
miscellaneous AG-rich RNAs (West et al. 2016). Recently, mRNAs encoding 
mitochondrial proteins (Wang et al. 2018b) as well as pri-miRNAs being 
processed by the Microprocessor (Jiang et al. 2017) have also been found to 
be retained in the paraspeckles. 
Studies using electron and super-resolution microscopy have revealed the 3D 
arrangement of NEAT1_2 within paraspeckles and the characteristic “core-
shell” structure of paraspeckles (Souquere et al. 2010, West et al. 2016, Fox
et al. 2018) (Figure 1.6). Computational analysis has suggested that long-
range interactions, but not sequence conservation, are required for the 
structural function of NEAT1_2 (Lin et al. 2018), with the repeat-rich middle 
region of NEAT1_2 being essential for paraspeckle assembly (Yamazaki et al.
2018).
Paraspeckles are stress-responsive nuclear bodies and various physiological 
and pathological stimuli, such as viral infection (Saha et al. 2006), 
differentiation (Sunwoo et al. 2009) and proteasome inhibition (Hirose et al.
2014), can upregulate NEAT1_2 expression, and increase paraspeckle 
number and size. The physiological functions of paraspeckles discovered so 
far are as follows: i) Retention of A-to-I hyper-edited RNAs within the nucleus 
and rapidly release them to the cytoplasm for translation during stress, 
thereby regulating stress response (Prasanth et al. 2005, Chen et al. 2008, 
Chen and Carmichael 2009); ii) transcriptional regulation by sequestering 
important regulatory factors, such as splicing factor proline and glutamine rich 
(SFPQ) (Hirose et al. 2014, Imamura et al. 2014); iii) modulation of pri-miRNA 
processing (Jiang et al. 2017).
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1.2.3. Paraspeckles and ALS
1.2.3.1. Evidence of paraspeckle dysregulation in ALS
Post-mortem studies in ALS/FTLD patients have demonstrated that 
neurodegeneration in ALS is accompanied by altered NEAT1 and paraspeckle 
abundance. The first report on NEAT1 dysregulation in ALS was published in 
2013, when paraspeckles were detected in spinal motor neurons in a subset 
of sALS patients (Nishimoto et al. 2013). Considering the fact that motor 
neurons are generally devoid of NEAT1_2 under physiological conditions
(Nakagawa et al. 2011), this finding was somewhat unexpected. 
Subsequently, a study in a different cohort of sALS patients also confirmed 
hyper-assembly of paraspeckles in spinal motor neurons (Shelkovnikova et al.
2018). Moreover, this phenomenon was also observed in ALS-C9 and ALS-
TDP cases, suggesting that paraspeckle hyper-assembly is a common 
pathological feature of ALS cases with different aetiology (Shelkovnikova et al.
2018).
Genetic evidence also points to the strong association between 
NEAT1/paraspeckles and ALS pathogenesis. Among ~25 proteins genetically 
linked to ALS/FTLD, eight proteins, namely, FUS, TDP-43, SFPQ, hnRNPA1, 
EWS, TAF15, CREST and matrin3,  are paraspeckle proteins, and some of 
them regulate NEAT1 levels and paraspeckle assembly (Naganuma et al.
2012, Shelkovnikova et al. 2014b, Banerjee et al. 2017, Shelkovnikova et al.
2018) (Table 1.2). 
TDP-43 is known to bind NEAT1 (Polymenidou et al. 2011, Tollervey et al.
2011) and its depletion in cultured cells stimulates NEAT1_2 accumulation 
and paraspeckle assembly (Shelkovnikova et al. 2018). TDP-43 protein 
cytoplasmic aggregation and concomitant nuclear depletion occur in about 
95% of sALS cases, thus enhanced paraspeckle assembly in the spinal cord 
of ALS patients is most likely caused by TDP-43 loss of function in the nucleus 
(Shelkovnikova et al. 2018). Similarly, FUS protein loss of function in the 
nucleus, due to the mutations and/or abnormal aggregation in the cytoplasm, 
also affects paraspeckle functions by perturbing their higher-order structure
(West et al. 2016). 
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ALS-associated mutant proteins also compromise paraspeckle structure and 
function through a gain of function mechanism. Pathological aggregates 
formed by mutant FUS are found to sequester paraspeckle proteins that can 
directly regulate NEAT1 levels, such as NONO (Shelkovnikova et al. 2014b). 
Likewise, nuclear aggregates containing mutant CREST can entrap FUS 
(Kukharsky et al. 2015). Moreover, pathological nuclear RNA foci formed by 
C9orf72 hexanucleotide repeat expansions also retain paraspeckle proteins, 
such as TDP-43, hnRNPK and EWS (Lee et al. 2013). 
Compared to ALS, evidence of NEAT1 dysregulation in FTLD is scarce. Two 
research groups reported upregulated NEAT1 levels in the brain of FTLD 
patients (Tollervey et al. 2011, Tsuiji et al. 2013). According to the 
unpublished observations of our group, unlike in ALS spinal cord, NEAT1_2 
upregulation and paraspeckle formation is not typical for the frontal cortex in 
FTLD.
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Table 1.2 Paraspeckle proteins genetically associated with ALS
Protein
Importance for paraspeckle 
assembly
Regulation 
of NEAT1_2 
levels
Role in ALS
Role in other 
neurodegenerative 
diseases
FUS
Essential, >75% loss upon 
knockdown (Naganuma et al. 2012, 
Shelkovnikova et al. 2014b)
No or minimal
>50 mutations in fALS and sALS 
(Deng et al. 2010, Lattante et al. 2013)
FTLD (FTLD-FUS) 
(Neumann et al.
2009)
TDP-43
Depletion enhances paraspeckle 
assembly (Shelkovnikova et al.
2018)
Yes (more 
NEAT1_2 
upon TDP-43 
depletion) 
>60 mutations in fALS and sALS; TDP-
43 proteinopathy in cases with TDP-43 
mutations and in 95% of all sALS 
cases (Neumann et al. 2006, 
Mackenzie et al. 2010b, Lattante et al.
2013)
FTLD (FTLD-TDP) 
(Neumann et al.
2006); AD (Wilson et 
al. 2011)
TAF15
Important, 30-75% loss upon 
knockdown (Naganuma et al. 2012)
No 
6 mutations in 6 unrelated sALS cases 
and 2 mutations – in 2 fALS cases 
(Couthouis et al. 2011, Ticozzi et al.
2011)
FTLD (FTLD-FUS) 
(Neumann et al.
2011)
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EWS
Important, 30-75% loss upon 
knockdown (Naganuma, Nakagawa 
et al. 2012)
yes
2 mutations in 2 unrelated sALS 
cases (Couthouis, Hart et al. 2012)
FTLD (FTLD-FUS) 
(Neumann, Bentmann et 
al. 2011)
hnRNPA1
Important, 30-75% loss upon 
knockdown (Naganuma et al. 2012)
No
2 mutations in fALS cases; 2 rare 
variants (Kim et al. 2013, Liu et al.
2016)
Multisystem 
proteinopathy (MSP)
(Kim et al. 2013)
CREST** ND ND
4 mutations in 4 unrelated sALS 
cases (Chesi, Staahl et al. 2013, 
Teyssou, Vandenberghe et al. 2014)
N/A
MATR3
Depletion enhances paraspeckle 
assembly (Banerjee et al. 2017)
Yes (more 
NEAT1_2 
upon MATR3 
depletion) 
~10 mutations in fALS and sALS 
cases (Johnson et al. 2014, Leblond
et al. 2016)
Initially diagnosed 
myopathy with vocal 
cord paralysis, diagnosis 
changed to ‘ALS’ 
(Senderek et al. 2009)
SFPQ
Essential, >75% loss upon 
knockdown (Naganuma et al. 2012)
Yes
2 mutations in 2 sALS cases 
(Thomas-Jinu et al. 2017)
N/A
** CREST is a neuro-specific protein, therefore its effect on paraspeckles in stable cell lines could not be tested.
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1.2.3.2. Paraspeckles and ALS pathomechanisms
i Proteasome dysfunction
Collapse of proteostasis is the most apparent pathological mechanism 
underlying ALS/FTLD, and dysfunctional UPS and autophagosome-lysosome 
systems are the main culprits responsible. Proteasome inhibition is a well-
known trigger of NEAT1 upregulation and paraspeckle hyper-assembly 
(Hirose et al. 2014). Both NEAT1 isoforms increased in cells treated with 
proteasome inhibitors, such as bortezomib or MG132. Paraspeckle 
enlargement causes excessive protein retention within the structure, resulting 
in up to 50% depletion of the nuclear pool of paraspeckle proteins, many of 
which are transcription regulators. Therefore, the augmented paraspeckle 
assembly under these conditions could potentially have a profound effect on 
the gene expression profile. However, how exactly the dysfunctional 
proteasome system signals to NEAT1 and paraspeckles is not clear. NEAT1 
is known to have a heat shock responsive element within its promoter region, 
and induction of heat shock transcription factor 1 (HSF1) has been shown to 
upregulate NEAT1 expression (Lellahi et al. 2018). Therefore, accumulation of 
HSF1 due to its impaired clearance (Raychaudhuri et al. 2014) can at least 
partly explain the NEAT1 upregulation under proteasome inhibition. 
ii miRNA biogenesis
Altered miRNA expression in the CNS is known to contribute to neuronal 
damage. Several paraspeckle proteins, such as SFPQ, NONO, FUS, TDP-43, 
and EWS, have established functions in the regulation of the miRNA pathway 
(Kawahara and Mieda-Sato 2012, Morlando et al. 2012, Bottini et al. 2017, 
Ouyang et al. 2017). A recent study reported that paraspeckle components, 
NEAT1 and SFPQ-NONO heterodimer, act to enhance global miRNA 
biogenesis by binding to pri-miRNA molecules and attracting the 
Microprocessor complexes (Jiang et al. 2017). The role for NEAT1_1 in this 
process is less known, however, it may potentiate NEAT1_2 function. It 
remains to be established whether NEAT1_1, in the absence of NEAT1_2, 
contributes to miRNA biogenesis in neurons.
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iii Neuroinflammation
Neuroinflammation, caused by the activation and proliferation of resident 
immune cells in the nervous system, is believed to play a role in ALS/FTLD. 
Initially discovered as a virus-inducible RNA in the brain (Saha et al. 2006), 
NEAT1 is heavily involved in the antiviral immunity (Zhang et al. 2013a, 
Imamura et al. 2014). During RNA virus infection, paraspeckles sequester 
SFPQ away from the promoters of genes encoding cytokines and 
chemokines, such as interleukin 8 (IL8) or C-C motif chemokine ligand 5 
(CCL5), thereby alleviating the inhibitory effect of SFPQ upon these genes 
(Imamura et al. 2014). Endogenous double-stranded RNA (dsRNA) 
accumulation can also induce NEAT1 upregulation and paraspeckle assembly 
in cultured cell lines (Shelkovnikova et al. 2018). NEAT1 responds to foreign 
DNAs as well. Upon double-stranded (dsDNA) exposure, NEAT1 activates 
cGAS-STING-IRF3 pathway and interferon signalling through its binding to the 
HEXIM P-TEFb complex subunit 1 (HEXIM1) protein (Morchikh et al. 2017). 
Bacterial infection can also stimulate NEAT1 expression, which promotes the 
expression of chemokines and cytokines, such as interleukin 6 (IL6) and C-X-
C motif chemokine ligand 10 (CXCL10), in human monocytic cells (Zhang et 
al. 2017). 
iv Cell death
Programmed cell death including apoptosis and necroptosis is the primary 
cause of neuron loss in ALS/FTLD (Su et al. 2000, Sathasivam et al. 2001, Re
et al. 2014). NEAT1 knockout in mouse fibroblasts rendered them more 
sensitive to cell death upon proteasome inhibition (Hirose et al. 2014). 
Similarly, downregulation of NEAT1 potentiated dsRNA toxicity in human cells 
(Shelkovnikova et al. 2018). Furthermore, NEAT1 protected cells against 
apoptosis under oxygen and/or glucose deprivation (Choudhry et al. 2015, 
Zhong et al. 2017). These studies suggested that paraspeckle assembly 
downstream of increased NEAT1_2 expression is responsible for the 
protection against cell death by sequestrating transcription factors to regulate 
gene expression (Hirose et al. 2014, Choudhry et al. 2015) or by regulating 
miRNA biogenesis (Shelkovnikova et al. 2018). Whether upregulated 
NEAT1_1 also plays anti-apoptotic roles or is merely a bystander needs 
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further investigation. The levels of p53 protein, which is one of the key factors 
in cellular apoptosis, are increased in affected regions of the CNS both in 
patients and in disease models of neurodegenerative diseases, including ALS 
(Martin 2000, Chang et al. 2012). Interestingly, NEAT1 expression can be 
stimulated by p53 (Adriaens et al. 2016, Mello et al. 2017). While much is 
known on the interplay between p53 and NEAT1 in the context of cancer, 
limited information is available on their interaction in the CNS. Precise 
molecular mechanisms that underlie the co-operation of NEAT1 and apoptotic 
pathways still remain to be elucidated. 
v Neuronal excitability
Increased excitability in upper and lower motor neurons is one of the early 
disease signs in ALS (Vucic et al. 2008), and has been considered as a 
possible disease mechanism (Saxena and Caroni 2011). NEAT1 expression 
in human brain is activity-dependent – it is expressed in the high-spiking 
“active” regions in the CNS and it is responsive to neuronal depolarisation 
(Lipovich et al. 2012, Barry et al. 2017). NEAT1 depletion in cultured human 
neurons resulted in significant increase in the expression of ion channel 
components, suggesting that NEAT1 might negatively regulate neuronal 
excitability by controlling transcription of this class of genes (Barry et al. 2017). 
In addition, NEAT1 can also directly bind to potassium voltage-gated channel 
subfamily A regulatory beta subunit 2 (KCNAB2), a potassium channel-
interacting protein that is important in controlling excitability of neurons (Barry
et al. 2017). Upon depolarisation, NEAT1 is acutely downregulated to aid the 
cytoplasmic translocation of KCNAB2, where the latter modulates excitatory 
response via interacting with membrane channels (Barry et al. 2017). 
1.2.4. Stress granules
1.2.4.1. Stress granules: structure
SGs are large cytoplasmic RNP granules that form in response to translational 
arrest due to various cellular stresses (Anderson and Kedersha 2009b, 
Buchan and Parker 2009). In mammalian cells, their size ranges from 0.1 to 
0.2 μm, and their main components include polyadenylated mRNA, PABP, 
translation initiation factors, small ribosome subunits and a number of RBPs 
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(Loschi et al. 2009). Protein composition of SGs depends on many factors 
including cell type and the nature and duration of stress (Anderson and 
Kedersha 2009b). Stressors known to induce SG assembly are oxidative 
stress, ER stress, viral infection, hyperosmolarity, heat shock, hypoxia, UV 
irradiation, among others. Some physical stresses, such as X-irradiation and 
DNA-damaging agents, do not induce SGs (Anderson and Kedersha 2009b). 
When the stress is sensed by one of four kinases, namely protein kinase R 
(PKR), heme-regulated eIF2α kinase (HRI), general control nonderepressible 
2 (GCN2), and PKR-like ER kinase (PERK), the kinase becomes activated, 
and its activated form phosphorylates eukaryotic translation initiation factor 2α 
(eIF2α), thereby initiating the molecular cascade leading to SG assembly 
(McCormick and Khaperskyy 2017). Different stress types activate different 
kinases. For example, dsRNA, ER stress, oxidative stress and nutrient 
starvation activate PKR, PERK, HRI and GCN2, respectively (Anderson and 
Kedersha 2009b). Phosphorylation of eIF2α results in translation arrest by 
blocking the recruitment of large ribosomal subunit, leading to the
accumulation of stalled 48S mRNPs. This exposes polysome-free mRNAs to 
RBPs, such as TIA1, TIA1-related protein (TIAR) and RAS GTPase-activating 
protein SH3 domain-binding protein 1 (G3BP1) (McCormick and Khaperskyy 
2017). These proteins and many other SG proteins are known to possess low-
complexity, intrinsically disordered domains (IDRs), and binding to RNA 
triggers their rapid aggregation. Small mRNP aggregates further and fuse to 
form mature, large SGs that concentrate hundreds of proteins and RNAs 
(Tourriere et al. 2003, Gilks et al. 2004, Kedersha et al. 2013). There also 
exists an eIF2α-independent way of inducing translational arrest through 
inhibition of the mammalian target of rapamycin (mTOR), which blocks the 
formation of translation initiation complex. However, translation arrest induced 
by this pathway does not promote stress granule formation (McCormick and 
Khaperskyy 2017). 
SGs that are induced by different stresses assemble through different 
pathways, and therefore their composition varies. For example, self-interaction 
of G3BP1 and a closely related protein G3BP2 is important in SG assembly 
upon oxidative stress. However, they are not required for SG formation under 
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osmotic stress (Tourriere et al. 2003, Kedersha et al. 2016). Similarly, yeast 
proteins Gtr1, Rps1b and Hgb1 promote SG formation under glucose 
starvation, whereas under heat shock conditions they suppress SG assembly 
(Yang et al. 2014). 
SGs could also be induced by pharmacologically inhibiting translation initiation 
or by depleting translation initiation factors or even by overexpressing certain 
RBPs (Anderson and Kedersha 2008). For example, overexpression of TIA1 
and TIAR induces SG assembly in the absence of stress (Kedersha et al.
1999).
Since persistence of SGs requires constant influx of translationally stalled 
mRNPs, drugs like cycloheximide and emetine that inhibit translation 
elongation and thus trap mRNA in polysomes, dissolve SGs (Kedersha et al.
2000, Brengues et al. 2005, McCormick and Khaperskyy 2017). 
SGs are highly dynamic structures that exhibit liquid-like behaviour – they 
“flow” freely in the cytoplasm, undergo fusion like liquid droplets and 
continuously and rapidly exchange components with the rest of the cytoplasm. 
SGs disassemble very quickly after stress is removed, which typically takes 20 
– 60 min (Kedersha et al. 2005, Buchan and Parker 2009, McCormick and 
Khaperskyy 2017). These properties are found to be dependent on adenosine 
triphosphate (ATP), as impaired ATP production is shown to eliminate SG 
movement and diminish the recovery of G3BP1 after photobleaching (Jain et 
al. 2016). 
Studies using super-resolution microscopy have revealed the complex 3D 
structure of SGs. Instead of being a uniform structure, each SG is composed 
of a cluster of sub-structures, where a dense and less dynamic core is 
surrounded by a relatively loose and more dynamic shell (Jain et al. 2016). 
These cores can be biochemically purified, and proteomic analysis has found 
that over half of SG core proteins are RBPs (Jain et al. 2016). Due to the 
dynamic and liquid-like biophysical properties of SGs, it is plausible that they 
are formed, at least partly, by LLPS. Although it is still unclear whether 
intermolecular interactions or LLPS is the main force driving SG assembly, 
currently the widely accepted model is as follows: In the cytoplasm, 
translationally stalled mRNPs first concentrate into core structures through 
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strong RNA-protein, protein-protein interactions as described previously. 
Subsequently, as these cores grow by joining of other cores, the high local 
concentration of IDRs within these structures trigger LLPS, thereby forming 
the dynamic shell structure surrounding the cores (Jain et al. 2016). 
Once the stress is resolved, SGs disappear either by passive disassembly or 
by autophagic clearance (Buchan et al. 2013). Persistence of SGs due to their 
increased stability or impaired autophagy is believed to increase the 
susceptibility of IDR-containing protein components to aggregation. These 
persistent granules might become seeds for non-reversible protein deposits 
causative for neurodegenerative diseases, including ALS and FTLD (Li et al.
2013, Ramaswami et al. 2013).
1.2.4.2. Stress granules: function
As a conserved protective mechanism of eukaryotic cells against 
environmental stress, SGs play central roles in cell survival and recovery. 
Cells expressing mutant form of eIF2α that is non-phosphorylatable cannot 
form SGs in response to sodium arsenite-induced oxidative stress and show 
increased sensitivity to low doses of arsenite (Anderson and Kedersha 
2009b). 
During stress, bulk protein synthesis shut-off helps limit energy consumption, 
however, mRNAs encoding proteins that play key roles in survival still must be 
translated. SGs help re-programme protein expression towards cell survival by 
sequestering 'housekeeping' transcripts for silencing while excluding mRNAs 
that encode molecular chaperones and repair enzymes to allow their 
preferential translation (Anderson and Kedersha 2009b). For example, 
transcripts that encode heat shock proteins (HSP), such as HSP70 and 
HSP90, are selectively excluded from SGs (Kedersha and Anderson 2002). In 
addition, SGs facilitate cell survival by recruiting pro-apoptotic proteins, 
including Receptor For Activated C Kinase 1 (RACK1), 2-Oxoglutarate And 
Iron Dependent Oxygenase Domain Containing 1 (OGFOD1), as well as cell 
growth regulators angiogenin and caprin-1 (Droppelmann et al. 2014).
SGs also participate in dynamic RNA triage under stress conditions by 
interacting with P bodies. P bodies are constitutive RNP granules that are 
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further induced by stress. Unlike SGs, P bodies represent sites of mRNA 
degradation by mediating mRNA decay including NMD and RNA interference 
(Jain and Parker 2013). The ultimate purpose of SG and P body assembly in 
eukaryotic cells is to collect untranslated mRNAs that exceed the capacity of 
the translation and/or decay machineries (Anderson and Kedersha 2009b). 
SGs and P bodies are found to actively interact to facilitate the exchange of 
RNA and protein components. This interaction helps to sort RNA molecules 
for storage, translation or degradation, thereby maintaining RNA homeostasis 
during stress attack (Anderson and Kedersha 2008, Li et al. 2013) (Figure 
1.7). 
Figure 1.7 Stress granules and P bodies participate in RNA triage during stress
Stress granules and P bodies play important roles for RNA sorting, storage and 
degradation during stress and recovery. When stress triggers translation arrest, non-
translating mRNAs are recruited into stress granules and P bodies. Although formed 
and regulated independently, stress granules and P bodies often exchange 
components through “docking” to each other. RNAs recruited into P bodies are 
targeted for degradation. When stress resolves, mRNAs in stress granules are 
released for translation. This figure is modified from (Li et al. 2013). 
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SGs exert their functions via two routes: i) by bringing together various SG 
components, it helps shift the equilibriums of interacting molecules towards 
associated states, thus, facilitates their interactions; ii) by sequestering various 
proteins and RNAs leading to their depletion from the sites of their normal 
function (Protter and Parker 2016). These mechanisms of action can be 
illustrated very well using the case of viral infection.
Antiviral immunity is one of the most studied functions of SGs. Their assembly 
blocks viral replication and helps cells fight against the virus while supporting 
cell survival. Firstly, translation arrest provides very early protection by 
blocking viral protein synthesis before the expression of antiviral genes of 
infected cells commences (McCormick and Khaperskyy 2017). Secondly, SGs 
recruit viral sensors and signalling proteins thereby modulating host signalling 
cascade. On one hand, it provides a platform to enhance virus recognition and 
antiviral signal transduction by putting together innate immune sensors and 
RNA/protein ligands (Onomoto et al. 2012). On the other hand, it suppresses 
the pro-apoptotic signalling cascade downstream of tumour necrosis factor 
(TNF) activation by sequestering TNF receptor-associated factor 2 (TRAF2) to 
prevent cell death (Kim et al. 2005). Finally, SGs could also trap viral factors 
preventing them from participating in the normal viral replication cycle 
(McCormick and Khaperskyy 2017). 
Proteomic analysis of biochemically purified SG cores found that non-RNA 
binding SG proteins include post-translational modification enzymes, 
metabolic enzymes, and protein/RNA remodelling complexes, i.e. the key 
components of signalling pathways (Jain et al. 2016). SGs also contain the 
Argonaute family proteins and miRNAs, mRNA-editing enzymes and RNAs 
and proteins required for transposon activity, such as RNA from LINE1 
retrotransposons and its protein product ORF1 as well as reverse 
transcriptase (Anderson and Kedersha 2009a, Anderson and Kedersha 
2009b).
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1.2.5. Stress granules and ALS molecular pathology
SGs and ALS pathology are strongly linked. Firstly, pathological inclusions 
found in neurons and glial cells of ALS and FTLD patients show 
immunoreactivity for core SG proteins, such as TIAR or TIA1 (Liu-Yesucevitz
et al. 2010). Secondly, 70% of ALS-associated genes encode proteins that are 
recruited into SGs upon stress, such as TDP-43, FUS, hnRNPA1, hnRNPA2, 
TAF15 and VCP (reviewed in (Aulas and Vande Velde 2015)). Finally, 
pathogenic mutant proteins encoded by some of ALS-associated genes could 
form constitutive cytoplasmic assemblies containing SG proteins in cultured 
cells in the absence of cellular stress (Liu-Yesucevitz et al. 2010, Wolozin 
2012, Shelkovnikova et al. 2014a). 
As already mentioned, TDP-43 and FUS are among the most frequently 
dysregulated proteins in ALS and FTLD pathology. Although they are 
predominantly nuclear proteins, they shuttle rapidly between the nucleus and 
cytoplasm for the transport of mRNA (Zinszner et al. 1997). Interestingly, upon 
various cellular stresses, a small amount of nuclear TDP-43 and FUS shuttle 
to the cytoplasm and incorporate into SGs. When the stress is resolved and 
SGs disassemble, they return to the nucleus (Ayala et al. 2008, Dormann et 
al. 2010). Therefore, TDP-43 and FUS are normal SG components and their 
recruitment is a physiological and reversible process. 
However, cells expressing mutant TDP-43 show attenuated SG assembly and 
increased propensity to form abnormal SGs (Liu-Yesucevitz et al. 2010, 
McDonald et al. 2011). Moreover, TDP-43 mutation can cause persistent 
cytoplasmic aggregation and/or SGs after the stress is resolved (Liu-
Yesucevitz et al. 2010). Similarly, cells expressing FUS mutants display 
delayed SG formation under oxidative stress, and the extent of delay is 
correlated with the cytoplasmic level of mutant FUS. Mutant FUS incorporation 
also increases the size and abundance of SGs, and alters the dynamics of the 
SGs. However, unlike TDP-43, mutant FUS accelerates SG disassembly 
following removal of stress (Baron et al. 2013). Existing experimental evidence 
supports two non-mutually exclusive models of the effect ALS mutants have 
on SGs. 
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The gain of function model implies that ALS-linked mutant proteins acquire a 
novel toxic function within SGs. According to this model, as mutant TDP-43 
and FUS are more prone to localise to SGs than their WT forms (Bosco et al.
2010, Dormann et al. 2010), their excessive localisation within SGs results in 
increased local concentration of IDRs, raising the risk of insoluble fibrillary 
aggregates formation (Bosco et al. 2010, Dormann et al. 2010, Liu-Yesucevitz
et al. 2010, Wolozin 2012). In addition, incorporation of mutant proteins might 
change the protein-protein and protein-RNA interaction network within SGs, 
which would further lead to changes in SG dynamics and function. For 
example, abnormal SGs interfere with the localisation of mRNPs that are 
required for RNA sorting and processing, resulting in compromised RNA 
homeostasis during stress (Johnson et al. 2009, Sun et al. 2011, Baron et al.
2013). Moreover, altered SGs might also diminish the localisation of internal 
ribosome entry site (IRES)-containing mRNAs thereby inhibiting translation of 
anti-apoptotic factors and proliferative factors essential for cell survival (Li et 
al. 2013). Intriguingly, mutant TDP-43 and FUS that are incompetent in RNA 
binding show significantly reduced toxicity without affecting their aggregation 
(Elden et al. 2010, Voigt et al. 2010, Sun et al. 2011, Daigle et al. 2013),
suggesting that protein aggregation alone is not sufficient to cause cellular 
toxicity. Interacting with RNA might cause TDP-43 or FUS change their 
conformation to a toxic form that will aggregate more. Alternatively, RNA-
binding activity of TDP-43 and FUS may allow entrapment of RNAs and 
proteins that are essential for cell survival.  
The loss of function model argues that absence of normal TDP-43 or FUS 
disrupts SG assembly and turnover. Knockdown of TDP-43 by siRNA in HeLa 
cells and neuroblastoma cells affected SG assembly and disassembly as 
evidenced by delayed formation, reduced average size, decreased stability 
and quicker disassembly upon the removal of stress, partly resembling the 
phenotype caused by mutant TDP-43 expression (McDonald et al. 2011, 
Aulas et al. 2012). Therefore, it is possible that ALS-linked mutations in TDP-
43 impair protein-protein or protein-RNA interactions of SG components, 
which are essential for SG formation, maintenance, clearance and, ultimately 
function. In contrast, knockdown of FUS in HeLa cells or in HEK-293 cells had 
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no impact on SG assembly under oxidative stress (Aulas et al. 2012), 
suggesting that FUS might not be an essential SG component. 
In conclusion, ALS-associated mutant proteins can alter dynamics and 
function of SGs, and persistent SGs and possibly inadequate stress response 
are important mechanisms underlying ALS pathogenesis.
1.2.6. Stress granules vs. pathological RNP granules formed 
by mutant FUS
As described above, persistent SGs are thought to be the “seeds” of 
pathological inclusions found in degenerating neurons in ALS. However, for 
FUS, it has been shown that when mutated, this protein can initiate the 
assembly of a novel type of RNP granule, distinct from the SG. 
Mutant FUS accumulated in the cytoplasm can form small granules (termed 
FUS granules, or FGs) spontaneously when FUS level reaches a certain 
threshold (Shelkovnikova et al. 2014a). This was shown both in non-neuronal 
cultured cell lines and in primary neurons. When the cells are exposed to 
stress, unlike diffuse FUS protein that are recruited into SGs, preformed FGs 
further cluster to form large aggregates (FUS aggregates, FAs), which also 
contain SG proteins and require RNA as a structural component. However, 
high-resolution microscopy showed that while SGs are characterised by 
compact appearance with “smooth” surface, FAs appear as non-compact, 
irregularly shaped collection of small granules. Furthermore, FAs often 
undergo further aggregation to form larger structures, which is not typical for 
mature SGs. Importantly, a subset of FAs are negative for SG proteins that 
are essential for SG formation, suggesting that they are dispensable during 
FA biogenesis. Moreover, the ribosomal protein S6, a component of pre-
initiation complex which builds SGs, is absent from FAs (Shelkovnikova et al.
2014a). Therefore, mutant FUS can form a pathological RNP granule different 
from SGs in composition, organisation and dynamics.
Interestingly, since RNA is essential for FA maintenance, depletion of free 
RNA due to the transcriptional arrest resulted in their disassembly. However, 
50
upon prolonged transcriptional repression, solubilised mutant FUS 
reassembled into insoluble aggregates that do not require free RNA 
(Shelkovnikova et al. 2014a). Likewise, it has been reported that C-terminally 
truncated FUS protein lacking RNA-binding domains can spontaneously 
assemble into aggresomes under basal condition (Shelkovnikova et al.
2013b). These aggresomes morphologically resemble FAs formed under 
persistent transcriptional arrest described above. In agreement with these 
findings, it has been reported recently that high RNA concentration keeps 
RBPs, including FUS, soluble while depletion of RNA promotes excessive 
phase separation (Maharana et al. 2018). In a nutshell, cytoplasmically 
mislocalised FUS protein, if accumulated beyond a certain threshold, can form 
irreversible aggregates when free RNA is not available or the protein is 
incapable of RNA binding. Importantly, RNA binding and subsequent 
recruitment into SGs is shown to prevent cytoplasmic FUS from forming 
aggresomes (Shelkovnikova et al. 2013b), suggesting that SG assembly is a 
protective mechanism against the development of FUSopathy. It is observed 
in cultured cells that the presence of FGs or FAs perturbs the assembly of 
SGs by competing for their shared protein and RNA components, which will 
compromise the protective SG function.
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1.3. Aims
Our understanding of the pathomechanisms underlying ALS-FUS has 
increased greatly since the discovery of the causative link between FUS gene 
mutation and ALS. Now it is clear that mutant FUS protein mislocalises to the 
cytoplasm where it forms insoluble aggregates – a pathological hallmark of 
FUSopathy. Both nuclear loss of function and cytoplasmic gain of function of 
FUS protein are considered to contribute to the disease development, hence
understanding the behaviour of mutant FUS protein both in the nucleus and in
the cytoplasm is crucial in understanding the disease mechanisms.
As described in the previous chapter, FUS is an important component of 
nuclear paraspeckles, a structure deeply implicated in ALS. Although it is 
known that FUS knockout compromises paraspeckle integrity, it is not clear 
how mutant FUS present in the nucleus (as in ALS-FUS patient cells) affect 
their structure and function. Since NEAT1 level is very sensitive to FUS 
protein levels, existing cellular models overexpressing mutant FUS protein is 
not ideal for paraspeckle studies. The advent of CRISPR/Cas9 gene editing 
technology has allowed us to study paraspeckles in the cells expressing 
mutant FUS at physiological levels. Therefore, the aims of the first part of the 
thesis are:
1) Generate and characterise stable human cell lines with FUS gene 
modifications (Chapter 3).
2) Investigate the pathological impact of mutant FUS protein on 
paraspeckle structure and function using cellular models generated
(Chapter 4).
To achieve the first aim, a region of FUS gene encoding NLS domain of FUS 
protein, where most ALS-causing mutations occur, was deleted (or completely 
disrupted) by CRISPR/Cas9. Single-cell clones with desired modifications 
were generated and characterised in terms of FUS gene sequence, FUS 
protein subcellular localisation, FUS mRNA and protein expression levels etc..
For the second aim, NEAT1 levels and paraspeckle formation, the interaction 
between FUS protein and core paraspeckle components as well as
paraspeckle function were studied in mutant FUS clones established above.
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Results obtained from the cellular models were confirmed in fibroblasts and
spinal cord tissues from ALS-FUS patients. 
In addition to the pathological behaviour of mutant FUS protein in the nucleus, 
the thesis also explored the possible stresses that could possibly trigger the 
formation of insoluble FUS aggregates in the patient neurons. Since 
overexpressed FUS is highly prone to aggregate spontaneously, FUS clones 
expressing physiological levels of mutant FUS protein can be extremely 
valuable in this study. Therefore, the third aim of the thesis is:
3) Investigate the possible triggers of FUSopathy using cellular models 
generated (Chapter 5). 
For this, several neurodegeneration-relevant stresses were tested on FUS 
clones for their ability to trigger persisting FUS-positive cytoplasmic 
assemblies. Antiviral immune response induced by poly (I:C), a synthetic 
molecule mimicking viral dsRNA, emerged as a promising environmental 
trigger and other aspects of virus-induced FUSopathy were further studied. 
Finally, the thesis also aimed to study FUS truncation mutations focusing on 
the C-terminal peptide “tails” resulted from frameshift.
4) Investigate pathological roles of C-terminal peptide “tails” generated 
from FUS truncation mutations.
To this end, FLAG-tagged truncated FUS proteins with or without a “tail” were 
expressed in human SH-SY5Y neuroblastoma cells as well as in mouse 
hippocampal primary neurons to compare their subcellular distribution and 
aggregation. This is a preliminary study of a currently ongoing project in the 
lab, which should yield interesting results when studied further. 
Overall, this thesis aimed to provide important insight into the pathological 
functions of mutant FUS protein in the nucleus as well as into the nature of the 
environmental stress that could trigger or exacerbate FUSopathy.    
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Chapter 2. Materials and Methods
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2.1. Generation of stable cell lines with targeted 
modification of the FUS gene
2.1.1. Construction of plasmids carrying guide RNA 
sequence
pX330-U6-Chimeric_BB-CBh-hSpCas9 vector (pX330) (Addgene), which 
allows simultaneous expression of human codon-optimised SpCas9 and a 
chimeric guide RNA (gRNA), was selected, and the cloning was performed 
following the protocol provided by Addgene (https://www.addgene.org/), with
modifications. The vector map, structure of the chimeric gRNA and gRNA 
cloning site are shown in Figure 2.1. Locations of gRNA target sequences and 
how they have been selected are described in detail in section 3.2.1. 
Briefly, pX330 vector was linearised with FastDigest BbsI (ThermoScientific) 
and purified from the agarose gel using QIAquick Gel Extraction Kit (Qiagen) 
following the manufacturer’s instructions. Double-stranded DNA insertions 
containing gRNA sequence were synthesised (Sigma) as instructed by 
Addgene, and these insertions contained overhangs complementary to the 
overhangs on the digested pX330 vector. Ligation reaction was performed 
between digested vector and DNA insertions in the molar ratio of 1:10 using 
T4 DNA ligase (New England Bioloabs, NEB).
The ligated plasmids were delivered into chemically competent E. coli cells 
(NEB #C2987H) through transformation (protocol see below) and ampicillin-
resistant positive colonies were further amplified. Plasmid DNA from each 
positive colony was sequenced to verify the correct insertion of the target 
sequence using U6 primer. All the sequencing services for this project were 
provided by Eurofins and all the sequence analysis was carried out using ApE 
software.
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Figure 2.1 Construction of pX330 plasmid carrying guide RNA (gRNA)
sequence.
A) Simplified map of pX330 vector. This vector can express both gRNA and 
humanized S.pyogenes Cas9 (hSpCas9) under U6 promoter. B) The sequence of 
chimeric gRNA and its location in the pX330 vector is shown. gRNA is inserted into 
the site created by BbsI restriction endonuclease. CBh: chicken beta-actin promoter; 
NLS: nuclear localisation signal; bGHpA: bovine growth hormone polyadenylation 
signal. 
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2.1.2. Transfection and stable single-cell clone generation
Calcium phosphate transfection was used to deliver pX330 constructs into 
human neuroblastoma SH-SY5Y cells (ATCC line, Sigma). SH-SY5Y cells 
were chosen for their human origin, neuron-like properties and ease of 
maintenance. The day before transfection, SH-SY5Y cells were plated onto a 
35 mm dish at 50-60% density, and the culture medium was replaced by fresh 
medium 1 h prior to the transfection.
Reagents used for calcium transfection are given in Table 2.1. Solution A was 
90 μl 2X HEPES buffered saline (HBS), and solution B was a 90 μl mixture 
containing 3.6 μg pX330 constructs and 245 mM CaCl2. Solution B was added 
to solution A dropwise while the mixture was continuously agitated, and the 
mixture was applied on the surface of the culture medium evenly as small 
droplets. The dish was returned to the incubator overnight. 
Table 2.1 Components of the calcium phosphate transfection reagents
Solutions Components Final concentration
CaCl2 *
CaCl2 • 2H2O 2 M
H2O N/A
2X HBS (solution A) 
**
(pH=7.05)
HEPES 50 mM
NaCl 280 mM
Na2HPO4 • 7H2O 1.5 mM
H2O N/A
* filtered through 0.22 μm filter, stored at 4 °C. 
** filtered through 0.22 μm filter, stored at -20 °C, and defrosted at room temperature 
before use.
The culture medium was replaced by fresh medium at 24 h post-transfection, 
and cells were allowed to recover for 4 h. Cells were split onto 10 cm culture 
dishes at a density of ~ 200 cells/dish. After 2 weeks, single cell-derived 
colonies were picked by sterile 200p pipette tips, and transferred to 96-well 
plates for further expansion. When the cells reached ~ 70-80% confluency, 
colonies were screened by polymerase chain reaction (PCR) and 
immunostaining. Primers flanking the deleted region were used for PCR 
screening, and therefore, the presence of shorter PCR product relative to that 
from WT cells indicated gene editing (section 3.2.2). Immunostaining of FUS 
58
protein showed cytoplasmic mislocalisation due to the deletion/disruption of 
NLS or FUS protein absence, in FUS ΔNLS clones and FUS KO clones, 
respectively. Positive clones were further expanded and stored in liquid 
nitrogen in BAMBANKER™ serum free cell freezing medium (Lymphotec Inc). 
Schematic illustration of this protocol is available in Figure 2.2.
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Figure 2.2 Generation of stable single-cell-derived clones with FUS gene modification.
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2.2. Molecular biology and biochemical experiments
2.2.1. Molecular cloning
2.2.1.1. TOPO cloning
Zero Blunt® TOPO® vector (Life Technologies) was used for the sequencing 
of PCR fragments. PCR product extracted from the agarose gel was subjected 
to blunting reaction using DNA Polymerase I, Large (Klenow) Fragment (NEB) 
at room temperature for 30 min, in a solution supplemented with 0.1 mM 
dNTP (Sigma). Blunt-ended PCR product was cloned into TOPO® vector 
following the manufacturer’s instructions. Cloned vectors were delivered into 
chemically competent E. coli by transformation and the plasmid DNA was 
extracted from bacteria colonies. After confirming the insertion by EcoR I 
endonuclease (Thermo Scientific) digestion, positive plasmids were sent for 
sequencing. 
2.2.1.2. Plasmid cloning for protein expression
pFLAG-CMV-4 vector (Sigma) was used for the construction of plasmids 
expressing N-terminal FLAG-tagged truncated FUS proteins with/without a C-
terminal “tail”. Human WT cDNA synthesised from WT SH-SY5Y cells served 
as the PCR template for the amplification of DNA fragments that code for the 
proteins of desired peptide sequences. The primers were therefore designed 
to contain sequence alterations that would introduce frameshift mutations to 
the protein products (Table 2.2). A list of truncated FUS proteins produced 
and details about the C-terminal “tail” are shown in Chapter 6. Primers also 
contained restriction digest sites for asymmetric sub-cloning. After TOPO 
cloning and sequence verification, PCR fragments were excised from the 
TOPO® plasmid by restriction endonuclease digestion (HindIII and BamHI, 
both from NEB). Purified PCR fragments were then cloned into pFLAG-CMV-4 
vectors using T4 DNA ligase, with the vector and insert molar ratio of 1:3. 
Ligated constructs were expanded in the E.coli and correct insertions were 
confirmed by sequencing.
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Table 2.2 Primer sequences used for cloning fragments of truncated FUS gene with a frameshift.
Construct Reverse primer sequence
FUS466fs 5’-CGGGATCCCTAATTAATACGGCCTCTCCCTGCGATCCTGTCTGTGCTCACCCCCATGTGAGAGCCACCTG -3’
FUS491 5’- CGGGATCCTTAACGGTCCCCGCCGCGGCCCCGGTAG -3’
FUS491tail
5’- CGGGATCCTTAATTAATACGGCCTCTCCCTGCGATCCTGTCTGTGCTCACCCCTGGAATCCATCTTGCCAGG
GCCAAAGCCACCTCTGTCCCCACCACCCCACGGTCCCCG -3’
FUS503 5’- CGGGATCCTTATCTGTCCCCACCACCCCGGC -3’
FUS503tail 5’- CGGGATCCTTACCCCTGGAATCCATCTTGCCAGGGCCAAAGCCATCTGTCCCCACCACCCCGGC -3’
FUS514tail 5’- CGGGATCCTTACCTTCCTGATCGGGACATCGATCTGGAATCCATCTTGCCAG -3’
FUS513tail2
5’- CGGGATCCTTACAAAATAACGAGGGTAACACTGGGTACAGGACAAAAAGCTGTTCCAGAACCTGGGGAGAC
TGCAGAATTCGA -3’
Common forward primer sequence
All 
constructs
5’- GCTAAAGCAGCTATTGACTG -3’
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2.2.2. Bacterial cell transformation and plasmid purification
The bacterial cell transformation was optimised from the protocol provided by 
NEB. Briefly, one vial of 5-alpha competent E.coli cells were mixed with 2 µl 
plasmid DNA (10 ng), and were incubated on ice 15 min. Cells were subjected 
to heat shock at 42°C for 45 sec, followed by 5 min cooling on ice. Cells were 
resuspended in S.O.C Outgrowth Medium (NEB) and kept shaking for 1 h at 
37°C. Cells were plated on a 1% selective agar plate containing 50 µg/ml 
ampicillin or kanamycin and incubated at 37°C overnight. Positive colonies 
grown on the plate were inoculated into 2.5% Luria Broth media (Invitrogen) 
supplemented with 50 µg/ml ampicillin or kanamycin and incubated overnight 
in a shaker at 37 °C. Plasmid DNA was purified from overnight culture using 
QIAGEN Plasmid Miniprep kit as instructed by the manufacturer.
2.2.3. Genomic DNA extraction and PCR
A made in-house digest buffer, which contains 100 mM NaCl, 50 mM Tris 
Buffer (pH 8.0), 2 mM ethylenediaminetetraacetic acid (EDTA) and 2 mg/ml 
proteinase K (all Sigma), was used for genomic DNA extraction from cultured 
mammalian cells. Cells washed with phosphate-buffered saline (PBS) were 
pelleted down, resuspended in digest buffer and then incubated at 55 °C for 2 
h. After inactivating proteinase K by incubating the samples at 85 °C for 15 
min, clear supernatants, which contain genomic DNA, were obtained by 
centrifugation at 13,000 rpm for 15 min. 
The PCR, for the purpose of either PCR-based single-cell screening
(explained in section 2.1.2) or molecular cloning, was performed in a 50 µl 
reaction volume containing 0.75 µl of each primer (forward, reverse, 10 µM 
stock), 2 µl of genomic DNA sample (100~500 ng/µl), 0.25 µl of Taq DNA 
polymerase (NEB) and 5ul 10X Standard Taq Reaction buffer. Parameters of 
PCR program were as follows. 95°C for 2 min, (95°C for 15 s, 58°C for 45 s, 
68°C for 45 s) X 35 cycles, 68°C for 2 min 30 s, but they were adjusted for 
different targets amplification – annealing temperature was adjusted 
depending on primer melting temperature and elongation time was adjusted 
depending on the product size. PCR products were separated by 
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electrophoresis in 1 - 3% agarose gel and visualised and imaged using Gel 
Doc™ EZ system (Bio-Rad). Primer sequences are given in Table 2.3.
Table 2.3 Primer sequences for PCR and PAT assay.
* for FUS ΔNLS clone screening; ** for FUS KO clone validation by 
sequencing; *** for PAT assay.
2.2.4. RNA extraction, cDNA synthesis, and qPCR
Total RNA was extracted from mammalian cells either using GenElute™ Total 
RNA Purification Kit (Sigma) or using QIAzol (Qiagen) following the 
manufacturers’ instructions. When extracting RNA using RNA purification kit, 
DNase I (Qiagen) on-column treatment was performed to eliminate DNA 
contamination. NEAT1_2 transcripts are known to be “semi-extractable”, 
which means that heating or shearing step must be included in the standard 
Acid Guanidinium Thiocyanate-Phenol-Chloroform (AGPC)-based RNA 
purification methods to extract them efficiently (Chujo et al. 2017). Therefore,
an additional heating step was introduced to the standard QIAzol RNA 
extraction protocol in semi-extractability analysis. For that, cell lysates in 
QIAzol reagent were incubated at 55 °C for 10 min. The purity and 
concentration of RNA were measured using NanoDrop™ 1000 
Spectrophotometer (Thermo Fisher Scientific) and RNA concentration was 
was diluted to the same concentration within each set for first strand cDNA 
synthesis.
Target Forward primer sequence Reverse primer sequence 
FUS*
5’-TGGGGACAGAGGTGGCT
TTG -3’
5’-CCTTCCTGATCGGGACATC
G -3’
FUS**
5’ ACCATTTGAGAAAGGCAC
GCT -3’
5’-CACGGATTAGGACACTTCCA
GT -3’
FUS***
5’- GTCCAGCCCATGTGAGA
CTT -3’ (p1)
5’-AACCTCCAGCATAAAAGGG
CT -3’ (p2)
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First strand cDNA was synthesised using SuperScript™ IV Reverse 
Transcriptase (Invitrogen). The reaction was performed in 20 µl volume 
containing 300 – 500 ng RNA, 1 µl random primers (Promega, 500 µg/ml), 1 µl 
dNTP mixture (Sigma, 10 mM), 1 µl DTT (Invitrogen, 0.1 M), 1 µl reverse 
transcriptase and 4 µl 5X buffer. Solutions containing RNA, random primers 
and dNTPs were incubated at 68 °C for 5 min to break RNA secondary 
structure before adding the rest of reagents followed by the incubation at room 
temperature for 5 min to allow annealing of random primers to the targets.  
Reverse transcription was performed at 55 °C for 15 min followed by the 
inactivation step at 85 °C for 10 min. First strand cDNA was diluted 5 times in 
nuclease-free water for qPCR. 
Quantitative PCR (qPCR) reaction was performed using TrueStart Hot Start 
Taq DNA Polymerase (Thermo Scientific) following the manufacturer's 
instruction. Each reaction contained 2 µl cDNA, 0.2 µl dNTP mixture (Sigma, 
10 mM), 0.1 µl forward primer, 0.1 µl reverse primer (Sigma, 10 µM), 2 µl 
MgCl2 (Thermo Scientific, 25 mM), 0.2 µl SYBR Green (Bio-Rad), 0.2 µl ROX 
reference dye (Thermo Scientific), 0.125 µl Taq DNA polymerase, 2 µl 10X 
buffer and nuclease-free water up to 20 µl. A two-step PCR was performed on 
Applied Biosystems StepOne™ system with the settings as follows: 95 °C for 
10 min, (95 °C 15 s, 60 °C for 1 min) X 40 cycles. Primer sequences used are 
shown in Table 2.4. 
For miRNA measurement, first strand cDNA was prepared using miScript II 
RT (Qiagen), following the manufacturer's instruction. miRNA levels were 
measured by qPCR using forward miRNA-specific primer and the universal 
reverse primer (unimiR). The primer sequences are given in Table 2.4.
2.2.5. Poly(A) tail-length (PAT) assay
Poly(A) tail length was measured using USB® Poly(A) Tail-Length Assay Kit 
(Thermo Scientific) following the manufacturer’s instructions (Figure 2.3). A 
stretch of guanosine and inosine residues (G/I tail) was added on the 3’-ends 
of RNA molecules by poly(A) polymerase. Tailed RNAs were then reverse 
transcribed into cDNAs using the G/I tails as the priming sites. PCR 
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amplification was carried out from the cDNAs using two primer sets: first 
primer pair was designed upstream of the polyadenylation start site, and it 
was used as a control for the gene-of-interest (p1 and p2 in Figure 2.3); the 
second primer pair was the gene-specific forward primer and the universal 
reverse primer recognising the tail region (p1 and p3 in Figure 2.3), and this 
pair amplifies poly(A) tail of the gene. PCR products were run on 3% agarose 
gel for the comparison of poly(A) tail lengths. The primer sequences are given 
in Table 2.3.
Figure 2.3 The principle behind poly(A) tail-length assay.
p1 and p2 are gene-specific primers. p3 is the universal primer provided with the kit.
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Table 2.4 Primer sequences for qPCR.
Target Forward primer sequence (5' - 3') Reverse primer sequence (5' - 3')
GAPDH 5’- TCGCCAGCCGAGCCA -3’ 5’- GAGTTAAAAGCAGCCCTGGTG -3’
FUS WT 5’- GTGAGCACAGACAGGATCGC -3’ 5’- GAGGGTAACACTGGGTACAGG -3’
FUS ex7- 5’- CAGAGGTGGCATGGGGC -3’ 5’- TGTAACATTCTCACCCAGGC -3’
FUS total 5’- GGAACTCAGTCAACTCCCCA -3’ 5’- TACCGTAACTTCCCGAGGTG -3’
NEAT1 total 5’- CTCACAGGCAGGGGAAATGT -3’ 5’- AACACCCACACCCCAAACAA -3’
NEAT1_2 5’- AGAGGCTCAGAGAGGACTGTAACCTG -3’ 5’- TGTGTGTGTAAAAGAGAGAAGTTGTGG -3’
MALAT1 5’- GGATCCTAGACCAGCATGCC -3’ 5’- AAAGGTTACCATAAGTAAGTTCCAGAAAA -3’
NEAT1_1 pA 5’- TCACGCATGTATGGGGAAGT -3’ 5’- ACCATACAGAGCAACATACCAGT -3’
ADARB2 5’- ATATTCGTGCGGTTAAAAGAAGGTG -3’ 5’- ATCTCGTAGGGAGAGTGGAGTCTTG -3’
miR-18a_for 5’- CATCATCGGTAAGGTGCATC -3’ 5’- GAATCGAGCACCAGTTACGC -3’ (unimiR)
miR-19b_for 5’- GCACTGACATGTGCAAATCC -3’ unimiR
miR-20a_for 5’- CGCACGACTAAAGTGCTTATAG -3’ unimiR
miR-92a_for 5’- GAGTCTATTGCACTTGTCCC -3’ unimiR
miR-105_for 5’- TCAAATGCTCAGACTCCTGTGGT -3’ unimiR
miR-106a_for 5’- AAAAGTGCTTACAGTGCAGGTAG -3’ unimiR
STAT1 5’- CTGTGCGTAGCTGCTCCTTT -3’ 5’- GGTGAACCTGCTCCAGGAAT -3’
CHOP 5’- TTAAAGATGAGCGGGTGGC -3’ 5’- GCTTTCAGGTGTGGTGATGTA -3’
FUS pre-mRNA 5’- GAACCACCTCCAGAAAGGGG -3’ 5’- TGGGGCAAACCCATTTGGTA -3’
FUS pre-mRNA 5’- GAAGCCGCGGAGAAGAGTAA -3’ 5’- AAGAAAAGACTTCCCGCCCC -3’
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2.2.6. RNA sequencing
For RNA-Seq and gene expression analysis, total RNA from cells was 
extracted using PureLink total RNA extraction kit (Life Technologies) and 
possible DNA contamination was removed using RNase free DNase kit 
(Qiagen). RNA-Seq analysis was performed at School of Biosciences 
Genomics Research Hub. Libraries were prepared using the TruSeq stranded 
mRNA kit (Illumina) and single-end sequencing was performed on Illumina 
NextSeq500 (read length: 75 bp; coverage ~20 million reads/sample). Reads 
were aligned to the human reference genome (GRCh38) using STAR (Dobin 
et al, 2013) and FPKM values were obtained using DESeq2 (Love, Huber et 
al. 2014). Reads were viewed in the IGV browser (Thorvaldsdottir, Robinson 
et al. 2013).
2.2.7. Protein extraction and western blot
Total protein lysates were obtained from cells or tissues by lysing them in 2X 
Laemmli buffer supplemented with 5% 2-mercaptoethanol. Lysates were 
heated up to 95 °C for 10 min before being used for sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). 
Protein samples was loaded to SDS-PAGE gel (8%, 10% or 16% depending
on the molecular weight of the protein of interest) and proteins with different 
molecular weights were separated by electrophoresis, which was followed by 
semi-dry transfer onto Hybond- polyvinylidene fluoride (PVDF) membrane 
(Amersham). Membranes were blocked in 4% milk prepared with Tris-buffered 
saline with Tween 20 (TBS-T) for 1 h at room temperature and then incubated 
in primary antibodies diluted in 4% milk/TBS-T at 4 °C overnight. On the 
following day, the membranes were washed with TBS-T and incubated in 
HRP-conjugated secondary antibodies (Amersham) diluted in 4% milk/TBS-T 
(1:3000) at room temperature for 1.5 h. WesternBright enhanced 
chemiluminescence (ECL) horseradish peroxidase (HRP) substrate 
(Advansta) was used for detection on an X-ray film (CL-XPosure, Thermo 
Scientific). Membranes were re-probed for beta-actin. The list of primary 
antibodies are given in Table 2.5.
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For puromycin labelling of nascent polypeptides, puromycin (Sigma) was 
added to the culture medium 30 min before lysis at the final concentration of 
10 µg/ml. For negative control, cycloheximide (Sigma) was added to a final 
concentration of 10 µg/ml together with puromycin. Puromycilated proteins 
were detected by western blot using an antibody recognising puromycin.
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Table 2.5 Antibodies used for immunostaining and western blot
Targets Type
Dilution
(immunostaining)
Dilution
(western blot)
Manufacturer
Product 
code
FUS (full) r. pol. 1:1000 1:1000 Proteintech 11570-1-AP
FUS (NT) r. pol. 1:500 1:1000 Abcam ab84078
FUS (mid) m.mono. 1:1000 1:1000 Santa Cruz sc-47711
FUS (CT) r. pol. N/A 1:1000 Bethyl A300-294A
G3BP1 m.mono. 1:1000 N/A BD Biosciences 611126
TIAR m.mono.
1:1000 N/A
BD Biosciences
610352
610352
CC3 r. pol. 1:500 N/A Cell Signaling 9661
IFNAR1 r. pol. N/A 1:1000 Bethyl A304-290A
OPTN r. pol. 1:500 1:1000 Bethyl A301-829A
puromycin m.mono N/A 1:1000 Merck Millipore MABE343
eIF2α r. pol. N/A 1:1000 Cell Signalling 9722
p-eIF2α (Ser51) r. pol. N/A 1:1000 Abcam ab32157
Nup107 r. pol. 1:500 N/A Proteintech 19217-1-AP
Nup98-Nup96 r. pol. 1:500 N/A Proteintech 12329-1-AP
KPNA2 r. pol. 1:500 N/A Proteintech 10819-1-AP
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TNPO1 r. pol. 1:500 N/A Proteintech 20679-1-AP
Beta-III-tubulin r. pol. 1:500 N/A Sigma T2200
beta-actin m.mono. N/A 1:1000 Sigma A5441
FLAG tag r. pol. 1:500 N/A Sigma F7425
SFPQ r. pol. 1:500 1:1000 Abcam ab177149
SFPQ r. pol. 1:500 1:1000 Bethyl A301-322A
NONO r. pol. 1:500 1:1000 Sigma N8664
* r.pol.: rabbit polyclonal antibody; m.mono.: mouse monoclonal antibody; N/A: not applicable.  
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2.2.8. Subcellular fractionation
Subcellular fractionation was carried out as described (Suzuki et al. 2010a). 
Briefly, WT SH-SY5Y cells and mutant FUS clones were grown as monolayers 
in 6 cm culture dishes to 80-90% confluency (~4 x 106 cells). Cells were 
washed with ice-cold PBS (pH 7.4) and scraped from the surface on ice and 
collected in 1.5 ml Eppendorf tubes containing 1 ml ice-cold PBS. After brief 
centrifugation, supernatant was removed and the cell pellet was resuspended 
in 900 μl of ice-cold 0.1% NP40 (Calbiochem) solution in PBS. After pipetting 
the solution using p1000 pipette for 5 times, 300 μl of the lysate was moved to 
a separate Eppendorf tube as “total cell lysate” and 100 μl 4X Laemmli buffer 
was added to it, then kept on ice. The rest of 600 μl lysate was centrifuged at 
800xg for 5 min and 300 μl supernatant was moved to a separate Eppendorf 
tube as “cytosolic fraction” and was kept on ice after adding 100 μl 4X 
Laemmli buffer. The remaining 300 μl supernatant was removed and the pellet 
was resuspended in 1 ml of ice-cold 1% NP40 and centrifuged for at 800xg for 
1 min. After removing the supernatant, the pellet was mixed in 180 μl 2X 
Laemmli buffer and labelled as “nuclear fraction”. Subcellular fraction samples 
were boiled at 95°C for 5 min for western blot.
2.2.9. Preparation of soluble nuclear extract
Soluble nuclear extract (SNE) was prepared following the protocol by Werner 
and Ruthenburg (Werner, Ruthenburg, 2015). WT SH-SY5Y cells and mutant 
FUS clones were grown as monolayers in 10 cm culture dishes to 80-90% 
confluency (~9 x 106 cells). Cells were scraped into 15 ml centrifugation tubes 
(Corning) containing 10 ml ice-cold PBS and centrifuged at 1500 rpm for 1 
min. The cell pellet was resuspended in 200 μl ice-cold lysis buffer composed 
of 0.15% NP-40, 10mM Tris buffer (pH 7.5) and 150 mM NaCl using p1000 
pipette, followed by 5 min incubation on ice. The lysate was layered onto 500 
μl 24% sucrose buffer prepared in 10mM Tris buffer (pH 7.5) containing 
150mM NaCl, and centrifuged at 13,000 rpm for 10 min at 4°C. After removing 
the supernatant, the nuclear pellet was gently resuspended using p200 pipette 
in 200 μl 50% glycerol buffer prepared with 20 mM Tris (pH 7.9) containing 75 
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mM NaCl, 0.5 mM EDTA, and 0.85 mM dithiothreitol (DTT). After that, 200 μl 
ice-cold buffer composed of 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (pH 7.6), 7.5 mM MgCl2, 0.3M NaCl, 
1% NP-40, 1M urea, 1mM DTT and 0.2 mM EDTA was added to the samples. 
Pulse vortexing was applied to the samples followed by centrifugation at 
13,000 rpm for 2 min at 4°C. The supernatant was kept and used as the SNE.
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2.3. Tissue culture and differentiation
2.3.1. Cell culture, transfection and treatment
SH-SY5Y neuroblastoma cells and human fibroblast cells were maintained in 
1:1 mixture of Dulbecco’s Modified Eagle’s Medium (DMEM) and F12 medium 
supplemented with 10% fetal bovine serum (FBS), 50 U/ml penicillin-
streptomycin, and 500 μM L-glutamine (all Invitrogen).  The medium was 
replaced every 3 or 4 days, and when cells reach ~90% confluency, they were 
split into ~25% confluency. 
Lipofectamine™ 2000 Transfection Reagent (Thermo Scientific) was used for 
the transfection following the manufacturer's instruction. 200 ng of plasmid 
DNA or 250 ng of polyinosinic:polycytidylic acid (poly (I:C)) (Sigma) or 250 ng 
of siRNA (NEAT1 Silencer Select® from Life Technologies, or STAT1 from 
Sigma) were used per well in a  24-well plate (~1.5 x 105 cells). DNA/siRNA-
Lipofectamine complexes were applied onto the cells for 4h, after which an 
equal amount of full medium was added. Medium was replaced with fresh 
medium on the following day. 
All chemicals used in the studies are listed in table 2.6.
Table 2.6 Chemical compounds used for cell treatment.
Chemical compound Final concentration Manufacturer
Actinomycin D 5 μg/ml Sigma
Cycloheximide 10 μg/ml Sigma
DRB 25 μg/ml Sigma
DTT 1 mM Sigma
Interferon beta 1X104 IU Sigma
MG132 50 μM Calbiochem
Pifithrin-μ 5 μM Enzo Life Sciences, UK
Puromycin 10 μg/ml Sigma
Sodium arsenite 0.5 mM Sigma
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2.3.2. Mouse hippocampal neuron preparation and culture
Hippocampi were obtained from mice on postnatal day 1, washed with cold 
Hank's Balanced Salt Solution (HBSS) twice and digested for 40 min at 37°C
in 0.1% trypsin diluted with HBSS. Digested hippocampi tissue was
dissociated by pipetting up and down in Neurobasal A medium containing 100 
U/ml penicillin/streptomycin, 0.2% 2-mercaptoethanol, 500 μM L-Glutamine 
and 10% horse serum. Cell pellet was collected from these tissue 
suspensions by centrifuging at 1,500 rpm for 5 min. The pellet was
resuspended in fresh medium and plated on dishes or coverslips coated with 
poly-L-lysine. On the following day, the medium was replaced by serum-free 
medium containing B27 supplement. All the reagents used in this preparation 
were from Invitrogen.
Transfections or treatments on the mixed neuronal/glial cells were done 5 
days after plating, after the neurite network was formed. Transfection was 
performed using Lipofectamine2000 following the standard protocol (see 
section 2.3.1), except that complexes were left on cells for 1 h and replaced 
with fresh full medium after that.
2.3.3. Human motor neuron differentiation from embryonic 
stem cells
The human embryonic stem cells (ES) H9 cell line was maintained in 
mTESR2 media (Stemcell Technologies) on Matrigel® (Corning)-coated 
dishes. Confluent hES H9 cells were switched to the differentiation medium 
composed of advanced DMEM/F12 (ADF) supplemented with 500 μM 
GlutaMax (Gibco), 50 U/ml penicillin-streptomycin (Gibco) and 10 μM 
SB431542 (Abcam). On day 4, 1 μM purmophamine (Cayman Chemicals) and 
0.1μM retinoic acid (Sigma) were added to the above medium. Cells were split 
in a 1:2 ratio on day 8. On day 16, neuronal progenitors were detached from 
the culture surface using Accutase® (Sigma) and plated on poly-L-
lysine/Matrigel® -coated dishes and cultured in ADF medium supplemented 
with 500 μM GlutaMax, 50 U/ml penicillin-streptomycin, 2% B27 supplement
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(Gibco), 1% N2 supplement (Gibco) and 10 ng/ml BDNF (Miltenyi). On day 23, 
differentiated neurons were dissociated with Accutase and plated onto poly-L-
lysine/laminin (Sigma)-coated dishes or coverslips and maintained in the 
same medium described above, except that 50:50 mixture of ADF/Neurobasal 
A (Gibco) was used instead of ADF medium until day 40. 
2.4. Staining and imaging
2.4.1. Immunocytochemistry
Cells grown on coverslips were washed once with cold PBS and fixed with 4% 
cold paraformaldehyde for 15 min at room temperature. After washing with 
PBS, cells were treated with cold methanol for 5 min to permeabilise 
membranes followed by two washing steps with PBS to remove residual 
methanol. Cells were incubated in primary antibodies diluted with phosphate-
buffered saline with Tween-20 (PBS-T) containing 5% goat serum at room 
temperature for 2 h or at 4 °C overnight (dilution rate of antibodies see Table 
2.5). Cells were washed with PBS and incubated in the fluorochrome 
conjugated secondary antibodies (AlexaFluor, Life Technologies) diluted to 
1:1000 in PBS-T at room temperature for 1.5 h. Cells were kept away from 
light from this step henceforth. After washing with PBS, nuclei were stained 
with 1:10,000 4′,6-diamidino-2-phenylindole (DAPI) solution (Sigma,10mg/ml 
stock) for 2 min at room temperature, and coverslips were mounted on the 
glass slides using Immu-Mount media (Thermo Scientific). 
2.4.2. Immunohistochemistry
Human spinal cord paraffin sections (7 µm thick) from a group of clinically and 
histopathologically characterised ALS cases and neurologically healthy 
individuals were obtained from the Medical Research Council (MRC) London 
Neurodegenerative Diseases Brain Bank and Sheffield Brain Tissue Bank. 
Consent was obtained from all subjects for autopsy, histopathological 
assessment, and research was performed in accordance with local and 
national Ethics Committee approved donation. Immunohistochemistry was 
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performed using Elite plus kits (Vector laboratories) and 3,3’ –
diaminobenzidine (DAB) (Sigma) as a substrate. Human spinal cord paraffin 
sections mounted on the glass slides were deparaffinised in xylene, and 
rehydrated through a series of ethanol with decreasing percentage. Slides 
were boiled in microwave in 10 mM sodium citrate buffer (pH 6) for 10 min for 
antigen retrieval, and cooled down to room temperature. Tissues were 
incubated in 3% hydrogen peroxide in methanol at 4°C for 30 min to quench 
the background oxidase activity. After blocking with 10% goat serum/PBS-T 
for 30 min at room temperature, tissues were incubated in the primary 
antibodies diluted in the blocking solution at 4°C overnight (dilution rate of 
antibodies see Table 2.5). The following day, tissues were washed with PBS 
and then incubated in the biotinylated secondary antibodies (Vector 
Laboratories) diluted to 1:1000 in PBS-T at room temperature for 1 h. After 
washing with PBS, Avidin-biotin HRP complexes (Vector Laboratories) were 
applied to the slides for 45 min followed by washing with PBS. Tissues were 
incubated in 10 mg/ml DAB solution for around 5 min until a dark brown 
pigment developed, and then slides were washed with water and dehydrated 
through a series of ethanol solutions with increasing concentration. Slides 
were incubated in xylene and mounted in DPX mounting medium (Thermo 
Fisher).
2.4.3. RNA Fluorescence In Situ Hybridisation (ISH) and 
RNAscope® ISH
For RNA Fluorescence In Situ Hybridisation (RNA-FISH) cells grown (1~2 x 
104 cells) on coverslips were fixed in 4% cold paraformaldehyde for 15 min at 
room temperature, which was followed by membrane permeabilisation in cold 
methanol for 5 min at room temperature. After washing with PBS, cells were 
kept in 70% ethanol solution at 4 C overnight. Human spinal cord tissues were 
deparaffinised, re-hydrated and antigen-retrieved the same way as for 
immunohisgology. Coverslips/slides were washed in 2X Saline Sodium Citrate
(SSC) solution prepared with diethylpyrocarbonate (DEPC)-treated water at 
room temperature three times. Coverslips/slides were then incubated in 
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hybridisation buffer (10% formamide/2XSCC) for 10 min at room temperature. 
Commercially available NEAT1 probes, either against 5’ or middle region of 
human NEAT1 (Stellaris® Quasar® 570-labelled, Biosearch Technologies), or 
oligo(dT)30 probe that was targeting polyA+RNA (Cy5-labelled, Sigma), were 
diluted in the hybridisation buffer (2 µl probe in 100 µl buffer). 
Coverslips/slides were incubated with the probe overnight at 37 C in a 
humidified chamber. On the following day, coverslips/slides were washed with 
2XSSC, incubated in DAPI for nuclei staining and then mounted. Where RNA-
FISH was used in combination with immunocytochemistry, the second day 
after overnight incubation in the RNA probes, cells were incubated in primary 
antibody diluted in PBS for 30 min and then Alexa488-conjugated secondary 
antibody diluted to 1:1000 in PBS for 30 min before proceeding to DAPI 
staining and mounting. 
RNAscope® ISH, a novel RNA ISH technology which relies on a unique probe 
design strategy that allows simultaneous signal amplification and background 
suppression to achieve single-molecule visualization while preserving tissue 
morphology, was used for paraspeckle detection in human spinal cord tissues 
(Wang et al. 2012). Hs-NEAT1-long (411541) probe (Advanced Cell 
Diagnostics) was used in conjunction with RNAscope® 2.5 HD Detection 
Brown kit according to manufacturer’s instructions.
All the solutions used in these experiments were prepared with DEPC-treated 
water to prevent RNA degradation.
2.4.4. Proximity Ligation Assay
To detect the interaction between endogenous FUS and a paraspeckle protein 
(NONO or SFPQ) in situ, Proximity Ligation Assay (PLA) is performed. The 
principle of PLA is shown in figure 2.4. Briefly, FUS and SFPQ (or NONO) are 
detected by two primary antibodies raised in different species. A pair of 
secondary antibodies labelled with oligonucleotide (PLA probes) then binds to 
the primary antibodies. Next, connector oligos and DNA ligase are introduced 
to join the PLA probes forming circular DNA template only if they are in close 
proximity to each other. These circular DNA template is then amplified through 
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a rolling-circle amplification using PLA probe as a primer generating 
concatemer which is still tethered to the PLA probe. This allows up to 1000-
fold signal amplification. Finally, labelled oligos with complementary sequence 
with concatemer were introduced to visualise the amplicon, which appear as 
individual spots under microscope. 
Here, PLA was performed using Duolink® In Situ Orange Starter Kit 
Mouse/Rabbit (Sigma) using anti-FUS (mouse monoclonal, Santa Cruz) 
antibody in combination with rabbit anti-NONO (Sigma) or anti-SFPQ (Bethyl) 
antibody. The assay was carried out strictly following manufacturer’s 
instructions. 
Figure 2.4 Schematic of PLA.
(A) Primary antibodies recognise FUS and SFPQ. (B) PLA probes bind to the primary 
antibodies. (C) When the probes are in close proximity, connector oligos join the PLA 
probes generating circular DNA. (D) Circular DNA template becomes amplified by 
DNA polymerase. (E) Fluorescently labelled detection oligos hybridize to the 
amplicons. (F) PLA signals under fluorescent microscope. This image is modified 
from the original chematic available from manufacturer’s website. 
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2.4.5. Imaging of fixed cells and image processing
Fluorescent images were taken using BX61 fluorescent microscope equipped 
with F View Soft Imaging digital camera and Cell F software (all Olympus). 
Confocal fluorescent images were taken using the Airyscan LSM880 upright 
confocal microscope with ZEN software (Zeiss). Bright-field images of human 
spinal cord tissues were taken using Olympus X53 microscope. Plot profiles 
and surface profiles were generated using the plot profile function and
interactive 3D surface plot plugin in Image J, respectively. Figures were 
prepared using Photoshop CS3 or PowerPoint 2016 software.
2.4.6. Live imaging
To observe FUS aggregate formation dynamically, SH-SY5Y cells were plated 
on glass-bottomed culture dishes (Mattek) and transfected with a plasmid 
expressing GFP-tagged FUS R522G. After 24 h, cells were transfected with 
poly(I:C) before the live imaging. Imaging was conducted under a Leica TCS 
SP2 MP confocal microscope using Fluotar L 63 x 1.4 oil objective. Cells were 
maintained in the HEPES-buffered medium, and kept in the on-scope 
incubator during the imaging for temperature control. A stack of images were 
taken every 7 min for 12 hours, deconvoluted and compiled into a movie using 
Leica Application Suite AF software.
2.5. Data analysis
Statistical analysis was performed using GraphPad Prism 7 software. 
Distribution of normality was tested using D’Agostino & Pearson normality 
test, and when p>0.05, the corresponding data set is considered to be normal 
distribution. For the comparison of two data sets with normal distribution, the 
Student’s t test was used to compare their means, and for the comparison of 
three or more data sets with normal distribution, the One-way ANOVA test and 
Tukey’s multiple comparison test were used. For the data sets that failed to 
pass the normality test, non-parametric tests were performed instead. For two 
data sets comparison, Mann-Whitney U test was used, whereas for three or 
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more data sets comparison, Kruksal-Wallis test and Dunn’s multiple 
comparison test were used. The specific statistical tests used for each data 
set were indicated in the figure legends.
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Chapter 3. Characterisation of stable cell lines 
with FUS gene modification
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3.1. Overview
Establishing cellular models that can closely recapitulate FUSopathy would be 
of enormous benefit in developing effective therapeutic strategies against 
diseases caused by FUS malfunction. Most of the cellular models that are 
commonly used nowadays rely on transient over-expression of mutant FUS 
proteins in various cell lines or primary neurons. These models recapitulate 
FUSopathy to some extent, and have helped provide us with valuable 
information on the underlying molecular mechanisms of the disease. 
Nevertheless, FUS protein over-abundance is certainly not a physiological 
feature of the cells, and therefore should be avoided when possible. 
Fibroblasts and iPSCs derived from patients carrying FUS mutations are good 
options, yet they are not readily available and relatively costly to establish and 
maintain. Recent advances in CRISPR/Cas9 technology allowed us to 
generate better cellular models that express physiological level of FUS protein 
through targeted FUS gene modification in human neuroblastoma SH-SY5Y 
cell line. A panel of stable sub-clones have been generated through the 
plasmid transfection and colony screening procedure described in the 
Materials and Methods chapter. These clones will be used to study 
pathological effects of mutant FUS protein on paraspeckles (Chapter 4) as 
well as potential triggers of FUSopathy (Chapter 5). This chapter aims to give
detailed characteristics of each sub-clones, such as FUS gene sequence at 
the site of modification, FUS protein subcellular distribution, FUS mRNA and 
protein expression levels.
3.2. Results
3.2.1. Target sequence selection in the FUS gene
A FUS gene region spanning from the end of exon 14 to the end of exon 15
(Figure 3.1), which encode NLS domain of the protein, was selected for 
deletion. All potential CRISPR/Cas9 target sequences flanked by a NGG 
protospacer adjacent motif (PAM) sequence at the 3’ end were screened 
using Feng Zhang lab’s Target Finder (http://crispr.mit.edu/) within this region. 
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Top three or four sequences that were predicted to have the lowest chance of 
off-target effects on each end of the target region were shortlisted for further 
evaluation. All possible editing outcomes, such as changes in mRNA splicing 
causing transcript degradation and consequent protein modifications, 
generated by each combination of upstream and downstream target 
sequences were examined, under the assumption that Cas9 would cleave 3-4 
nt upstream of PAM sequence and minor errors may occur during non-
homologous end joining (NHEJ) DNA repair process. One pair of sequences 
that showed the highest possibility to generate the desired deletion was finally 
selected (Figure 3.1).
Figure 3.1 Selection of the CRISPR/Cas9 target sequences in the FUS gene.
A) Schematic illustration of the editing strategy for the deletion of the NLS domain of 
FUS protein. A grey bar under FUS WT protein diagram shows FUS gene exons 
corresponding to protein domains. FUS gene region targeted for deletion is indicated 
with a red line. B) Partial FUS gene sequence with gRNA target sequences is
indicated. Exons and introns are in bold and regular letters, respectively; target 
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sequences are marked with pink lines; PAM sequences are boxed; stop codon is 
highlighted in yellow.
3.2.2. FUS gene sequences and predicted protein 
sequences of stable clones
The region of the FUS gene spanning the sites of gene modification was 
amplified from the genomic DNA extracted from all stable ΔNLS clones 
(Figure 3.2A). The pair of primers used for PCR should produce a fragment of 
595 bp from WT FUS gene, whereas the edited form of FUS, only when the 
gene editing worked as expected, should give rise to an amplicon of 265 bp. 
According to the PCR results, most of the clones appeared to be 
‘heterozygous’, where only one copy of FUS gene has been edited (Figure 
3.2B). Two clones, ΔNLS4 and ΔNLS7, were homozygous, with both of FUS
alleles edited. Figure 3.2C shows RNA sequencing result, which was carried 
out later in the project on a panel of selected clones. Compared to the WT 
cells, ΔNLS8 heterozygous clone had a significantly decreased number of 
reads in exons 14 and 15, which corresponded to the deletion area, whereas 
in ΔNLS4 homozygous clone, almost no reads were present in this region. 
Two clones, ΔNLS5 and ΔNLS10, did not show the shorter fragment in the 
PCR. This is explained in Figure 3.4 below. These clones were obtained 
during the sub-cloning of ‘mixed clones’, which showed the shorter fragment in 
the initial round of PCR screening, but appeared to be mixtures of two or more 
clones with different FUS protein subcellular localisation pattern by 
immunostaining; presumably they originated from two or more cells with 
different gene modifications. The ‘mixed clones’ were passed through the 
single-cell selection procedure again, and the sub-clones were screened by 
FUS immunostaining to identify ‘pure’ clones. ΔNLS5 and ΔNLS10 clones 
were obtained in this immunostaining screening process.
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Figure 3.2 Validation of the FUS gene editing.
A pair of primers flanking the region to be deleted was used to amplify FUS gene 
from a series of single cell-derived stable ΔNLS clones. A) A fragment of human FUS
gene is given with the region to be deleted indicated using a red line. The FUS gene 
region amplified in the PCR is indicated with a black line. B) An agarose gel image 
showing results of PCR screening in all ΔNLS clones. Clones were named according 
to the order of establishment. L, DNA ladder. C) RNA sequencing result for selected 
clones. The deleted region is indicated with two vertical dashed lines on both ends. Y 
axis indicates the number of reads.
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Sequencing of the PCR fragments (both long and short) revealed the exact 
outcome of the FUS gene modifications, which covered a diverse range of 
results that could arise during DNA recovery through the NHEJ pathway 
(Figure 3.3). The most frequent result was the removal of the intermediate 
sequence and direct joining of exons 14 and 15, and this accounted for 50% 
(11/22) of all outcomes. Among these cases, small indels of single or multiple 
nucleotides could be found at the junction at the frequency of 27% (3/11). For 
example, in ΔNLS8 allele 2, a single nucleotide adenosine (A) was deleted at 
the junction; in ΔNLS2 allele 2, 20 nucleotides were missing from the junction 
(Figure 3.4). In about 18% (4/22) of all alleles sequenced, small indels at the 
upstream and/or downstream Cas9 cleavage sites were the only modifications 
that could be found in the region (“scarring”), such as allele 2 of ΔNLS5 clone, 
where a 2-nucleotide insertion and a 4-nucleotide deletion were found at the 
upstream and downstream Cas9 cleavage sites, respectively (Figure 3.4). 
About 14% of alleles (3/22) showed the re-insertion of the excised fragment 
but in the opposite orientation, such as ΔNLS1 allele 2, where the fragment 
between the two target sites to be deleted was inverted and re-inserted to its 
original site (Figure 3.4). Due to the undesirable DNA repair outcomes 
described above, different degrees of frameshifts were caused in most cases, 
and therefore a stretch of novel amino acids (‘tail’) with FUS-unrelated 
sequence was added to the C-terminus of FUS protein, replacing its normal 
NLS sequence. Only four clones out of 11 (ΔNLS2, ΔNLS8, ΔNLS10 and 
ΔNLS11) were confirmed to be true heterozygotes by sequencing (Figure 3.4). 
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Figure 3.3 A summary of the outcomes of FUS gene modification in ΔNLS 
clones.
This summary is from a total of 11 FUS ΔNLS clones (22 FUS alleles) analysed. The 
red arrows indicate Cas9 cleavage sites. DNA fragment between two arrows is 
coloured in orange and yellow in order to distinguish between top and bottom 
strands. The red crosses indicate small indel mutations.
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Figure 3.4 Partial FUS gene sequences of all the ΔNLS clones and their predicted protein sequences.
WT FUS gene sequence of the same region and partial WT FUS protein sequence are given for comparison. Exons are in bold letters and introns 
are in regular letters. Upstream and downstream CRISPR/Cas9 target sequences are in pink and blue respectively, and PAM sequences are in 
green. Original stop codons are highlighted in yellow, and the alternative stop codons in pink. Single or double nucleotide insertions are indicated 
using red letters (e.g. ΔNLS3 allele 2), and nucleotides deletions are indicated with red letters with a strikethrough (e.g. ΔNLS5 allele 2). Re-
insertion of excised fragments inverted is indicated with red letters (e.g. ΔNLS1 allele 2). Primers used for PCR are underlined. Novel peptide 
sequences caused by the frameshift are indicated using red letters. Numbers below the protein sequence indicate the order of the amino acid 
pointed on the FUS protein. Asterisks mark the end of the protein sequence.
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In addition to FUS ΔNLS clones, a FUS KO clone was also generated. This 
clone is obtained during my initial attempt to generate clones expressing 
mutant FUS proteins with larger FUS C-terminal truncation, which removes all 
domains downstream of RRM (protein domain see Figure 3.1). For this, target 
sequences were selected on exon 11 and exon 15. However this attempt did 
not yield cells with desired modification. Instead, I obtained a clone expressing 
no visible FUS protein either by immunostaining or by western blot. 
Sequencing of the target site on exon 11 revealed that both alleles in the FUS 
KO clone have a single nucleotide insertion at the Cas9 cleavage site, which 
was inserted during the DSB repair through the NHEJ pathway. This caused
frameshift and therefore a pre-mature stop codon on exon 11 (Figure 3.5A), 
which eventually led to FUS mRNA degradation through the NMD pathway. It 
should be noted that modified FUS mRNAs in ΔNLS clones, such as ΔNLS1 
allele 2, also possess a pre-mature stop codon, but escaped NMD 
surveillance and produce mutant proteins (Figure 3.4). Figure 3.5B illustrates 
the mechanism underlying this discrepancy. NMD is triggered when a pre-
mature stop codon is found upstream of the last exon-exon junction. In 
contrast, when no exon-exon junction is present downstream of a pre-mature 
stop codon, the mRNA is regarded as normal. In FUS KO clone, FUS mRNA 
was degraded because its pre-mature stop codon was located upstream of 
the last stop codon. However, in ΔNLS1 clone, mRNA was preserved because 
the last exon-exon junction (between exons 14 and 15) was destroyed due to 
the intron14 retention, which rendered the pre-mature stop codon to be 
located downstream to the last exon-exon junction (between exon 13 and 14).
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Figure 3.5 Generation of the FUS KO clone using CRISPR/Cas9 gene editing.
A) Sequencing across the CRISPR target site in exon 11 of FUS gene of the FUS KO 
clone revealed an indel mutation on the Cas9 cleavage site, which caused a 
frameshift and therefore mRNA degradation. Single nucleotide insertion is indicated 
in red, and the pre-mature stop codon is highlighted in pink. CRISPR/Cas9 target 
sequence in underlined and the PAM sequence is boxed. B) A schematic illustration 
describing the mechanism underlying the selective degradation of FUS mRNA 
through NMD in FUS KO clone, but not in certain ΔNLS clones that also possess pre-
mature stop codons. Vertical lines indicate exon-exon junctions, and the last exon-
exon junction is marked in red. Green flag and green pin indicate start codon and 
normal stop codon, respectively. Grey pin indicates premature stop codon. The red 
vertical line indicates the last exon-exon junction.
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3.2.3. FUS protein subcellular distribution
Distribution of FUS in all clones was visualised using an antibody detecting 
the N-terminus of the protein (Abcam). While FUS was mainly detectable in 
the nucleus in WT SH-SY5Y cells, mutant FUS in heterozygous clones 
(ΔNLS_het hereafter) exhibited mild to moderate cytoplasmic mislocalisation 
(Figure 3.6 upper panel). Compared to ΔNLS_het clones, homozygous clones 
(ΔNLS_ho hereafter) displayed more pronounced FUS cytoplasmic 
mislocalisation (Figure 3.6 lower panel). In line with the previous report, where 
cytoplasmic FUS showed strong affinity to SGs (Dormann et al. 2010), mutant 
FUS in these clones was also readily recruited into SGs induced by sodium 
arsenite (SA) (Figure 3.7). Although in the majority of the clones, mutant FUS 
showed diffuse distribution in the cytoplasm, in ΔNLS2_het and ΔNLS11_het 
clones, spontaneously assembled small FUS granules (FGs) could be seen 
(Figure 3.6 inset). No FUS immunoreactivity was detected in the FUS KO 
clone.
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Figure 3.6 FUS immunostaining in FUS mutant clones.
∆NLS_het clones show mild to moderate degree of FUS cytoplasmic mislocalisation, 
and ∆NLS_ho clones exhibit severe FUS redistribution. Two ∆NLS_het clones, 
ΔNLS2 and ΔNLS11, developed spontaneous cytoplasmic FUS granules (FGs). No 
FUS immunoreactivity was detectable in the FUS KO clone. FUS was visualised 
using an antibody against N-terminus of the protein. Scale bar is 10 μm.
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Figure 3.7 Cytoplasmically mislocalised FUS protein is recruited into stress 
granules formed under oxidative stress.
Confocal microscope images showing colocalisation of cytoplasmic FUS and SG
marker proteins, G3BP1 and TIAR, in cells treated with sodium arsenite for 1 h. FUS 
was visualised with an antibody against N-terminus of the protein. Profile plots 
generated along the green arrows in merged images show almost complete 
colocalisation of FUS and SG proteins. Scale bars are 10 μm.
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3.2.4. FUS mRNA expression
Two pairs of primers were designed to measure total FUS and WT FUS 
mRNA expression level in the clones by qPCR (Figure 3.8A). In the majority of 
ΔNLS clones, both heterozygotes and homozygotes, total FUS expression 
was increased by ~1.5-fold compared to WT cells. Since FUS expression is 
subject to autoregulation (Zhou et al. 2013), this increase is presumably 
resulted from FUS autoregulation to make up for the nuclear deficiency 
caused by protein mislocalisation. However, there were exceptions –
ΔNLS8_het, ΔNLS7_ho and ΔNLS9_ho clones displayed slightly lower FUS 
mRNA levels, possibly because modified mRNAs in these clones might have 
shorter half-lives due to certain sequences within them (Figure 3.8B, left). 
When measuring the levels of WT FUS mRNA only, the result was in 
agreement with total FUS mRNA levels. Heterozygotes only have one copy of 
WT gene, hence they should produce half the amount of WT FUS mRNA 
compared to that in WT cells; whereas homozygotes clones should produce 
no WT FUS mRNA since they do not possess WT alleles. However, as 
described above, many alleles still carry the intermediate fragment after gene 
modification, and the retained fragment has the WT FUS primer-binding site. 
Figure 3.8C summarises data of the clones that have the intermediate 
fragment, and it explains the unusually high levels of ‘WT’ FUS mRNA in 
ΔNLS10_het, ΔNLS3_ho and ΔNLS5_ho clones (Figure 3.8B, right). Residual 
amount of FUS mRNA was still detectable in FUS KO clone despite the 
absence of detectable FUS protein (Figure 3.6, Figure 3.9). 
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Figure 3.8 Total FUS and WT FUS mRNA levels in FUS clones measured by 
qPCR.
A) FUS transcript, position of deletion (del) and primer locations. (not drawn to scale;
‘for’ and ‘rev’ stand for forward and reverse primer, respectively) B) qPCR results for
total FUS (left) and WT FUS (right) mRNA expression in clones. Bars representing 
∆NLS_het and ∆NLS_ho clones are orange and red, respectively. N ≥ 4 for each
clone. Data pooled from all ∆NLS_het or ∆NLS_ho clones (bars filled with diagonal 
pattern) are also shown. Mann-Whitney U test is used. #p<0.01, *p < 0.05, **p < 0.01, 
***p < 0.001. C) A table summarises the presence of FUS WT forward primer-binding 
sequence in all ΔNLS clones. Alleles which possess the sequence are marked with 
‘+’. Genetically modified alleles that still carry the WT primer binding sequence are 
highlighted in yellow. FUS mRNA sequences of ΔNLS10 and ΔNLS5 retaining the 
WT primer binding sequence (highlighted in red on the sequence). Upstream and 
downstream CRISPR/Cas9 target sequences are in pink and blue. PAM sequences 
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are in green. Indel mutations at the cleavage sites are in red letters (insertion) or in 
red letters with a strikethrough (deletion). Pre-mature stop codons are highlighted in 
pink.
3.2.5. FUS protein expression
A panel of antibodies recognising different parts of FUS protein were used to 
measure FUS protein expression levels and protein sizes by western blot. 
FUS (full, Proteintech) recognises the whole protein; FUS (NT, Abcam) 
recognises the first 50 amino acids on the N-terminus; FUS (mid, Santa Cruz) 
recognises aa. 370 -467 in the middle and FUS (CT, Bethyl) recognises the 
last 27 amino acids on the C-terminus. In this analysis, ΔNLS1_ho clone 
showed two separate bands, in line with the predicted protein sizes – 512 aa. 
and 545 aa (Figure 3.9A). The separation was not obvious in ΔNLS2_het 
clone where the size difference between the two protein products (WT protein 
and mutant protein with a tail) is small (526 aa. and 528 aa.)(Figure 3.9A). 
FUS CT antibody, which recognises the NLS domain of FUS protein, showed 
no immunoreactivity in ΔNLS1_ho clone, where both alleles produce FUS 
proteins with disrupted NLS. In ΔNLS2_het clone, FUS CT detected half of the 
amount of WT FUS protein (Figure 3.9A). In FUS KO cells, neither the full size 
FUS nor the truncated form of FUS (~ 55 KDa, assuming the modified mRNA 
with a pre-mature stop codon is somehow translated) were detectable (Figure 
3.9A). 
It has been noticed that ΔNLS_het clones often displayed mild FUS 
redistribution, even though half of FUS protein produced by the clones is 
mutated. In contrast, ∆NLS_ho clones displayed severe FUS mislocalisation, 
with the boundaries of the nuclei sometimes undetectable (Figure 3.9B). The 
extent of FUS cytoplasmic mislocalisation was quantified by measuring FUS 
protein levels in the cytoplasmic fraction and total lysates. The 
cytoplasmic/total FUS ratio was about 8 times higher in ∆NLS_ho clones than 
in ∆NLS_het clones (Figure 3.9C), which was different from the predicted two-
fold increase. The finding suggests that the presence of non-mutated, nuclear 
localised FUS partially protects mutant FUS from mislocalisation to the 
cytoplasm.
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Figure 3.9 FUS protein expression levels of FUS clones measured by western 
blot.
A) A panel of FUS antibodies recognising different parts of FUS protein are used to 
detect FUS proteins. Neither WT FUS (70 KDa) nor a possible truncated form (55 
KDa) is detectable in FUS KO clone using any of the antibodies. FUS (full) antibody 
is raised against the whole protein, whereas FUS (NT) recognises aa.1-50, FUS (CT) 
recognises aa.500-526, and FUS (mid) recognises aa.370-467 of FUS protein. Actin 
is measured as a control for equal loading. B) FUS distribution in representative 
∆NLS_het and ∆NLS_ho clones. Nuclei border in ∆NLS_ho cells is indicated with a 
dashed line. Scale bar is 10 μm. C) FUS levels in total lysates and cytoplasmic 
fraction from WT and ΔNLS clones. Ratio C/T, ratio cytoplasmic to total FUS levels. 
Small proteins absent from the cytoplasmic fraction (arrows) may correspond to 
histones.
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3.2.6. Characterisation of cytoplasmic granules formed by 
endogenous mutant FUS
Overexpressed cytoplasmic FUS protein is known to spontaneously form 
small granules when the protein accumulates to a certain amount in the 
cytoplasm (Shelkovnikova et al. 2014a). These granules (exogenous FGs, 
exoFGs hereafter), are about 150-200 nm in size and require RNA for their 
structural integrity. It was unknown whether mutant FUS protein expressed at 
the endogenous level, as in ΔNLS clones from the current study, could 
nucleate such FGs (endogenous FGs, endoFGs hereafter) under basal 
conditions. I found that their formation is indeed possible in some ΔNLS 
clones (Figure 3.6, Figure 3.10). The morphology of endoFGs formed in 
ΔNLS2_het and ΔNLS11_het clones was examined using a confocal 
microscope. These endoFGs were roughly spherical in shape, with the 
diameter ranging between 200 and 300 nm. They were evenly distributed 
throughout the cytoplasm without obvious clustering (Figure 3.10A) and were 
negative for core SG proteins G3BP1 or TIAR (Figure 3.10B, C).
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Figure 3.10 FUS granules (endoFGs) in ΔNLS clones are negative for stress 
granule markers.
A) Confocal microscopy images of endoFGs in ΔNLS11_het clone visualised using
FUS N-terminus antibody. On the right, is the enlarged image of the inset. B) Single 
optical sections of confocal images of endoFGs showing that they do not colocalise
with either G3BP1 or TIAR. C) Profile plots and surface plots are generated from the 
confocal images in B. Both plots confirm non-overlapping signal distribution between 
FUS and SG proteins.
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RNA has been suggested to be essential for the integrity of exoFGs and 
similar structures containing FUS, such as transport granules (Kanai et al.
2004, Shelkovnikova et al. 2014a). I tested whether endoFGs are also 
sensitive to RNA depletion. Indeed, when ΔNLS11_het cells were exposed to 
the global transcription inhibitor actinomycin D for 18 h, endoFGs 
disassembled into smaller particles (Figure 3.11A) as evidenced by the 
increased granule numbers and significantly decreased average sizes (Figure 
3.11B). No further changes were observed in granule numbers and sizes upon 
prolonged transcription inhibition (Figure 3.11A, B).
Figure 3.11 RNA is required for the integrity of endoFGs.
A) Immunostaining of endoFG-containing ΔNLS11_het clone treated with 
actinomycin D for the indicated period of time using FUS antibody detecting middle 
region of FUS. A representative region of each image is enlarged. Scale bar is 10
μm. B) EndoFG numbers and their average sizes are quantified for each time point 
using Analyze Particles function of image J (6~8 cells). Kruskal-Wallis test and 
Dunn’s multiple comparison tests are used. #p=0.1, *p<0.05, **p=0.001.
106
3.2.7. Differentiation of FUS clones into neuron-like cells
Next, SH-SY5Y clones with the endogenous FUS gene modified were 
differentiated into neuron-like cells using retinoic acid and brain-derived 
neurotrophic factor (BDNF). All clones were shown to express high levels of 
beta III tubulin, the post-mitotic neuron marker, and display neuron-like 
morphology, with a small, round cell body and, long processes (Figure 3.12). 
This result suggested that targeted modification of the FUS gene and 
subsequent single-cell cloning process did not affect their capability to 
differentiate. Differentiated ΔNLS cells still preserved original FUS subcellular 
localisation pattern, and ΔNLS2_het clone still had FGs in the cytoplasm after 
differentiation.
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Figure 3.12 FUS clones can be differentiated into neuron-like cells.
A) Co-staining for FUS and beta III tubulin of FUS clones before (A) and after (B) differentiation. Scale bars are 10 μm.
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3.3. Discussion
Cellular models established by overexpression of mutant FUS have been 
widely used to address many questions regarding the roles of mutant FUS 
protein in the development of FUSopathy. However, the reliability of these 
models is sometimes questioned because protein overexpression per se can 
trigger many undesirable effects. For example, protein overexpression causes 
resource overload within the cell by monopolising cellular machinery and 
molecules required for protein synthesis and turnover. Furthermore, 
overexpression of regulatory proteins can cause promiscuous interaction and 
abnormal pathway modulation (Moriya 2015). Indeed, it has been proven that 
overexpression of otherwise benign proteins is sufficient to cause detrimental 
effects on cellular functions and growth (Makanae et al. 2013, Tomala and 
Korona 2013). Therefore, cellular models expressing endogenous levels of 
mutant FUS protein will be extremely valuable for studying FUSopathy in a 
more physiological context. 
Here I successfully established a panel of single cell-derived stable clones 
expressing physiological levels of mutant FUS protein lacking NLS (ΔNLS) as 
well as a clone that is devoid of FUS expression (FUS KO), by directly 
modifying FUS gene in human neuroblastoma SH-SY5Y cells using 
CRISPR/Cas9 gene editing. Primary characterisation of the clones has 
allowed the establishment of the FUS gene editing outcomes including 
changes in gene sequence, expression levels and subcellular localisation of 
mutant proteins. As I have expressed Cas9 in the cells without a repair 
template, DSBs created were repaired through the NHEJ DNA repair pathway, 
which often introduces small indels at the repair sites (Lieber 2010, Hsu et al.
2014). This error-prone nature of NHEJ has been exploited to create the FUS 
KO clone, where a single nucleotide was inserted at the repair site, inducing 
mRNA decay due to the ORF frameshift. However, when it comes to the 
precise deletion of the region encoding the NLS, repair errors become 
disadvantageous, as in nearly half of the alleles sequenced, highly 
heterogeneous indels result in mutant proteins with C-terminal peptide “tails” 
that vary in length and sequence. Other, more advanced and sophisticated 
versions of CRISPR/Cas9 gene editing system are required to guarantee a 
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more precise and efficient modification of the FUS gene in the future studies. 
A host of strategies have been developed to improve editing precision and 
efficiency over the past few years, and this will be discussed in detail in the 
general discussion chapter.  
FUS protein is known to regulate its own expression levels by controlling 
alternative splicing of its pre-mRNA (Zhou et al. 2013). Exon 7 of FUS gene is 
subjected to alternative splicing: FUS mRNA with exon 7 skipped undergoes 
NMD while mRNA containing exon 7 produces normal protein. FUS protein 
overexpression represses exon 7 splicing, thereby downregulating total FUS 
protein levels and vice versa. In light of this, decreased nuclear FUS protein 
levels in ΔNLS clones due to FUS cytoplasmic mislocalisation could alleviate 
the suppressive effect of FUS protein on exon 7 splicing, resulting in FUS 
upregulation. Indeed, the majority of ΔNLS clones exhibited elevated total 
FUS mRNA levels. In regard to the decreased mRNA levels in some ΔNLS 
clones, I speculate that certain sequence elements present in mutant FUS 
transcripts in these clones might be responsible for their compromised stability 
(Guhaniyogi and Brewer 2001, Hollams et al. 2002). It is surprising that a 
small amount of FUS mRNA was still detectable in FUS KO cells, although no
FUS protein was detectable either in immunostaining or in western blot using 
antibodies against different domains of the protein. Probably, these mRNAs 
are not yet fully degraded residual transcripts that are not capable of being 
translated.          
Mutant FUS proteins with the NLS sequence deleted or replaced by cryptic 
sequences display cytoplasmic mislocalisation, and they are recruited into 
SGs assembled under oxidative stress, which is consistent with previous 
reports (Dormann et al. 2010, Gal et al. 2011, Ito et al. 2011a, Kino et al.
2011). As only one copy of the FUS gene is edited in the heterozygous 
clones, one would expect that about half of the protein would be redistributed 
to cytoplasm. However, a very mild mislocalisation of FUS is observed in 
heterozygous clones, with most FUS protein remaining in the nucleus, 
suggesting that a putative, less potent NLS signal(s) might be present in the
unmodified region of FUS. This possibility has also been discussed by others 
(Dormann et al. 2010). In addition, although FUS mislocalisation was more 
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pronounced in the homozygous clones than heterozygous ones, the 
difference, however, was not proportional. It seems that WT FUS may help 
retain mutant FUS within the nucleus. It has been proposed that the degree of 
cytoplasmic export of shuttling proteins is determined primarily by their 
intranuclear interactions (Schmidt-Zachmann et al. 1993). FUS is known to 
self-interact through low-complexity prion-like domain on its N-terminus 
(Monahan et al. 2017). Therefore, I reason that higher local concentration of 
FUS in the nuclei of heterozygous cells facilitated the retention of mutant FUS 
proteins in the nucleus, thereby alleviating their cytoplasmic accumulation. My 
finding is consistent with the observations from post-mortem studies of ALS-
FUS cases (which are nearly all heterozygous for FUS mutation) where 
affected neurons with cytoplasmic FUS inclusions still have considerable 
amount of FUS in the nucleus (Kwiatkowski et al. 2009, Vance et al. 2009, 
Rademakers et al. 2010).
To the best of my knowledge, this study is the first to report the capability of 
endogenous mutant FUS to spontaneously assemble into stable granules in 
the cytoplasm. This is very important for understanding the mechanisms 
underlying the formation of pathological inclusions in the degenerating motor 
neurons in ALS-FUS patients. There is an ongoing debate on the initial 
structure that might give rise to the pathological inclusions. SGs, being the 
most extensively studied cytoplasmic RNP granules that contain FUS, are
considered to be the foci where pathological FUS aggregates emerge. It is 
proposed that SGs that fail to disassemble are the precursors for pathological 
inclusions, as supported by the findings where incorporation of ALS-
associated mutant proteins into SGs reduces their dynamics (Dewey et al.
2011, Boeynaems et al. 2017, Zhang et al. 2018c). In the case of FUS 
mutations, while some reported persistent SGs in mutant FUS expressing 
cells (Acosta et al. 2014), others found accelerated SG disassembly after 
removal of stress (Baron et al. 2013). Another hypothesis states that 
pathological inclusions may arise from FUS aggregates, a stress-induced 
cytoplasmic structure nucleated from spontaneously assembled FGs 
(Shelkovnikova et al. 2014a). Observations leading to this hypothesis were 
based on cellular models overexpressing mutant FUS, therefore it was not 
clear whether endogenous mutant FUS could nucleate such granules under 
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basal conditions. My results indicate that even endogenous levels of mutant 
FUS in cells with one FUS gene copy modified can drive formation of such 
granules. Further studies into the behaviour of these granules under stress 
conditions will shed light on the possible mechanisms underlying the formation 
of pathological FUS inclusions. 
In conclusion, cellular models expressing endogenous levels of mutant FUS 
protein have been successfully generated by targeted modification of the FUS
gene, and the modified proteins mislocalise to the cytoplasm and even form 
spontaneous granules in some clones, making these clones valuable 
FUSopathy models.
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Chapter 4. Paraspeckles and ALS-FUS
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4.1. Overview
Cytoplasmic mislocalisation of FUS protein and formation of FUS-positive 
inclusions in the neurons and glial cells of spinal cord is the histopathological 
hallmark of ALS-FUS (Kwiatkowski et al. 2009, Vance et al. 2009, Hewitt et al.
2010). However, significant FUS mislocalisation is rare among ALS-FUS 
cases, and even in these cases, only a subset of neurons display dramatic 
FUS mislocalisation (Hewitt et al. 2010, Mackenzie et al. 2010b, King et al.
2015). This suggests that mutant FUS in the nucleus can exert toxic functions 
that can drive pathological changes sufficient to cause the disease. Indeed, 
mutant FUS proteins showing only mild cytoplasmic redistribution, such as 
R521G(H), are proven to be detrimental in vitro and in vivo models (Qiu et al.
2014, Rulten et al. 2014, Sephton et al. 2014, Wang et al. 2018a). In addition, 
ALS-associated FUS mutations outside the NLS-coding region have been 
identified (Ticozzi et al. 2009), and corresponding mutant FUS can also cause 
pathological cellular phenotypes (Nomura et al. 2014, Patel et al. 2015). 
Finally, in mouse models of FUSopathy, mutant FUS is capable of causing 
neurodegeneration in the absence of cytoplasmic FUS aggregation and even 
without significant mislocalisation, indicating that FUS nuclear gain of function 
is an important disease mechanism (Devoy et al. 2017, Lopez-Erauskin et al.
2018). Our understanding of the cytoplasmic gain of function of mutant FUS 
has improved significantly during the past decade, however, less is known 
about its nuclear toxic functions. 
Multiple lines of evidence support the strong association between 
paraspeckles and ALS pathogenesis – many ALS-associated mutations affect 
paraspeckle proteins, and human spinal motor neurons, which normally lack 
paraspeckles, develop paraspeckles in ALS patients (discussed in Chapter 1). 
FUS is an essential paraspeckle protein since its depletion eliminates 
paraspeckles (Naganuma et al. 2012, Shelkovnikova et al. 2014b). However, 
little is known regarding whether and how the paraspeckles are affected in the 
presence of mutant FUS protein in ALS-FUS. Since NEAT1 levels are 
sensitive to intracellular FUS levels (Shelkovnikova et al. 2014b), cellular 
models based on FUS protein overexpression have limited value in studying 
the effect of mutant FUS protein on paraspeckles. FUS ΔNLS clones 
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expressing mutant FUS proteins at endogenous levels can provide an 
excellent platform for investigating paraspeckle dysregulation in ALS-FUS.
This chapter aims to investigate pathological impact of mutant FUS on 
paraspeckles using FUS ΔNLS clones. 
4.2. Results
4.2.1. Excessive paraspeckle formation in ΔNLS_het clones 
Three homozygous (ΔNLS1_ho, ΔNLS4_ho and ΔNLS7_ho), three 
heterozygous (ΔNLS2_het, ΔNLS8_het, ΔNLS 11_het) clones and FUS KO 
clone were included in this study. RNA-FISH was performed using a probe 
recognising the 3’ region of NEAT1_2 on the clones. As predicted, 
paraspeckles were hardly detectable in FUS KO clone (Figure 4.1A). 
ΔNLS_ho clones showed a similar phenotype, although some cells still had 
residual paraspeckles, and this is consistent with the significant cytoplasmic 
mislocalisation of FUS in these clones (Figure 4.1A, arrowheads). FUS is 
known to contribute to the structural integrity of paraspeckles by holding 
together the individual NEAT1 RNP complexes (Yasuda et al. 2013). In 
agreement with this, numerous small NEAT1-positive particles, likely 
corresponding to the NEAT1 RNP complexes – the “primary units” of 
paraspeckles, were detected in FUS KO and ΔNLS_ho cells (Figure 4.1A, 
bottom panel insets). What surprised me, however, was the significantly 
enhanced paraspeckle formation in ΔNLS_het clones, which was further 
confirmed by paraspeckle quantification (Figure 4.1 and 4.2). In fact, the 
paraspeckle numbers in this analysis may be an underestimation since 
paraspeckles often exist as clusters, which were counted as single foci, 
particularly in ΔNLS_het cells (Figure 4.1A, arrows). Total NEAT1-positive 
area per nucleus was also quantified, which showed a two-fold increase in 
ΔNLS_het cells (Figure 4.2). According to the current definition, paraspeckles 
are structures composed of both NEAT1_2 and an essential protein 
component (Naganuma et al. 2012). Therefore, cells were double-labelled 
using NEAT1_2 RNA-FISH in combination with NONO immunostaining, which 
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confirmed the colocalisation of NONO with NEAT1_2-positive foci in 
ΔNLS_het clones (Figure 4.1B).
Figure 4.1 Augmented paraspeckle assembly in ΔNLS_het clones.
A) RNA-FISH using NEAT1 probe reveals increased number of paraspeckles in 
ΔNLS_het clones, whereas ΔNLS_ho clones and FUS KO clone were almost devoid 
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of paraspeckles. Yellow arrows point to clusters of paraspeckles in ∆NLS_het clones; 
yellow arrowheads indicate residual paraspeckles in ∆NLS_ho clones. Insets in upper 
panel (WT cells and ΔNLS_het clones) show paraspeckles; Insets in lower panel 
(FUS Ko and ΔNLS_ho clones) show paraspeckle primary units. B) A core 
paraspeckle protein NONO colocalises to NEAT1_2 in paraspeckles of ΔNLS_het 
clones. Scale bars are 10 μm.
Figure 4.2 Quantification of paraspeckles in ΔNLS_het clones.
The number of paraspeckles and NEAT1-positive area per cell are quantified for 
∆NLS_het clones. Total cell numbers analysed are indicated within each bar. One-
way ANOVA with Holm-Sidak test is used. *p < 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001.
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4.2.2. NEAT1 isoforms are upregulated in ΔNLS clones 
Since paraspeckle formation depends on NEAT1_2, augmented paraspeckle 
assembly in ΔNLS_het clones is very likely resulted from NEAT1_2 
upregulation. NEAT1_2 transcripts are known to be “semi-extractable” (Chujo
et al. 2017), therefore, a heating step was introduced during RNA purification 
using QIAzol for the accurate measurement of NEAT1_2 levels. As expected,
qPCR showed upregulation of NEAT1_2 in ΔNLS_het clones; however, 
similar upregulation was also observed in ΔNLS_ho clones (Figure 4.3A).
Adenosine deaminase RNA specific B2 (ADARB2) is one of the genes 
negatively regulated by NEAT1 (Hirose et al. 2014). As predicted, ADARB2 
levels were dramatically downregulated in ΔNLS clones as measured by RNA-
Seq and qPCR, and NEAT1 knockdown was able to limit its downregulation 
(Figure 4.3B).
Interestingly, NEAT1 levels in FUS KO clone, which lacks paraspeckles, were 
normal (Figure 4.3A), suggesting that elevated NEAT1 level is not caused by 
compensatory upregulation triggered by paraspeckle disruption, but is more 
likely resulted from the presence of mutant FUS. 
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Figure 4.3 NEAT1 is upregulated in ΔNLS clones.
A) NEAT1_2 levels are measured by qPCR. N = 4 for each clone; one-way ANOVA; 
***p < 0.001, ****p < 0.0001. Representative tracks for poly(A)-captured RNA-Seq 
analysis of NEAT1 gene in ΔNLS8_het and ΔNLS4_ho clones are also shown.
Higher peaks within first 1/5 region on the left correspond to reads from both NEAT1 
isoforms and much lower peaks across the rest of the region correspond to NEAT1_2 
reads. Due to much lower abundance of NEAT1_2 relative to NEAT1_1, NEAT1_2 
peaks in WT cells are almost absent in the graph. B) ADARB2, a gene supressed by 
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NEAT1, is downregulated in ΔNLS clones as measured by RNA-Seq and qPCR. N 
= 3 for each line; one-way ANOVA with Dunnett’s test; ****p < 0.0001. C) Knockdown 
of NEAT1 (both isoforms) upregulates ADARB2 in WT and ΔNLS cells. Cells were
analysed 48 h after siRNA transfection. N=3; Mann-Whitney U test; *p<0.05. For all 
quantifications, data from three heterozygous (ΔNLS2_het, ΔNLS8_het and 
ΔNLS11_het) and three homozygous (ΔNLS1_ho, ΔNLS4_ho and ΔNLS7_ho) clones 
are pooled.
Increased level of NEAT1_2 could be explained by increased expression of 
SFPQ and NONO. These two proteins are essential paraspeckle components, 
and their binding to NEAT1_2 is known to stabilise the transcript, therefore, 
increase its steady-state levels (Naganuma et al. 2012). However, their 
expression levels and distribution did not differ significantly between WT and 
ΔNLS clones (Figure 4.4) suggesting a different mechanism of NEAT1 
upregulation. 
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Figure 4.4 Distribution as well as mRNA and protein expression levels of core 
paraspeckle proteins are not significantly affected in ΔNLS clones.
A) Representative images of ΔNLS clones immunostained for FUS, NONO and 
SFPQ are shown. Scale bar is 10 µm. B) mRNA levels of NONO and SFPQ are 
measured by RNA-Seq and the corresponding fragments per kilobase of transcript 
per million mapped reads (FPKM) values are shown. Data from three heterozygous 
(ΔNLS2_het, ΔNLS8_het and ΔNLS11_het) and three homozygous (ΔNLS1_ho, 
ΔNLS4_ho and ΔNLS7_ho) clones are pooled. N=3. C) Protein expression levels of 
SFPQ and NONO are measured by western blot. 
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4.2.3. Overexpression of normal or mutant FUS restores 
paraspeckles in ΔNLS_ho and FUS KO cells
Although FUS does not stabilise NEAT1_2, it is required for paraspeckle 
maturation downstream of NEAT1_2 synthesis (Naganuma et al. 2012, West
et al. 2016). I asked whether expressing exogenous mutant FUS would rebuild 
paraspeckles in FUS KO and ΔNLS_ho cells. Green fluorescent protein 
(GFP)-tagged FUS WT, ALS-linked FUS R524T and R518K (predominantly 
nuclear), and ΔNLS (predominantly cytoplasmic) (Shelkovnikova, Robinson et 
al. 2014) mutants were expressed in the cells. Overexpression of all the above 
FUS variants resulted in the appearance of bright NEAT1-positive foci in the 
majority of transfected FUS KO and ΔNLS1_ho cells (Figure 4.5A,B), and this 
was accompanied by the disappearance of paraspeckle precursors (Figure 
4.5B, inset). All FUS variants showed the similar capability of paraspeckle 
nucleation (Figure 4.5C), despite the fact that in the cells expressing GFP-
tagged ΔNLS, nuclear levels of ectopic protein were much lower than in cells 
expressing other variants (Figure 4.5A). This suggests that nuclear mutant 
FUS, when its level exceeds a certain threshold, is able to form and maintain 
visible paraspeckles.
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Figure 4.5 Overexpression of FUS or its mutants restores paraspeckles in FUS 
KO and ΔNLS_ho cells.
A) Expressing GFP-tagged WT FUS or FUS ΔNLS in ΔNLS1_ho cells restores 
paraspeckls as revealed by NEAT1 RNA-FISH. ΔNLS1_ho cells expressing GFP is 
included as a negative control. B) Restoration of paraspeckles in FUS-deficient cells 
results in the disappearance of paraspeckle precursors (inset). Transfected and non-
transfected cells are highlighted with green and red circles, respectively. Note the 
presence of the precursors in non-transfected cells (inset). In both A and B, 
arrowheads point to mature paraspeckles. Scale bars are 10 μm. C) Efficient 
restoration of paraspeckles by overexpression or either normal or mutant FUS. 
Fractions of cells with one or more paraspeckles among transfected ΔNLS1_ho and 
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FUS KO cells are quantified. Numbers of cells analysed are indicated within each 
bar. One-way ANOVA with Holm-Sidak test; **p < 0.01, ***p < 0.001, ****p < 0.0001.
4.2.4. Interactions between FUS and core paraspeckle 
components are decreased in ΔNLS clones
Although nuclear FUS levels in ΔNLS_het clones are sufficient for the 
assembly of visible paraspeckles, it is unclear whether these structures differ 
from normal paraspeckles in terms of structural integrity and functionality. 
During paraspeckle formation, NONO and SFPQ heterodimers bind to 
NEAT1_2 to form paraspeckle precursors, which are subsequently held 
together by FUS (West et al. 2016). I measured FUS interaction with SFPQ 
and NONO using proximity ligation assay (PLA), which revealed significantly 
decreased interaction of FUS with both proteins within the nuclei of ΔNLS_het 
and ΔNLS_ho clones (Figure 4.6). 
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Figure 4.6 The interaction of FUS with SFPQ and NONO is reduced in ΔNLS 
clones.
A) Proximity ligation assay (PLA) was performed to measure the interaction between 
FUS and SFPQ or NONO in a heterozygous and a homozygous clone. FUS KO cells 
were included as a negative control. Representative images are shown. Scale bars 
are 10 µm. B) Number of interactions are quantified from the PLA images. Numbers 
of cells analysed are indicated within each bar. One-way ANOVA with Holm-Sidak 
test; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
Weakened interaction of FUS with SFPQ and NONO indicates that its 
interaction with NEAT1_2 might also be affected. It is known that interaction 
between FUS and NEAT1_2 renders NEAT1_2 difficult to extract using 
standard Trizol-based RNA extraction method unless an additional heating 
step is introduced (Chujo et al. 2017). Therefore, I hypothesised that 
NEAT1_2 should be extracted more efficiently if the interaction between FUS 
and NEAT1_2 becomes weaker due to the mutation. To assess the interaction 
between FUS and NEAT1_2, NEAT1_2 levels were compared between two 
RNA samples prepared with or without heating step during the QIAzol RNA 
purification process. In WT cells, the extractability of NEAT1_2 increased ~ 
3.5-fold with heating, while the extractability of another lncRNA, Metastasis 
Associated Lung Adenocarcinoma Transcript 1 (MALAT1), was not affected 
(Figure 4.7).  In FUS KO cells, which lack paraspeckles, NEAT1_2 was almost 
fully extractable as the ratio of heated/non-heated was close to 1. Similarly, 
ΔNLS_ho clones that do not form visible paraspeckles also exhibited 
significantly increased NEAT1_2 extractability. Importantly, ΔNLS_het clones, 
which show enhanced paraspeckle formation, also showed significantly 
elevated NEAT1_2 extractability, albeit to a lesser extent than ΔNLS_ho or 
FUS KO cells (Figure 4.7).
Therefore, mutant FUS showed compromised interaction with core 
paraspeckle components – NEAT1_2, SFPQ and NONO, compared to WT 
FUS. 
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Figure 4.7 Increased extractability of NEAT1_2 in the ΔNLS clones indicates 
reduced binding of FUS to NEAT1_2.
A) NEAT1_2 but not MALAT1 is semi-extractable in WT neuroblastoma cells. B)
Increased NEAT1_2 semi-extractability in ΔNLS clones. Note that near-complete 
NEAT1_2 extraction is achieved in FUS KO cells (fold extraction ~ 1). N = 3 per 
clone; One-way ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. In A and 
B, NEAT1_2 extractability is measured by comparing its levels in heated versus non-
heated QIAzol-lysed samples (“fold extraction”) by qPCR. 
4.2.5. NEAT1_1 accumulates in the nucleoplasm outside 
paraspeckles in ΔNLS clones
FUS CLIP-Seq studies have reported that FUS protein preferentially binds to 
NEAT1_1 since the read density was highest at the 5’ region of NEAT1
(Lagier-Tourenne et al. 2012). This finding raises the possibility that NEAT1_1 
is recruited into the paraspeckles via its interaction with FUS during the 
higher-order assembly of paraspeckles, and the deficiency of mutant FUS in 
paraspeckles assembly would lead to insufficient NEAT1_1 recruitment. It has 
been shown that NEAT1 gene products are highly enriched (~10-fold) in 
chromatin-bound fraction (Werner and Ruthenburg 2015), suggesting that 
paraspeckles can be co-pelleted with chromatin during cell fractionation. I 
obtained a soluble nuclear extract (SNE) from ΔNLS clones and WT cells and 
prepared cDNAs using oligo(dT) primer to amplify only NEAT1_1 which is 
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polyadenylated, but excluding NEAT1_2 that do not have poly(A) tails. Indeed, 
NEAT1_1 levels in SNE were significantly higher in ΔNLS clones compared to 
WT cells as measured by non-saturated PCR and qPCR (Figure 4.8A), 
indicating decreased recruitment and retention of NEAT1_1 within 
paraspeckles in the cells expressing mutant FUS.
I speculated that under stressful conditions, which normally trigger 
paraspeckle hyper-assembly/enlargement, the functional deficiencies of 
mutant FUS in maintaining paraspeckle structure might become more 
apparent. To test this, I stimulated cells with poly(I:C), a synthetic viral mimic 
that has been reported to increase NEAT1 levels and enhance paraspeckle 
formation (Imamura et al. 2014). A significant proportion of poly(I:C)-
stimulated cells in ΔNLS_het clones displayed a diffuse NEAT1 signal, which 
was in contrast to the signal located only in well-defined paraspeckles in all 
WT cells (Figure 4.8B,C). This suggests that stress-induced paraspeckle 
formation is indeed impaired in cells expressing mutant FUS. A similar 
observation was made in the cells treated with proteasome inhibitor MG132, 
another paraspeckle-inducing stressor (Hirose et al. 2014) (Figure 4.8D).
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Figure 4.8 NEAT1_1 accumulates in soluble nuclear extract (SNE) in ΔNLS 
clones, and cellular stress enhances non-paraspeckle NEAT1_1 accumulation.
A) Non-saturated PCR (26 cycles) (left) and qPCR (right) results show increased 
NEAT1_1 levels in SNEs of ΔNLS clones compared to WT cells. A primer pair 
located immediately upstream NEAT1_1 polyA-tail is used to quantify NEAT1_1 in 
cDNA prepared from polyadenylated RNA. Note that this primer pair does not detect 
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NEAT1_2 which is not polyadenylated. One-way ANOVA with Holm-Sidak test; *p 
< 0.05, **p < 0.01. N=3. B) RNA-FISH with total NEAT1 probe shows diffuse NEAT1 
distribution in poly(I:C)-transfected ΔNLS_het clones. Cells were analysed 8 h post-
transfection. Representative images are shown. C) Proportion of cells showing 
diffuse NEAT1 signal is quantified in ΔNLS_het clones transfected with poly(I:C). 
Numbers of cells analysed are indicated within each bar. D) MG132 treatment, 
another paraspeckle-inducing stress, causes diffuse NEAT1 distribution in a 
ΔNLS_het clone. Representative images are shown. Scale bars are 10 µm.
4.2.6. miRNA biogenesis regulated by paraspeckles is 
impaired in ΔNLS clones
The compromised structural integrity of paraspeckles in ΔNLS clones 
suggests that their functions might also be affected. One of the established
paraspeckle functions is the regulation of miRNA biogenesis. It has been 
reported that paraspeckles modulate pri-miR-17~92 transcript processing by 
enhancing Microprocessor activity (Jiang et al. 2017). I measured miRNA 
levels produced form this miRNA precursor, and found that all six miRNAs are 
significantly decreased in homozygous ΔNLS clones. In addition, some 
miRNA are also decreased in heterozygous ΔNLS clones (Figure 4.9). This 
suggests compromised functionality of paraspeckles in the cells expressing 
mutant FUS.  
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Figure 4.9 Paraspeckle-regulated miRNAs are decreased in ΔNLS clones.
Levels of six mature miRNAs generated from pri-miR17~92 are measured by qPCR.
Data from three heterozygous clones (∆NLS2_het, ∆NLS8_het and ∆NLS11_het) and 
three homozygous clones (ΔNLS1_ho, ΔNLS4_ho and ΔNLS7_ho) are pooled.
Mann-Whitney U test, *p < 0.05. N=3. 
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4.2.7. ALS-FUS patient fibroblasts display enhanced 
paraspeckles assembly and decreased NEAT1_1 
sequestration capability
I asked whether my findings in ΔNLS clones could be corroborated in another 
cellular system, human fibroblasts. Fibroblasts have a large nucleus with 
numerous paraspeckles, making them a well-suited system for paraspeckle 
studies. Fibroblasts derived from a patient with FUS P525L mutation, which 
impairs NLS of FUS protein, displayed only mild FUS cytoplasmic 
mislocalisation (Figure 4.10A). Consistent with the findings in ΔNLS clones, 
paraspeckle numbers and NEAT1-positive area are increased ~ 2-fold in the 
fibroblasts expressing mutant FUS compared to control fibroblasts (Figure 
4.10B). 
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Figure 4.10 Accumulation of NEAT1 and augmented paraspeckle assembly is 
found in patient fibroblasts bearing FUS mutation.
A) FUS is predominantly nuclear in human fibroblasts obtained from an ALS patient
carrying FUS P525L mutation. B) RNA-FISH using NEAT1_2 probe shows 
augmented paraspeckle assembly in FUS P525L human fibroblasts. The number of 
paraspeckles and NEAT1-positive area per cell are quantified. Numbers of cells 
analysed are indicated within each bar. Mann-Whitney U-test; *p < 0.05. Scale bars 
are 10 µm.
Although the morphology of paraspeckles in the FUS P525 cells appeared 
normal when detected by NEAT1_2 RNA-FISH (Figure 4.10B), NEAT1 signal 
was observed outside paraspeckles in these cells using the probe detecting 
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both NEAT1 isoforms (5’ segment of NEAT1) (Figure 4.11A, left). Since 
NEAT1_2 FISH did not produce a diffuse signal, the observed diffuse non-
paraspeckle NEAT1 corresponds to NEAT1_1. Interestingly, the area of 
diffuse NEAT1_1 signal largely overlapped with nuclear speckles, as detected 
by polyA+RNA (Figure 4.11B). A similar pattern of NEAT1_1 distribution, 
termed ‘microspeckle’, has been reported recently in the cells lacking 
NEAT1_2/paraspeckles (Li et al. 2017). In an independent fibroblast line 
expressing FUS P525L, obtained from the same individual before the disease 
onset, total NEAT1 probe detected the same paraspeckle abnormalities 
(Figure 4.11A, right). These findings are consistent with the NEAT1_1 
accumulation in the nucleoplasm of ΔNLS clones (Figure 4.8) and further 
confirm that ALS-linked FUS mutations compromise the ability of FUS protein 
to recruit NEAT1_1 into paraspeckles.
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Figure 4.11 Localisation of NEAT1_1 outside paraspeckles in patient fibroblasts 
bearing FUS mutation.
A) RNA-FISH using a probe recognising total NEAT1 shows diffuse, non-paraspeckle 
distribution of NEAT1 in two independent lines of FUS P525L fibroblasts. B) RNA-
FISH using a probe detecting total NEAT1 together with a probe detecting polyA+ 
RNA reveals that NEAT1_1 is abnormally localised to nuclear speckles in FUS P525L 
fibroblasts. Fraction of cells with speckle-localised NEAT1 is quantified. Numbers of 
cells analysed are indicated within bars. Scale bars are 10 μm.
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4.2.8. Paraspeckles are formed in spinal motor neurons and 
glial cells of ALS-FUS patients
De novo paraspeckle assembly is one of the pathological characteristics of 
spinal motor neurons and glial cells in sALS and fALS with TDP-43 pathology 
(Nishimoto et al. 2013, Shelkovnikova et al. 2018). We performed NEAT1 
RNA-FISH on human spinal cord sections of ALS-FUS patients to examine 
paraspeckle formation. Three ALS-FUS cases characterised by early disease 
onset and predominantly spinal motor neuron degeneration, clinically and 
histopathologically representing the majority of ALS-FUS cases, were included 
in the analysis (Table 4.1). sALS cases served as a positive control. 
Paraspeckles were detected in all three ALS-FUS cases, being present in on 
average ~27% of spinal neurons examined (Figure 4.12A), and this is 
comparable with what has been observed in sALS and other fALS cases 
(Shelkovnikova et al. 2018). Paraspeckles were also detected in glial cells 
(Figure 4.12A). This result was also confirmed using RNAscope® ISH with 
NEAT1_2 probe (Figure 4.12B). Therefore, augmented paraspeckle assembly 
in spinal cord cells is a shared pathological phenotype in the majority of ALS 
cases including ALS-FUS.
In conclusion, the presence of mutant FUS in the nucleus causes NEAT1 
accumulation and augmented paraspeckle assembly. However, these 
paraspeckles are structurally and functionally impaired due to weakened 
interaction of mutant FUS protein with core paraspeckle proteins and 
NEAT1_2. This in turn leads to abnormal accumulation of NEAT1_1 in the 
nucleoplasm outside of paraspeckles, which might have adverse effects on 
normal cellular functions.       
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Table 4.1 Characteristics of ALS-FUS cases used in the study
Patient 
No
Sex
Age at 
onset
Mutation FUS pathology in spinal cord References
Paraspeckles
(neurons positive for 
paraspeckles/ total 
neurons analysed)
1 M 33 p.R521C FUS-positive GCI
Vance et al., 2009; 
King et al., 2015
1/5
2 F 35 p.R521C FUS-positive NCI and GCI 3/10
3 F 35 p.R521H FUS-positive NCI and GCI 2/7
*GCI – glial cytoplasmic inclusions
*NCI – neuronal cytoplasmic inclusions
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Figure 4.12 Accumulation of paraspeckles in spinal neurons and glial cells in 
ALS-FUS.
A) Paraspeckle formation in spinal neurons and glia of ALS-FUS and sALS patients 
is visualised using RNA-FISH with a probe recognising total NEAT1. Images are 
taken in the orange (NEAT1) and green (Lipofuscin) channels to distinguish between 
specific NEAT1 signal and non-specific autofluorescence from lipofuscin. Arrowheads 
indicate paraspeckles in a glial cell. Scale bars are 10 μm. B) Representative images 
of paraspeckles in spinal neurons (left panels) and glial cells (right panels) in an ALS-
FUS patient visualised with RNAscope® ISH using NEAT1_2 probe. Neuronal nuclei 
are circled. Scale bars are 10 μm (left panels) and 50 μm (right panels). This dataset
is generated by Dr. Tatyana Shelkovnikova.
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4.3. Discussion
In this study, by analysing FUS ΔNLS clones, I have demonstrated 
upregulation of both NEAT1 isoforms in the presence of endogenous levels of 
mutant FUS protein. Since nuclear FUS is an important protein component 
required for the formation of higher order structure of paraspeckles (Yasuda et 
al. 2013), homozygous FUS ΔNLS clones did not form paraspeckles 
regardless of upregulated NEAT1_2. In contrast, in heterozygous FUS ΔNLS 
clones, where sufficient level of mutant FUS is present in the nucleus, hyper-
assembly of paraspeckles was observed due to elevated NEAT1_2. 
Nevertheless, the paraspeckles formed in heterozygous clones were defective 
in both structure and function, which is caused by decreased interaction 
between mutant FUS protein and core paraspeckle proteins. Hyper-assembly 
of structurally impaired paraspeckles was also confirmed in fibroblasts derived 
from ALS-FUS patients, and enhanced paraspeckle formation was also 
observed in the spinal cord of ALS-FUS patients. This study provides further 
evidence for the enhanced paraspeckle formation in spinal motor neurons and 
glial cells in ALS with different aetiology, even in the cases with the essential 
structural component of paraspeckles – FUS is mutated. 
Apart from paraspeckle abnormalities, other potential toxic effects of mutant 
FUS in the nucleus have also been suggested by others. Nuclear mutant FUS 
(FUS R514G) contributes to the loss of nuclear Gems, through its increased 
binding to survival motor neuron (SMN) protein – an essential protein 
component of Gems (Yamazaki et al. 2012, Sun et al. 2015). Although the 
exact function of nuclear Gems is not clear, it is generally believed that they 
might participate in snRNP maturation, and snRNP is crucial for the formation 
of spliceosomes, whose malformation is detrimental for RNA splicing process 
(Zhang et al. 2008, Lotti et al. 2012). Moreover, FUS is known to participate in 
DNA damage response by direct interaction with histone deacetylase 1 
(HDAC1), and mutant FUS (FUS R521C) binds to WT FUS to form a stable 
complex thereby interfering with normal FUS-HDAC1 interaction (Wang et al.
2013, Qiu et al. 2014). In addition, FUS regulates target gene expression 
through its direct interaction with single-stranded DNA response elements 
present in their promoter regions (Tan et al. 2012), therefore nuclear mutant 
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FUS could affect this interaction resulting in altered target gene expression, 
although there is no direct evidence to support this hypothesis yet. Taken 
together, nuclear gain-of-function of mutant FUS may play more important 
roles in the development of FUSopathy than previously appreciated.
NEAT1 expression level is known to increase in response to several 
environmental stimuli, such as viral infection and proteasomal inhibition. 
However, the molecular mechanism that upregulates the basal NEAT1 level is 
largely unknown. Certain paraspeckle proteins, such as SFPQ and NONO, 
are known to stabilise NEAT1_2 transcripts (Hirose and Nakagawa 2012), 
therefore accumulation of these proteins can result in NEAT1_2 upregulation. 
However, I could not detect significant upregulation of SFPQ and NONO in 
FUS ΔNLS clones, indicating that other regulatory mechanisms must be 
involved. Furthermore, according to unpublished data obtained in our 
laboratory, transcriptomic analysis of FUS ΔNLS clones did not highlight any 
cellular pathways, dysregulation of which might explain the upregulation of 
NEAT1. It is possible that slight alterations of multiple pathways caused by 
FUS mutations exert synergetic effect ultimately resulting in NEAT1 
upregulation. In addition, due to the relatively low read coverage of my 
transcriptomic analysis (~ 20 M reads/sample), changes of low-abundance 
transcripts that have impacts on NEAT1 expression might have been 
overlooked. Further studies are required to decipher the underlying 
mechanisms of NEAT1 upregulation in the cells expressing mutant FUS 
protein. 
An immediate consequence of disrupted paraspeckle integrity in the cells 
expressing mutant FUS is the increased release of free NEAT1_1 transcripts 
to the nucleoplasm. As one of the most abundant lncRNAs in human cells 
(Gibb et al. 2011, Li et al. 2017), NEAT1_1 likely has its own paraspeckle-
independent functions. For example, NEAT1_1 increases its target gene 
expression by directly interacting with histone H3 of chromatin, thereby 
promoting chromatin active state (Chakravarty et al. 2014, West et al. 2014). 
Therefore, it is highly likely that the accumulation of free NEAT1_1 in the 
nucleoplasm will alter the expression levels of multiple genes, causing 
widespread changes in cellular pathways. Recently, researchers reported that 
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in human cells where NEAT1_2 is specifically knocked out, NEAT1_1 
appeared as numerous nuclear foci (microspeckles) that are distinct from 
paraspeckles. They are found throughout the nucleus and a subset of them 
colocalise with splicing speckles (Li et al. 2017). In addition, NEAT1_1 has 
been shown to interact with the p53 pathway (Adriaens et al. 2016, Mello et al.
2017) and directly modulate neuronal excitability (Barry et al. 2017). The latter 
study is particularly interesting as elevated neuronal excitability is a well-
known phenomenon in ALS (Bae et al. 2013). Yet there is still a long way to 
go before we could answer how exactly NEAT1_1 function and how the 
accumulated NEAT1_1 contributes to the ALS-FUS. 
ADARB2, which encodes a subtype of RNA-editing enzymes that may play a 
regulatory role in A-to-I RNA editing (Bass 2002), is found to be significantly 
downregulated in FUS ΔNLS clones. ADARB2 is found sequestered in the 
pathological nuclear foci of C9orf72 RNA in the motor neurons of ALS-C9 
patients (Donnelly et al. 2013), suggesting loss of ADARB2 function in this 
subset of ALS, although the functional consequences of this pathological 
changes are not known yet. The results obtained in the current study, together 
with above report, suggest that ADARB2 depletion might constitute a 
converging mechanism of ALS-FUS and ALS-C9. 
One of the well-established paraspeckle functions is the nuclear retention of 
A-to-I hyper-edited RNAs (Zhang and Carmichael 2001, Prasanth et al. 2005, 
Chen and Carmichael 2009). Nuclear retention of hyper-edited RNA is 
considered beneficial for the robust response to environmental stresses, as 
these RNAs can be rapidly released to the cytoplasm and produce proteins 
required for cell survival (Prasanth et al. 2005). A large number of mammalian 
transcripts are believed to be regulated in a similar manner (Chen et al. 2008, 
Faulkner et al. 2009). How the dysregulation of paraspeckles in ALS-FUS 
affects nuclear retention of hyper-edited RNA as well as the stress response 
will be an interesting aspect of FUSopathy to study. 
Modulation of miRNA biogenesis is a recently identified function of 
paraspeckles, where NEAT1 and SFPQ-NONO heterodimer bind to a large 
number of pri-miRNAs and attract the Microprocessor complex to globally 
enhance miRNA biogenesis (Jiang et al. 2017). Consistently, in FUS ΔNLS 
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clones, mature miRNA produced from pri-miR-17~92 transcript are 
significantly decreased. Expression of more than 20-30% of all human protein-
coding genes are fine-tuned by miRNAs-induced silencing (Lewis et al. 2005), 
and altered miRNA expression in the CNS is a well-known pathomechanism 
of ALS. As paraspeckles seem to influence miRNA expression on a global 
scale, presumably, overall miRNA levels are downregulated in these cells.
Therefore, disrupted paraspeckle integrity due to the presence of mutant FUS 
could possibly contribute to the pathogenesis of ALS through miRNA 
dysregulation.
In conclusion, my study reports loss and gain of nuclear function for mutant 
FUS and their possible contribution to ALS-FUS pathogenesis.
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Chapter 5. Antiviral immune response, stress 
granules and ALS-FUS
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5.1. Overview
A multi-step model has been proposed to explain the formation of insoluble 
FUS aggregates in FUSopathy (Droppelmann et al. 2014, Shelkovnikova et al.
2014a). Although FUS readily aggregates in vitro, it has proven difficult to 
achieve its aggregation in vivo, especially in mammals. Rodent models 
expressing human FUS bearing ALS-associated point mutations do not
develop FUS-positive inclusions in affected neurons (Huang et al. 2011, 
Scekic-Zahirovic et al. 2016, Sharma et al. 2016, Devoy et al. 2017, Lopez-
Erauskin et al. 2018). Our group has previously demonstrated that in order to 
achieve FUS aggregation in the CNS of murine models, highly aggregate-
prone artificial FUS variants lacking both major RNA-binding domains and 
NLS have to be used (Shelkovnikova et al. 2013a, Robinson et al. 2015). 
Therefore, it is conceivable that an additional trigger is needed to promote 
robust FUS aggregation and inclusion formation in human diseases.
As discussed in Chapter 1, ALS-associated mutant FUS is known to have a 
strong affinity to SGs (Bosco et al. 2010, Dormann et al. 2010), cytoplasmic 
RNP granules heavily implicated in ALS pathogenesis. In addition to being 
recruited into SGs formed under stress conditions, overexpressed mutant FUS 
can also form spontaneous cytoplasmic RNP granules that sequester SG 
marker proteins, and it has been proposed that various cytoplasmic FUS 
assemblies, when persist, may become the precursors of the pathological 
FUS inclusions found in ALS-FUS neurons (Kino et al. 2011, Shelkovnikova et 
al. 2014a). Conspicuously, FUS-positive inclusions in ALS-FUS are also 
positive for SG markers (Dormann et al. 2010). However, the nature of the 
stressor(s) that could induce the prolonged presence of FUS assemblies and 
thereby act as the trigger for FUSopathy still remains elusive. I sought to 
identify a possible environmental stimulus that can provoke persistent FUS 
aggregation using ΔNLS clones.
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5.2. Results
5.2.1. Poly(I:C) transfection triggers formation of persistent 
stress granules in WT SH-SY5Y cells
A panel of known triggers of SG assembly that induce neurodegeneration-
relevant stresses, including oxidative stress (sodium arsenite, SA), ER stress 
(dithiothreitol, DTT) and proteasome inhibition (MG132) were tested for their 
ability to promote persistent SG formation in WT SH-SY5Y cells. I also included 
a combination of puromycin and the HSP70 inhibitor pifithrin-µ that is reported 
to cause SG formation by a simultaneous accumulation of misfolded proteins 
and polysome dissociation (Bounedjah et al. 2014). Viral infection is also a 
potent trigger of SG formation, therefore I also tested poly(I:C), the viral dsRNA 
mimic. It has been proposed that multiple SG assembly-disassembly cycles 
caused by repetitive stresses might result in the appearance of persistent SGs 
(Wolozin 2012). Since SA, DTT and MG132 are reversible stressors, I was able 
to examine the effect of repetitive stresses. The timeline of treatment for each 
stressor is shown in Figure 5.1. SGs were visualised by G3BP1 staining. 
Figure 5.1 Timelines of SG persistence experiments.
Red arrowheads indicate treatment or transfection. Blue arrowheads indicate wash-
off. Green arrowheads indicate cell fixation. 
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SA, DTT, MG132, pifithrin-µ/puromycin and poly(I:C) induced SGs in 100%, 
95.3±1.8%, 34.7±2.3%, 30.0±3.6% and 52.4±3.0% cells, respectively (Figure 
5.2). Two consecutive treatments with SA, DTT and MG132, separated by a 24 
h recovery period, did not increase the proportion of cells containing SGs 
following the second treatments (Figure 5.2). The viral infection was the only 
stressor capable of inducing prolonged SG presence among all the stressors 
tested. SGs were detectable in 47.6±3.5% and 27.7±4.0% the cells transfected 
with poly(I:C) at 24 h and 48 h post-transfection, respectively, but not in cells 
subjected to any other stressors (Figure 5.2). Interestingly, viral infection has 
been claimed to be a risk factor for ALS (Celeste and Miller 2018, Kury et al.
2018, Xue et al. 2018a), and an increasing number of viruses have been found 
to interact with the SG pathway (Protter and Parker 2016, McCormick and 
Khaperskyy 2017). Therefore, I decided to further investigate this SG-inducing 
stress.
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Figure 5.2 A viral dsRNA mimic triggers formation of persistent stress 
granules.
Representative images and quantification of SG-containing cells after stress and 
recovery. Scatter plots show percentage of SG-containing cells at each time-point. X-
axis labelling 1 ~ 4 correspond to 1st stress, 1st recovery, 2nd stress, 2nd recovery, 
respectively. Between 250 and 300 cells were analysed per time point for each 
stressor. Scale bar is 10 µm.
5.2.2. Cytoplasmic mutant FUS is recruited into the 
poly(I:C)-induced stress granules
Although several stresses, including oxidative stress, proteasome inhibition, 
heat shock and osmotic stress, are known to promote the assembly of FUS-
positive SGs in cells expressing mutant FUS protein (Dormann et al. 2010, 
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Sama et al. 2013, Shelkovnikova et al. 2014a, Mateju et al. 2017), mutant FUS 
incorporation into dsRNA-induced SGs has not been reported. First, I showed 
that overexpressed GFP-tagged FUS R522G and ΔNLS were readily recruited 
into SGs induced by poly(I:C) transfection (Figure 5.3A). Next, I transfected 
ΔNLS clones with poly(I:C) and found that endogenous mutant FUS was also 
readily recruited into poly(I:C)-induced SGs (Figure 5.3B). In WT cells FUS was 
absent from SGs induced by poly(I:C) (Figure 5.3B). Furthermore, significantly 
more cells contained SGs at 2 h and 4 h post-transfection in ΔNLS_het clones 
as compared to WT cells, and even after 24 h, ΔNLS_het clones still had more 
cells containing SGs (Figure 5.3C). In contrast, there was no difference in the 
numbers of SG-containing cells between ΔNLS_het and WT cells during the 
recovery from SA stress (Figure 5.3C).
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Figure 5.3 Mutant FUS is recruited to poly(I:C)-induced stress granules.
A) WT SH-SY5Y cells overexpressing GFP-tagged FUS protein lacking NLS 
(FUS∆NLS) or carrying ALS-associated point mutation (FUS R522G) were 
transfected by poly(I:C). Representative image of cells 4 h post-transfection is shown. 
Proportion of cells containing SGs among GFP-FUS R522G-expressing cells were 
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quantified over 24 h period after poly(I:C) transfection. ≥100 cells were analysed per 
clone/time-point. B) Endogenous mutant FUS is recruited to poly(I:C)-induced SGs 
in ΔNLS clones. Representative images of 4 h after poly(I:C) transfection are shown. 
C) Poly(I:C), but not sodium arsenite (SA), causes persisting SGs in ∆NLS_het 
clones. For quantification, data from two heterozygous clones (∆NLS8_het and 
∆NLS10_het) are pooled. Cells were treated with SA for 1 h, washed and analysed 
during recovery. ≥500 cells were analysed per clone/time-point; Student’s t-test; 
*p<0.05; **p<0.01; ***p<0.001. Scale bars are10 μm.
5.2.3. Poly(I:C) induces morphologically distinct stress 
granules
I noticed that poly(I:C)-stimulated cells usually developed large, few-per-cell 
SGs, while cells treated with other stressors formed multiple small- or medium-
sized SGs. The proportion of cells containing 1, 2 or >2 SGs per cell among all 
SG-positive cells, as well as mean SG sizes, were quantified in ΔNLS clones 
transfected with poly(I:C) for 6 h or treated with SA for 1.5 h. Indeed, 
quantification showed that poly(I:C)-transfected ΔNLS cells contained 1-2 large 
SGs per cell, as compared to SA-treated cells which developed smaller and 
more abundant SGs (Figure 5.4A), as confirmed by quantification (Figure 5.4B). 
Strikingly, in ΔNLS_ho cells, poly(I:C)-induced large SGs were able to 
sequester a substantial amount of FUS, causing its significant depletion from 
the nucleus (Figure 5.4C).
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Figure 5.4 Stress granules induced by poly(I:C) are morphologically distinct from 
stress granules induced by sodium arsenite.
A) Representative images showing SGs induced by SA and poly(I:C) in ∆NLS clones 
visualised using a FUS antibody. B) SG sizes and proportion of cells containing 1, 2 
and >2 SGs are quantified in FUS∆NLS cells transfected with poly(I:C). 250~400 
cells were analysed for SG size and 90~150 cells were analysed for SG number. C)
Poly(I:C)-induced SGs in ∆NLS_ho clone sequester significant amount of FUS 
protein causing its near-complete clearance from the nucleus. Nuclei of SA-treated 
cells are delineated with yellow circles. Nuclei of poly(I:C)-transfected and non-
transfected cells are delineated with blue and pink circles, respectively. Cells were 
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analysed 6 h after poly(I:C) transfection and 1.5 h after SA treatment. Scale bars are 
10 µm.
5.2.4. Preformed cytoplasmic FUS granules coalesce into 
persistent FUS aggregates in response to poly(I:C) 
stimulation
It has been demonstrated that exogenously expressed mutant FUS can form 
cytoplasmic FGs spontaneously in a fraction of unstressed cells (Kino et al.
2011, Shelkovnikova et al. 2014a). The presence of cytoplasmic FGs in some 
of my ΔNLS clones (ΔNLS2_het and ΔNLS11_het) proves that mutant FUS 
expressed at endogenous level can also support the assembly of FGs. Similar 
to exoFGs formed by overexpressed mutant FUS, the endoFGs in ΔNLS clones 
were negative for SG markers (shown in Chapter 3, Figure 3.10). 
In the cells treated with SA, exoFGs coalesce into large FUS aggregates 
(exoFAs hereafter), which sequester SG proteins (Shelkovnikova et al. 2014a). 
I found that poly(I:C) was also able to trigger the formation of FAs in cells 
containing endoFGs (Figure 5.5) and exoFGs (Figure 5.6). These FAs formed 
by endoFG coalescence, termed endoFAs, were morphologically distinct from 
FUS-containing SGs formed in endoFG-negative ΔNLS clones. Although 
endoFAs were capable of recruiting core SG proteins G3BP1 and TIAR, their 
distribution within the structure was different from FUS-containing SGs. In FAs, 
the immunofluorescent signal of G3BP1 and TIAR was intermingled with FUS 
signal, showing a “patchy” pattern, whereas in FUS-containing SGs, G3BP1, 
TIAR and FUS were distributed homogenously throughout the structure (Figure 
5.5A,B). Similar to FUS-positive SGs, poly(I:C)-induced endoFAs also persisted 
in ΔNLS_het cells, being present in 45.6±2.1% of cells 24 h post-transfection 
(Figure 5.5C). 
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Figure 5.5 Mimicking viral infection promotes formation of persistent cytoplasmic FAs in ΔNLS clones containing FGs.
A) In endogenous FUS aggregates (endoFAs) induced by poly(I:C) transfection, fluorescent signals of SG proteins G3BP1 and TIAR do not 
completely overlap with that of mutant FUS. However, in FUS-containing SGs formed in ∆NLS10_het clone, these signals are more homogeneous 
and overlap. Representative confocal images are shown; scale bars are 10 µm. B) Profile plots and surface profiles of endoFAs and FUS-
containing SGs are shown. C) Cells containing endoFAs in ∆NLS11_het clone transfected with poly(I:C) are quantified over a 24. ≥500 cells were 
analysed per clone/time-point.
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In order to study the dynamics of FA formation induced by poly(I:C), I recorded 
the assembly of exoFAs in SH-SY5Y cells containing exoFGs formed by GFP-
tagged FUS R522G, using confocal live imaging. Preformed exoFGs 
assembled into exoFAs promptly after poly(I:C) stimulation, and multiple small 
FAs grew by fusion, eventually forming one large aggregate per cell, and such 
cells stayed viable for at least 12 h of recording period (Figure 5.6).
Figure 5.6 Poly(I:C) induces persistent FAs in cells containing exogenous FGs 
(exoFGs).
Cells were transfected with a plasmid expressing FUS R522G GFP 24 h before 
poly(I:C) transfection. Immediately after poly(I:C) transfection, two cells with 
preformed exoFGs were followed up for 12 h using confocal live imaging. 
Arrowheads indicate two aggregates that eventually fuse to form one large 
aggregate. Scale bar is 10 µm.
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5.2.5. Poly(I:C)-induced mutant FUS assemblies sequester 
nucleocytoplasmic transport factors and the 
autophagy receptor optineurin
Aggregates composed of mutant FUS have been shown to trap other proteins, 
such as P body and paraspeckle components and SMN complex factors, 
resulting in their loss of function (Groen et al. 2013, Shelkovnikova et al. 2014a, 
Shelkovnikova et al. 2014b). Optineurin, an autophagy receptor protein 
encoded by ALS-associated OPTN gene, plays important regulatory functions 
in critical cellular processes on the crossroads of autophagy and anti-viral 
immunity (Ryan and Tumbarello 2018). Previously, optineurin has been found 
in the FUS-positive inclusions in ALS-FUS post-mortem tissue (Ito et al. 2011b). 
I found that optineurin was a component of poly(I:C)-induced SGs (Figure 5.7A) 
in WT SH-SY5Y cells, and significantly more optineurin was recruited into the 
FUS-containing SGs formed in ΔNLS clones compared to those in WT cells 
(Figure 5.7B). Furthermore, optineurin was also detected in the exoFAs formed 
by GFP-tagged FUS R522G under basal conditions (Figure 5.7C).
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Figure 5.7 Optineurin is recruited to stress granules induced by poly(I:C) and 
exoFAs under basal conditions. 
A) Poly(I:C)-induced SGs in WT SH-SY5Y cells contain optineurin. B) Poly(I:C)-
induced SGs containing mutant FUS protein sequester more optineurin compared to 
FUS-negative SGs. Arrowheads indicate SGs containing optineurin in WT cells. Cells 
were analysed 24 h post-transfection. Optineurin intensity in SGs is quantified (≥30
cells). ****p<0.0001. C) Under basal conditions, FAs formed by overexpressed FUS 
R522G GFP also sequester optineurin. Profile plots are generated along the green 
arrows in merged images. Scale bars are 10 µm.
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Recently, impaired nucleocytoplasmic transport has been suggested as one of 
the pathomechanisms contributing to ALS pathogenesis (Boeynaems et al.
2016). Several nucleocytoplasmic transport factors have been found 
sequestered into SGs, including transportin 1 (TNPO1), the major receptor for 
FUS nuclear import (Zhang et al. 2018a). I examined whether mutant FUS-
containing cytoplasmic assemblies induced by poly(I:C) also sequester 
transport factors. Proteins located at the inner ring of nuclear pore complex 
(NPC) - TNPO1 and Karyopherin Alpha 2 (KNPA2), as well as factors at the 
outer ring of NPC – nucleoporins Nup98 and Nup107, were examined in the 
poly(I:C)-transfected ΔNLS clones. Indeed, TNPO1, KNPA2, and Nup107 were 
found to be enriched in poly(I:C)-induced SGs and endoFAs (Figure 5.8).
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Figure 5.8 Nucleocytoplasmic transport factors Nup107, KPNA2 and TNPO1 are 
recruited to mutant FUS-containing cytoplasmic assemblies in poly(I:C)-
transfected ∆NLS cells.
Cells were analysed 6 h post-transfection. Profile plots are generated along the green 
arrows in merged images. Scale bar is10 µm.
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5.2.6. Cells expressing mutant FUS are hypersensitive to 
dsRNA toxicity
I asked whether the presence of mutant FUS renders cells more sensitive to 
dsRNA exposure. Indeed, upon poly(I:C) transfection, significantly more cells 
underwent apoptosis, as visualised by cleaved caspase 3 (CC3) 
immunostaining, at least in ΔNLS_ho clones compared to WT cells (Figure 
5.9A). The pro-apoptotic factor C/EBP homologous protein (CHOP) is also 
upregulated in ΔNLS clones (Figure 5.9B). Differences in survival were 
assessed by the number of CC3-positive cells between fibroblasts bearing FUS 
P525L mutation and control fibroblasts. CC3 immunostaining at 8 h post-
transfection showed significantly more cells undergoing apoptosis in the FUS 
P525L fibroblast cultures suggesting that mutant fibroblasts show increased 
susceptibility to poly(I:C)-induced cell death (Figure 5.9C). I concluded that cells
expressing mutant FUS are less competent in handling the dsRNA-induced 
toxicity.
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Figure 5.9 Cells expressing mutant FUS protein are hypersensitive to dsRNA 
toxicity.
A) More cells in ∆NLS_ho clone are positive for cleaved caspase 3 (CC3) upon  
poly(I:C) transfection. Representative images are shown. For quantification, data 
from two homozygous (∆NLS1_ho and ∆NLS4_ho) and two heterozygous 
(∆NLS10_het and ∆NLS11_het) clones are pooled. Cells were analysed 24 h post-
transfection. For each clone, ≥7 fields of view (x20 magnification) were analysed. 
Mann-Whitney U-test; *p<0.05. Scale bar is 50 µm. B) Pro-apoptotic factor CHOP is 
upregulated in ∆NLS clones compared to WT cells after poly(I:C) transfection. Cells 
were analysed at 24 h post-transfection. Data from three homozygous (∆NLS1_ho, 
∆NLS4_ho and ∆NLS7_ho) and three heterozygous (∆NLS2_het, ∆NLS10_het and 
∆NLS11_het) clones are pooled (N=3 for each clone). Mann-Whitney U-test; *p<0.05. 
C) Fibroblasts derived from an ALS patient carrying FUS P525L mutation are more 
sensitive to poly(I:C) toxicity compared to the fibroblasts from a healthy individual. 
CC3-positive cells are quantified at 8 h post-transfection. For control and patient 
fibroblasts, 9 and 12 fields of view (x20 magnification) were included into analysis, 
respectively. Arrowheads indicate CC3-positive cells. Student’s t-test; ****-p<0.0001.
Scale bar, 10 μm.
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5.2.7. Type I interferon stimulates accumulation of normal 
and mutant FUS protein
Previously, FUS was identified as a strong negative regulator of antiviral gene 
expression (Amit et al. 2009). Thus, it is plausible that cells may demand more 
FUS protein during the antiviral response. Indeed, in WT SH-SY5Y cells, FUS 
mRNA was upregulated upon poly(I:C) transfection as measured by qPCR 
(Figure 5.10A). Type I interferons (IFNs) are the principal drivers of gene 
expression changes in response to dsRNA. Therefore, I examined whether the 
FUS mRNA upregulation observed after poly(I:C) stimulation is downstream of 
IFN signalling. IFNbeta is the main type I IFN induced by poly(I:C) in SH-SY5Y 
cells (Shelkovnikova et al. 2018). As predicted, treatment of cells using IFNbeta 
resulted in a significant increase in FUS mRNA levels, an effect that peaked at 
4 h post-treatment and declined over time (Figure 5.10B). More pronounced 
FUS mRNA increase was achieved by IFNbeta treatment than by poly(I:C) 
transfection, consistent with <100% transfection efficiency and hence IFN 
induction only in a fraction of cells in poly(I:C)-stimulated cultures. In line with 
mRNA increase, FUS protein also accumulated in IFNbeta-treated cells in a 
time-dependent manner. IFN-alpha/beta receptor alpha chain (IFNAR1) 
degradation was observed following IFNbeta treatment, which was consistent 
with the well-established notion that IFNARs undergo degradation upon 
activation by ligands (de Weerd and Nguyen 2012) (Figure 5.10C).   
Next, I tested whether IFNbeta could exert a similar effect on mutant FUS. Like 
in WT cells, FUS protein levels increased in ΔNLS clones when measured after 
24 h IFNbeta treatment (Figure 5.10D). Strikingly, both normal and mutant FUS 
proteins continued to accumulate 24 h after IFNbeta withdrawal from the 
medium (Figure 5.10E). The subcellular localisation of FUS protein in ΔNLS 
clones remained unaffected (Figure 5.10F). 
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Figure 5.10 IFNbeta treatment causes accumulation of both WT and mutant 
FUS protein.
A) Poly(I:C) transfection causes upregulation of FUS mRNA levels in WT SH-SY5Y 
cells. Cells were analysed at 24 h post-transfection. N=4, *p<0.05. B) IFNbeta 
stimulation alone increases FUS mRNA level in WT SH-SY5Y cells. N=4-5. *p<0.05; 
**p<0.01; ***p<0.001. C) FUS protein accumulates upon IFNbeta treatment in a time-
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dependent manner in WT SH-SY5Y cells. Representative western blot and 
quantification are shown. N=3, *p<0.05. IFNAR1 ligand-dependent degradation is 
shown as the readout of receptor activation. D) IFNbeta treatment also causes
accumulation of mutant FUS proteins in ΔNLS cells. FUS KO clone was included as a 
negative control. Cells were analysed after 24 h treatment. E) FUS protein continues 
to accumulate after the removal of IFNbeta from culture media in both WT cells and 
ΔNLS clones. Cells were treated with IFN beta for 24 h, washed and analysed after 
another 24 h. Of note, the different appearances of the FUS protein bands of 
ΔNLS1_ho clone in panel D and E can be explained by the different gel used for 
western blot (Pre-cast gradient gel was used in panel D whereas house-made SDS-
PAGE gel was used in panel E). F) Subcellular localisation of WT and mutant FUS 
protein does not change upon IFNbeta treatment.
Of note, the levels of FUS protein did not increase in poly(I:C)-transfected 
cells despite mRNA upregulation (Figure 5.11A). Puromycin labelling of 
nascent proteins revealed significantly reduced protein translation in poly(I:C)-
transfected cells, but not in the cells treated with IFNbeta. This finding could 
explain the discrepancy between FUS mRNA and protein levels in poly(I:C)-
stimulated cells (Figure 5.11B).
Figure 5.11 Poly(I:C) transfection does not cause FUS protein accumulation 
due to impaired protein translation.
A) FUS proteins do not accumulate upon poly(I:C) transfection in WT or FUS∆NLS 
cells. Cells were analysed at 24 h post-transfection. B) Poly(I:C) transfection 
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significantly impairs protein translation due to eIF2α phosphorylation as revealed by 
puromycin labelling of nascent proteins. IFNbeta treatment did not affect protein 
translation up to 8 h of treatment. Cells collected at 8 h after poly(I:C) transfection, 
and at indicated time-points for IFNbeta treatment. Protein synthesis inhibitor 
cycloheximide (CHX) treatment was carried out as a negative control. 
5.2.8. IFNbeta induces FUS mRNA accumulation by
increasing its stability
In IFNbeta-treated cells, FUS mRNA can be increased either through a 
transcriptional upregulation or due to its increased stability. 
qPCR quantification revealed that the levels of FUS pre-mRNA did not increase 
upon IFNbeta stimulation (Figure 5.12A). Furthermore, transcription inhibition 
by actinomycin D or 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB)
did not prevent FUS mRNA upregulation (Figure 5.12B). IFNbeta signalling is 
mainly mediated by the transcription factor signal transducer and activator of 
transcription 1 (STAT1), and FUS gene is known to possess a STAT1-binding 
site in the promoter region. However, STAT1 knockdown by siRNA did not affect 
FUS mRNA upregulation in response to IFNbeta (Figure 5.12C). Taken together, 
these findings suggest that transcriptional mechanism is unlikely involved in the 
IFNbeta-induced FUS mRNA upregulation. 
Since the stability of mRNAs is mainly regulated by polyadenylation, I 
performed poly(A) tail-length assay (PAT) to compare the poly(A) tail length of 
FUS mRNA before and after IFNbeta treatment. IFNbeta exposure indeed 
shifted the intensity of PCR product smear towards longer poly(A) tails (Figure 
5.12D), indicating the presence of more stable FUS mRNA in the cells treated 
with IFNbeta.
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Figure 5.12 IFNbeta induces FUS mRNA accumulation by increasing its 
stability.
A) FUS pre-mRNA does not increase after IFNbeta treatment in WT SH-SY5Y cells. 
Intron sequences of FUS gene have been amplified using two pairs of primers from 
cDNA samples prepared from total RNA. N=3. B) Transcriptional inhibition using 
actinomycin D or DRB does not prevent FUS mRNA upregulation on IFNbeta 
treatment. Actinomycin D or DRB were added to the cells 1 h before IFNbeta 
treatment and FUS mRNA levels were measured at 4 h post-treatment of IFNbeta. 
Mann-Whitney U-test; **p<0.01; N=4. C) FUS mRNA upregulation after IFNbeta 
treatment is not dependent on STAT1. Cells were transfected with siRNAs 48 h 
before IFNbeta treatment, and FUS mRNA levels were measured 4 h post-treatment. 
Mann-Whitney U-test; ****p<0.0001; N=4. D) Poly(A) tail-length (PAT) assay revealed 
that FUS mRNA species with longer poly(A)-tails accumulate in cells treated with 
IFNbeta. Diagram on the left shows the principle behind PAT assay. p1 and p2 are 
FUS-specific primers. p3 is a universal reverse primer provided in the kit. ‘PA’ stands 
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for poly(A) tail (amplified using p1 and p2) and ‘int’ stands for the internal FUS 
fragment (amplified using P1 and p3). Gel electrophoresis image shows increased 
intensity of the smear corresponding to the longer poly(A) tails in IFNbeta treated PA 
lane (indicated with red square brackets). Profile plot is generated for PA lanes. 
Samples are collected at 8h after IFNbeta treatment.
5.2.9. IFN receptor IFNAR1 is highly expressed in spinal 
motor neurons and is downregulated in ALS-FUS
Type I IFNs modulate adaptive immune responses in many tissues and 
organs including CNS (Paul et al. 2007), and both neurons and glia express 
IFNs and their receptors (Chhatbar et al. 2018). Consistently, we also
detected a high level of interferon-alpha/beta receptor alpha chain (IFNAR1), 
one of the IFN receptor subunits, specifically in ventral horn neurons of the 
human spinal cord (Figure 5.13A). Further, we found that the spinal cord of 
two ALS-FUS patients displayed a dramatic decrease in IFNAR1 levels 
(Figure 5.13B). Since IFNAR1 is known to undergo ligand-dependent 
degradation during viral infection (de Weerd and Nguyen 2012), this 
observation raises the possibility of sustained antiviral signalling activation in 
the CNS of ALS-FUS patients.
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Figure 5.13 IFNAR1 is highly expressed in spinal motor neurons and is 
downregulated in ALS-FUS.
A) IFNAR1 immunohistochemistry (control 1 and ALS-FUS 1 is counterstained with 
H&E) in the spinal cord sections from control and ALS-FUS patients. Scale bars are 
50 and 10 µm in upper and lower panels, respectively. B) IFNAR1 levels are 
decreased in the spinal cord tissue of ALS-FUS patients as revealed by western blot.
This dataset is produced by Dr. Tatyana Shelkovnikova. 
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5.3. Discussion
Although dramatic cytoplasmic FUS accumulation and large FUS-
immunopositive inclusions that fill up the entire cytosolic space are the most 
prominent pathological features of ALS-FUS (Deng et al. 2010), even 
overexpression of ALS-causing mutant FUS in the rodent CNS is not sufficient 
to cause apparent FUS deposition and proteinopathy (Huang et al. 2011, 
Scekic-Zahirovic et al. 2016, Sharma et al. 2016, Devoy et al. 2017, Lopez-
Erauskin et al. 2018).
Based on the results of the current study, I suggest a model (schematically 
depicted in Figure 5.14) where a viral infection that induces dsRNA response
can trigger FUSopathy. Initially, nuclear import defects caused by ALS-causing 
mutations act as the “first hit” to relocalise FUS proteins to the cytoplasm, where 
they build up and possibly form FGs. Antiviral immune response serves as the 
“second hit” and leads to the formation of large persisting FUS-positive 
assemblies. These aggregates further exacerbate the proteinopathy by 
impairing nuclear import and aggrephagy through sequestration of 
nucleocytoplasmic transport factors and the autophagy receptor optineurin, 
respectively. In addition, IFNs produced during antiviral immune response 
promote accumulation of FUS protein, which also aggravates the condition. 
When these persistent cytoplasmic assemblies encounter a (yet unknown) 
“third hit”, they further transform to form stable aggregates that mark the onset 
of FUSopathy. This model is consistent with the recently proposed “multi-step 
model” for ALS development, where intrinsic and extrinsic risk factors are both 
required to initiate the pathological process in the individuals bearing genetic 
predisposition (Al-Chalabi et al. 2014). Consistent with the proposed role for 
environmental factors, others also reported that although gene mutations do 
decrease the number of steps required for the disease onset, 2 or 3 more steps 
would still be necessary (Chio et al. 2018).
The nature of the “third hit”, which triggers the formation of insoluble inclusions, 
still remains unclear. However, based on the facts that binding of specific target 
RNA protects FUS from irreversible aggregation (Shelkovnikova et al. 2014a, 
Maharana et al. 2018), and that viral infection often causes attenuated host 
gene expression and RNase L-mediated cleavage of cellular RNAs (Abernathy 
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and Glaunsinger 2015), I speculate that viral manipulation of the cellular RNA 
levels might contribute to the process, at least partly. 
Here the term “FUS-containing cytoplasmic assemblies” is used to refer to the 
two different types of cytoplasmic structures: SGs containing FUS protein and 
FAs composed of spontaneous FGs. The ability of mutant FUS to form FGs 
under basal conditions and subsequently transform them into FAs under 
stress has been demonstrated in many cellular models including cultured 
neurons (Kino et al. 2011, Shelkovnikova et al. 2014a, Japtok et al. 2015), 
although whether it indeed occurs in human disease is unknown. Regardless 
of their relative contributions towards the onset of FUSopathy, in my current 
study, I demonstrate that antiviral immune response can trigger the formation 
and persistence of both types of FUS assemblies.
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Figure 5.14 FUSopathy triggered by antiviral immune response.
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Other neurodegeneration-associated stresses, such as oxidative stress, ER 
stress and proteasomal dysfunction, can also trigger the assembly of 
cytoplasmic assemblies containing FUS in cultured cells including neurons 
(Ederle and Dormann 2017). However, these assemblies are unstable, and 
therefore they easily disassemble when the stress is resolved. Moreover, the 
above stresses are acute stresses, which could kill the cells within several hours, 
if not resolved. In this regard, viral infection is principally distinct from these 
stresses, because it leads to long-lasting SGs while maintaining cell survival. 
SG oscillation, which is the regular cycles of SG assembly and disassembly, is 
the unique feature of SGs induced by viruses, which ensures host cell survival 
while establishing chronic infection (Ruggieri et al. 2012). Therefore, viral 
infection may initiate FUSopathy in neurons while keeping these cells alive for 
a period of time long enough to allow FUS inclusion formation.
Compromised autophagy is a well-known mechanism underlying excessive 
protein deposition in ALS (Weishaupt et al. 2016). Previously, optineurin has 
been identified in the pathological inclusions in motor neurons of ALS-FUS 
patients (Ito et al. 2011b). Furthermore, it has been reported that mutant FUS 
can impede the autophagic protein clearance thereby contributing to 
FUSopathy development (Ryu et al. 2014, Soo et al. 2015). Autophagy plays 
important roles during antiviral response including viral replication control 
(Shelly et al. 2009). Therefore, many viruses have evolved to adopt various 
strategies to inhibit the autophagy pathway of host cells (Lee and Iwasaki 2008). 
My finding that optineurin is sequestered into FUS-positive assemblies 
suggests an additional mechanism of autophagy dysfunction in the cells 
expressing mutant FUS. 
I believe that type I IFN is the only treatment known so far that causes FUS 
protein accumulation. Apart from viral infection, type I IFN can also be induced 
by other immune stimuli, however, sustained IFN expression is only seen during 
antiviral response (Amit et al. 2009). Decreased IFNAR1 level in the ventral 
horn neurons of ALS-FUS patients suggests that there exists a sustained 
activation of antiviral signalling in the CNS of ALS-FUS patients. Interestingly, 
viral infection is known to induce paraspeckle assembly (Imamura et al. 2014), 
and paraspeckle hyper-assembly is a pathological feature of ALS including 
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ALS-FUS (Nishimoto et al. 2013, Shelkovnikova et al. 2018, An et al. 2019).
Therefore, paraspeckle signalling activation in the ALS spinal cord provides 
another piece of evidence supporting activated antiviral signalling in these 
tissues. 
The model proposed here is also applicable to other FUSopathies that usually 
do not involve FUS gene mutation, such as FTLD-FUS cases. In these cases, 
normal FUS protein is relocalised to the cytoplasm due to its impaired nuclear 
transport caused by yet unknown reasons, and viral infection can be one of 
them. Viruses are known to hijack the components NPCs to facilitate the 
trafficking of viral proteins, thereby causing NPC dysfunction (Le Sage and 
Mouland 2013). For example, enterovirus and cardiovirus can change NPC 
composition resulting in the cytoplasmic relocalisation of some nuclear proteins, 
whereas enterovirous can induce degradation of nucleoporins Nup62, Nup98 
and Nup 153 (Hindley et al. 2007). Therefore, viral infection itself and the 
secondary sequestration of NPC components into the virus-induced 
cytoplasmic FUS assemblies could together contribute to the compromised 
nucleocytoplasmic transport in FUSopathy.
In conclusion, my study lays the groundwork for further investigations into the 
roles the antiviral immune response plays during FUSopathy development. 
Further studies are needed to examine whether viral infection in other model 
systems, such as motor neurons derived from ALS-FUS patients and 
transgenic mouse models, is sufficient to trigger the formation of FUS 
inclusions and expedite the disease.
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Chapter 6. Analysis of FUS truncation 
mutations
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6.1. Overview
Most of ALS-causing FUS mutations are missense mutations, however, other 
types of mutations, such as indels, duplications, splicing site point mutations, 
have also been reported in rare fALS cases (Deng et al. 2014a). These 
mutations disturb the original open reading frame (ORF) of FUS downstream 
of the mutation site, leading to a complete disruption of downstream protein 
sequence, and a C-terminal “tail” of novel, frameshift peptide replaces the 
disrupted region. It has been reported repeatedly that patients bearing FUS
frameshift mutations display a more aggressive ALS phenotype, which is 
characterised by early disease onset, rapid progression and shorter life 
expectancy, compared to patients carrying missense mutations. For example, 
among individuals with FUS frameshift mutations, the majority develop muscle 
weakness in their teens or 20s and die within 1-2 years after disease onset 
(DeJesus-Hernandez et al. 2010, Yan et al. 2010, Yamashita et al. 2012, 
Waibel et al. 2013). The youngest patient reported to date developed the first 
symptoms as early as at the age of 12.5 years and survived for only 18 
months (Yan et al. 2010). In vitro studies found that FUS proteins with 
truncation mutations show more pronounced mislocalisation as compared to 
missense mutations (DeJesus-Hernandez et al. 2010, Yamashita et al. 2012). 
While it is clear that C-terminal truncations lead to deletion of FUS NLS and 
sometimes affect other functional domains of the protein (RGG domains), it 
still remains to be established whether the C-terminal peptide “tail” may confer 
additional pathological characteristics to the truncated proteins. 
To address these questions, I constructed a panel of plasmids expressing N-
terminally FLAG-tagged truncated FUS proteins with or without frameshift 
peptide “tails” (described in Chapter 2). I sought to compare their subcellular 
distribution and aggregation by expressing these constructs in SH-SY5Y cells 
and mouse hippocampal neurons.
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6.2. Results
Firstly, I reviewed the existing literature to collect information of all reported 
truncation mutations in the FUS gene (Table 6.1). I found information on 12 
different frameshift mutations, with the majority being deletion mutations. 
Mutant protein products in all these cases were predicted to have a C-terminal 
truncation and a stretch of frameshift peptide at the C-terminus, with the 
lengths of the “tail” varying between 7 and 54 aa. Certain peptide sequences 
appeared as the result of more than one type of FUS gene mutations (Table 
6.1), and these common sequences (VSTDRIAGRGRIN, 
GVVGTEVALALARWIPGVSTDRIAGRGRIN, WLWPWQDGFQG and 
SMSRSGR) were chosen for the study (Table 6.2). FUS ORFs with the 
corresponding truncation with or without the “tail” were inserted into pFLAG-
CMV-4 vector to express the proteins as N-terminal FLAG tag fusions.
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Table 6.1 A summary of FUS frameshift mutations reported
Gene mutation
Mutant 
protein
Mutation 
type
Predicted C-terminal frameshift peptide 
sequence
Age of 
onset
References
g.10747A>G; IVS13-
2A>G 
p.G466VfsX14
splicing 
mutation
VSTDRIAGRGRIN* 20
DeJesus-Hernandez, 
M., et al. (2010)
c.1432_1478del 
GGCTATGATCGAGGC
GGCTACCGGGGCCG
CGGCGGGGACCGTG
GAGG
p.G478LfsX23 deletion LPRGPGWWGQRWLWPWQDGFQG* 21, 26
Waibel, S., et al. 
(2013)
c.1419_1420insGT p.G474VfsX56 insertion
VVAEEAMIEAATGAAAGTVEASEGAGVVGTEVAL
ALARWIPGVSTDRIAGRGRIN*
26 Hara, M., et al. (2012) 
c.1449_1488del
CTACCGGGGCCGCG
GCGGGGACCGTGGA
GGCTTCCGAGGG
p.Y484AfsX32 deletion AGVVGTEVALALARWIPGVSTDRIAGRGRIN* N/A Yan, J., et al. (2010)
c. 1475delG p.G492EfsX37 deletion
EASEGAGVVGTEVALALARWIPGVSTDRIAGRGR
IN*
17
Yamashita, S., et al. 
(2012)
c.1483delC p.R495EfsX34    deletion EGAGVVGTEVALALARWIPGVSTDRIAGRGRIN* 23, 72 Yan, J., et al. (2010)
c. 1484delG p.R495QfsX34 deletion QGAGVVGTEVALALARWIPGVSTDRIAGRGRIN* 19
Belzil, V. V., et al. 
(2012)
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c.1485delA p.G497AfsX32    deletion AGVVGTEVALALARWIPGVSTDRIAGRGRIN* 12.5 Yan, J., et al. (2010)
c.1506dupA p.D502EfsX15  
duplicatio
n
EQRWLWPWQDGFQG* 49
Belzil, V. V., et al. 
(2011)
c.1509_1510delAG p.G504WfsX12 deletion WLWPWQDGFQG*
15, 23, 
33
Kent, L., et al. (2014)
c.1527insTGGC p.K510WfsX8 insertion WQDGFQG* 23, 46 Yan, J., et al. (2010)
c.1542-2A>C p.G515SfsX8
splicing 
mutation
SMSRSGR* N/A
Belzil, V. V., et al. 
(2010)
c.1554_1557delACAG p.Q519IfsX9 deletion IAGRGRIN* 18
Bäumer, D., et al. 
(2010)
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Table 6.2 FUS constructs expressing truncated FUS with/without “tails”
* FUS466 and FUS513 were already available in the lab.
* C-terminal “tail” sequences are labelled with the same colour code as in 
table 6.1.
Each of the constructs was transiently expressed in WT SH-SY5Y cells and 
subsequently in 5 days in vitro (DIV5) mouse hippocampal neurons. 
Microscopic analysis revealed that the same types of intracellular FUS 
distribution (diffuse, small granules and large aggregates) are formed in cells 
transfected with constructs expressing truncated FUS variants with or without 
the “tail”, either in SH-SY5Y cells or in the neurons (Figure 6.1 and 6.2).
Although this preliminary experiment did not reveal dramatic differences in 
FUS aggregation between truncated FUS proteins with or without a “tail”, 
more comprehensive studies are required in the future, which might highlight 
interesting aspects of FUSopathy caused by truncation mutations. This will be
discussed in Chapter 7. 
Construct
Truncated 
FUS
C-terminal frameshift peptide sequence
FUS466 FUS 1-466 none
FUS466fs FUS 1-466 VSTDRIAGRGRIN
FUS491 FUS 1-491 none
FUS491tail FUS 1-491 GVVGTEVALALARWIPGVSTDRIAGRGRIN
FUS503 FUS 1-503 none
FUS503tail FUS 1-503 WLWPWQDGFQG
FUS513 FUS 1-513 none
FUS514tail FUS 1-514 SMSRSGR
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Figure 6.1 Expression of truncated FUS proteins in WT SH-SY5Y cells.
No obvious difference in granule formation and protein aggregation between proteins 
with or without a C-terminal “tail” was observed. Proteins are N-terminally labelled 
with FLAG. Cells are stained with an anti-FLAG antibody 24 h post-transfection. 
Representative images are shown. Scale bar is 10 µm.
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Figure 6.2 Truncated FUS proteins expressed in the mouse hippocampal 
neurons display similar aggregation propensity.
Proteins are N-terminally labelled with FLAG. Cells are stained with an anti-FLAG 
antibody 24 h post-transfection. Representative images are shown. Scale bar is 10 
µm.
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6.3. Discussion
In this part of the project, I sought to investigate whether a stretch of 
frameshift peptide on the C-terminus of FUS protein caused by frameshift 
mutations has additional contribution to the aggregate formation, independent 
of the truncation itseft. Of note, among the “tails” tested, there is a “tail” with 
exactly the same amino acid sequence (VSTDRIAGRGRIN) as found in
ΔNLS10_het clone. By microscopic observation of two cellular models 
overexpressing mutant FUS (with or without a “tail”), I could not detect obvious 
differences in protein aggregation between truncated FUS protein and 
truncated FUS protein with any of the “tails”. 
The degree of cytoplasmic mislocalisation of FUS is suggested to be positively 
correlated to the disease severity (Dormann et al. 2010). FUS P525L and 
R522H mutations, which show the strongest degree of mislocalisation, are 
found in the patients with very early disease onset - 24 and 28.5 years, 
respectively (Chio et al. 2009, Kwiatkowski et al. 2009). Mutant FUS proteins 
encoded by the FUS gene bearing frameshift mutations showed more 
pronounced cytoplasmic redistribution compared to the missense mutations 
(DeJesus-Hernandez et al. 2010, Yamashita et al. 2012, Kent et al. 2014). 
While it is clear that the increased cytoplasmic FUS levels caused by almost 
complete disruption of NLS is one of the mechanisms behind the increased 
toxicity of the truncated FUS protein, the role of the de novo peptide “tails” in 
truncated proteins remained uncertain.
In the current study, I did not find dramatic differences in the pattern of 
subcellular distribution and aggregation between proteins with and without C-
terminal “tail”. However, I cannot exclude that subtle changes might still be 
present.
In conclusion, the exceptionally aggressive clinical manifestations observed 
among the patients carrying frameshift FUS mutations are very likely caused 
by the dramatic cytoplasmic mislocalisation due to the complete NLS loss of 
function, and the presence of C-terminal “tails” dose not further aggravate 
FUS aggregation. However, the possibility that the “tails” might perturb other 
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cellular pathways by promiscuous interaction with other proteins cannot be 
excluded, which requires further investigation.
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Chapter 7. Final discussion and perspectives
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7.1. Overview
A decade has passed since the link between FUS gene and ALS was first 
established, and data from hundreds of reports published since then have 
greatly improved our understanding of the molecular mechanisms underlying 
ALS-FUS. Ubiquitin-positive, TDP-43-negative cytoplasmic inclusions 
containing FUS protein are a pathological hallmark of affected neurons and 
glia in ALS-FUS (Kwiatkowski et al. 2009, Vance et al. 2009). ALS-associated 
mutations in FUS gene cause mislocalisation of the encoded protein to the 
cytoplasm by disrupting its NLS, and the degree of mislocalisation is 
correlated with the age of disease onset (Dormann et al. 2010, Ito et al.
2011a). Despite recent insights, there are still a number of important 
outstanding questions: how does mutant FUS exert its toxicity in the neurons 
and glial cells? Is cytoplasmic gain of function or rather nuclear loss/gain of 
function the main mechanism in the molecular pathogenesis of ALS? How do 
the pathological inclusions form? Does an external stress trigger FUSopathy 
and if so, what is the nature of the stress? 
Modification of the endogenous FUS gene has made it possible to study the 
pathogenic behaviour of ALS-associated mutant FUS in a more 
(patho)physiological setting. Using a panel of single cell-derived SH-SY5Y 
sub-clones with FUS gene modifications, I have identified two molecular 
mechanisms that may underlie ALS-FUS, namely, hyper-assembly of 
structurally and functionally abnormal paraspeckles and antiviral immune 
response. Hereafter, I will discuss broader implications of my findings and how 
FUSopathy modelling can be improved in the future. 
7.2. Modeling FUSopathy
Cellular models expressing endogenous mutant FUS protein provide a reliable 
platform for researchers to study cellular and molecular mechanisms leading 
to FUSopathy. These models can either be established from cells obtained 
from individuals bearing FUS gene mutation or be generated through gene 
modification in cultured cells. 
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Human iPSCs derived from fibroblasts of FUS mutation carriers are highly 
instrumental in the study of pathological behaviour of FUS proteins by 
modelling exact genetic background. In addition, they can be differentiated 
into disease-relevant cell types, such as spinal motor neurons, to recapitulate 
the microenvironment. In order to achieve adequate power to attribute certain 
cellular phenotypes to disease development, multiple independent iPSC lines 
are required. However, since FUS mutations account for only about 5% of 
total fALS cases, and fALS cases account only 10% of total ALS cases, this
resource is not readily available for most laboratories. Furthermore, the 
acquisition of human fibroblasts, their reprogramming into iPSCs and 
subsequent characterisation and maintenance is an expensive, time-
consuming, and technically challenging process, which until recently greatly 
hampered their widespread application. There also exists a flexibility issue, 
since patient-derived iPSCs can only model specific point mutations, they are 
not suitable for some research purposes such as functional dissection of the 
protein domains. 
Targeted gene modification by the CRISPR/Cas9 is an extremely versatile 
approach to obtain cellular models of FUSopathy. It can not only be used to 
model exact ALS-causing FUS gene point mutations but also be used to 
modify or delete any part of the gene in a variety of cell types. Recently, a 
number of groups have reported FUS cellular models generated by this 
method. Naumann and his colleagues used CRISPR/Cas9 to establish iPSCs 
expressing FUSP525L tagged with C-terminal GFP based on an iPSC line 
obtained from an ALS patient carrying FUS R521C mutation. That was 
achieved by correcting the original mutation and introducing a new c.1574C>T 
mutation together with C-terminal GFP sequence. The authors reported that 
impaired DNA damage response, that exacerbated FUS cytoplasmic 
mislocalisation and resulted in distal axonal pathology, is an early pathological 
event upstream of FUS aggregation (Naumann et al. 2018).  Marrone et al. 
also generated reporter iPSC lines expressing FUS P525L with C-terminal 
GFP to study SG dynamics. They found that SGs were more numerous and 
larger in mutant FUS-expressing iPSCs compared to isogenic WT lines, and 
enhancing autophagy ameliorated the phenotype (Marrone et al. 2018). 
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Our cellular models are different from above-mentioned models in three ways. 
First of all, instead of iPSCs, I opted for the human neuroblastoma SH-SY5Y 
cell line, whose manipulation is more cost-effective and less labour-intensive. 
It allowed us to achieve the desired results quickly with less cost. Secondly, 
rather than modelling just one specific disease mutation, e.g. FUS P525L, I 
deleted the entire NLS domain, which harbours the majority of ALS-associated 
FUS mutations, in order to put my cellular models on the more severe end of 
the ALS-FUS spectrum. In addition, this approach also significantly increased 
gene editing efficiency, since it relied on the removal of a target fragment 
during DNA repair through the highly efficient NHEJ mechanism, rather than 
through a less-efficient homology directed repair (HDR) mechanism which 
also requires a donor template to guide the creation of a point mutation (Cong
et al. 2013). Finally, I minimized the introduction of non-physiological elements 
in my clones, such as fluorescent tags or selection markers, to avoid any 
background effects that might be caused by these elements. Overall, the 
strategy I used to generate FUSΔNLS clones represents an easily accessible, 
fast and cost-effective way of creating reliable cellular models expressing 
endogenous mutant FUS protein.
However, due to the error-prone nature of NHEJ DNA repair pathway caused 
frameshift mutations in about half of the sequenced alleles, resulting in a 
stretch of amino acid “tail” on the C-terminus of FUS protein. The apparent 
solution to achieve error-free FUS gene editing is to simultaneously introduce 
a repair template to guide DNA repair through the HDR pathway (Ran et al.
2013). However, as HDR is relatively rare compared to the predominant NHEJ 
in mammalian cells, widespread application of this method is hampered by low 
efficiency (Cong et al. 2013, Canver et al. 2014). Several strategies have been 
suggested to increase HDR rate and inhibit NHEJ to improve the editing 
efficiency (Paquet et al. 2016, Aird et al. 2018), including the application of 
NHEJ pathway inhibitors or covalent tethering of DNA repair template to the 
gRNA-Cas9 complex.  Recently, the research focus has begun to shift 
towards improving the repair accuracy of the NHEJ pathway (Guo et al. 2018, 
Shen et al. 2018). For example, a machine learning model is used to 
accurately predict the spectrum of genotypic products at a target site of 
interest, enabling template-free genome editing with higher precision (Shen et 
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al. 2018). Therefore, modification of the FUS gene with greatly improved 
efficiency and accuracy will be achievable in future studies.
Another concern about gene modification is the “off-target” effect, i.e. the 
undesirable editing activities of CRISPR/Cas9 at the genomic foci outside the 
intended targeting site. Several strategies have been developed to tackle the 
problem. Modification of gRNAs, such as 5' end truncated or chemically 
modified gRNAs, can decrease the recognition of mismatched targets 
(Pattanayak et al. 2013, Fu et al. 2014, Doench et al. 2016, Cromwell et al.
2018, Listgarten et al. 2018). In addition, genetically engineered Cas9 variants 
can be used to improve editing specificity (Ran et al. 2013, Guilinger et al.
2014, Kleinstiver et al. 2016, Chen et al. 2017). Double nickase strategy, 
which exploits a mutant form of Cas9 that only cleaves single strand of DNA, 
is the most well-known example (Ran et al. 2013, Shen et al. 2014a), where 
only the specific sites containing two very close target sites can be cleaved by 
two nickases to create a DSB. Recently, a range of high-fidelity Cas9 
nuclease variants have been developed, which are proven to dramatically 
reduce off-target effects, such as pCas9-HF1 (Kleinstiver et al. 2016), 
eSpCas9 (Slaymaker et al. 2016) and HypaCas9 (Chen et al. 2017). Although 
off-target modifications cannot be completely eliminated, clonality issues can 
be bypassed by using a heterogeneous population of edited cells obtained, for 
instance, by fluorescence-activated cell sorting (FACS). I believe that 
synergistic use of the above-mentioned strategies will significantly improve the 
specificity in the future attempts to modify the FUS gene.
7.3. Paraspeckles in ALS pathology
Post-mitotic neurons are naturally devoid of paraspeckles due to low 
NEAT1_2 levels (Nakagawa et al. 2011), however, at the early stage of ALS, 
paraspeckles become detectable in the motor neurons and glial cells 
(Nishimoto et al. 2013). Enhanced paraspeckle assembly is not only evident in 
sALS spinal cord, but could also be identified in fALS cases with various 
genetic background, namely ALS-C9 and ALS-TDP43 (Shelkovnikova et al.
2018). In Chapter 4, I also reported paraspeckle hyper-assembly in ALS-FUS 
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spinal cord, further supporting the notion that de novo paraspeckle assembly 
is one of the pathological hallmarks of spinal cord motor neurons in ALS. What 
is the physiological or pathological significance of this change? Is it protective 
against neuronal death or detrimental for neuronal survival? Can we modulate 
the disease course by manipulating NEAT1_2 levels and paraspeckle 
formation? 
NEAT1_2 expression and paraspeckle assembly show a strict tissue-specific 
distribution in vivo: they are restricted to the surface epithelial cells of the 
gastrointestinal tract, which are exposed to harsh environmental conditions 
and undergo active renewal (Nakagawa et al. 2011), suggesting that 
paraspeckles might be required for stress response. In line with this 
assumption, NEAT1 was initially found increased in the mice brain infected 
with Japanese encephalitis virus (Saha et al. 2006). Furthermore, in in vitro
cellular models, paraspeckles are dramatically enlarged upon exposure to 
various stresses, including proteasome inhibition and viral infection. 
Therefore, in ALS motor neurons, NEAT1 expression and paraspeckle 
assembly are likely enhanced in response to internal or external stressful 
conditions, such as disrupted cellular homeostasis (e.g. collapse of 
proteostasis) or environmental stimuli (e.g. neuroinflammation).                
Paraspeckles are known to participate in the maintenance of cellular 
homeostasis in the stressful environment by sequestering transcription factors 
(Hirose et al. 2014, Imamura et al. 2014, Ma et al. 2017) and a specific 
subgroup of RNA molecules (Chen and Carmichael 2009, Hu et al. 2015). For 
example, paraspeckle formation as a part of antiviral response facilitates 
antiviral gene expression, such as IL8, CCL5 and retinoic acid-inducible gene 
I (RIG-I), by relocating SFPQ from the promoter region to paraspeckles 
thereby ameliorating its inhibitory effect on the antiviral genes (Imamura et al.
2014, Ma et al. 2017), and depletion of NEAT1_2 delayed innate immune 
response and accelerated viral replication in mice infected with Hantaan virus 
(Ma et al. 2017). Moreover, mouse embryonic fibroblasts (MEF) prepared from 
NEAT1 KO mice showed a dramatically decreased survival rate during 
proteasomal stress, indicating antiapoptotic roles of paraspeckles (Hirose et 
al. 2014). In addition, paraspeckle formation stimulated by p53 activation 
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prevented the accumulation of DNA damage in the cells under oncogenic 
stress (Adriaens et al. 2016). Hence, it is plausible that paraspeckle assembly 
in ALS neurons is a protective measure to maintain cellular homeostasis and 
promote neuronal survival. Indeed, in cellular models of TDP-43 
proteinopathy, paraspeckle hyper-assembly is proven to be beneficial for cell 
survival as disruption of them resulted in increased cytotoxicity (Shelkovnikova
et al. 2018). 
In ALS-FUS neurons, despite the increased NEAT1 level, this safety 
mechanism is significantly impaired since paraspeckles no longer maintain 
normal structure and function due to the presence of mutant FUS. In addition, 
increased release of free NEAT1_1 into the nucleoplasm further exacerbates
the condition. Making things even worse, the core paraspeckle protein NONO 
is found trapped in the cytoplasmic and nuclear FUS inclusions, which also 
diminishes paraspeckle integrity by decreasing the nuclear pool of NONO 
(Shelkovnikova et al. 2014b). Perhaps, inadequate protective response due to 
the impaired paraspeckle assembly could explain why ALS-FUS usually 
shows an extremely aggressive disease course compared to sALS and other 
forms of fALS cases (Shang and Huang 2016).    
Although much work still needs to be done, once we have sufficient 
knowledge about the functional significance of paraspeckles and NEAT1 
levels during ALS development, we can possibly modulate disease course by 
manipulating NEAT1 levels and paraspeckle assembly. Antisense 
oligonucleotides (ASOs), which are being tested as a candidate therapeutic 
approach for monogenic forms of neurodegenerative diseases, can also be 
used to modulate NEAT1 levels. However, it should be noted that an 
unconventional mechanism of ASOs action has been reported for NEAT1, 
where phosphorothioate (PS)-modified ASOs formed paraspeckle-like 
structures recruiting multiple paraspeckle proteins, which eventually led to 
rapid degradation of NEAT1 (Shen et al. 2014b). Moreover, it is also reported 
that widely used 2’F modified PS-ASOs induced degradation of NONO and 
SFPQ thereby downregulating NEAT1 levels (Shen et al. 2015). Therefore, 
careful design of ASOs is essential for their therapeutic applications. Since no 
clinically applicable chemical compounds which can regulate NEAT1 levels 
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are known, it will be of great value developing a cell-based assay to screen 
chemical compound libraries to identify potential modulators of NEAT1 in the 
future.
The strong association between NEAT1/paraspeckles and ALS is gaining 
more credence, although we have just started to paint the picture of their 
distribution, regulation and functions in the CNS and their changes during the 
disease. In order to fully appreciate the spectrum of effects of 
NEAT1/paraspeckles in ALS, there are a number of important knowledge 
gaps we need to fill in: 1) cell-specific pattern of NEAT1 expression and 
regulation in CNS, and whether this pattern can be recapitulated in cultured 
cells in vitro; 2) molecular and cellular functions of NEAT1 in normal neurons 
and other cells in the CNS; 3) mechanisms leading to NEAT1 upregulation 
and paraspeckle assembly and neuroprotection in motor neurons in ALS; 4) 
differential roles of the two NEAT1 isoforms during ALS development. In vivo 
and in vitro models lacking total NEAT1 or NEAT1_2 expression will be 
extremely instrumental in experimental studies aiming to answer these 
questions. Although no obvious neurological abnormalities have been 
reported in total NEAT1 KO mouse model (Nakagawa et al. 2011), thorough 
scrutiny of the neurons isolated from these mice should reveal the neuro-
specific roles of NEAT1.
7.4. Viral infection and ALS
I have demonstrated in Chapter 5 that the antiviral immune response triggers 
and aggravates FUSopathy by promoting FUS assembly persistence and FUS 
protein accumulation. In addition, possible impairment in aggrephagy and 
nucleocytoplasmic transport could also contribute to FUSopathy development. 
Here I will further discuss the link between viral infection and ALS to outline 
possible future directions of these studies. 
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7.4.1. Evidence supporting the connection between viral 
infection and ALS
Since decades ago, there has been accumulating epidemiological and clinical 
evidence suggesting the link between ALS and viral infection (Celeste and 
Miller 2018). Early on, it has been reported that individuals who have a history
of poliomyelitis showed an increased risk of developing MND later in their lives 
(Martyn et al. 1988). In addition, a large scale, multi-centre case control study 
reported a higher rate of enterovirus RNA detection in the cerebrospinal fluid 
(CSF) among ALS patients (Vandenberghe et al. 2010), which showed no 
seasonal pattern, indicating a persistent enteroviral infection. Interestingly, 
several common cellular and molecular phenotypes have been found between 
enteroviral infection and ALS (Ravits 2005, Vandenberghe et al. 2010). It has 
been reported that coxsackievirus B3 (CVB3) infection in HeLa cells results in 
cytoplasmic mislocalisation and cleavage of TDP-43, the most common 
pathological hallmark of ALS, via the action of CVB3-encoded proteinase 
(Fung et al. 2015). Enterovirus infection in the murine CNS resulted in cellular 
pathologies that are typically found in ALS including cytoplasmic inclusions 
containing TDP-43 (Xue et al. 2018b, Masaki et al. 2019). Notably, during the 
life cycle of enteroviruses, a dsRNA intermediate is formed, which is capable 
of triggering SG assembly (Lloyd 2016). 
Retroviral infection might also be involved in ALS. Patients infected with 
human immunodeficiency virus (HIV) or human T cell leukemia virus -1 
(HTLV-I) sometimes develop neurological conditions clinically resembling ALS 
(Alfahad and Nath 2013). Furthermore, human endogenous retrovirus (HERV) 
reactivation from the human genome has been recently associated with ALS 
(Brutting et al. 2017). About 8% of the human genome is composed of HERV 
sequences that are transcriptionally silent (Jern and Coffin 2008). However, 
certain viral infections, such as HIV and Epstein Barr virus, or hypoxia could 
reactivate them (Nellaker et al. 2006, Kewitz and Staege 2013). Expression of 
HERV-K, the biologically most active HERV family, is significantly upregulated 
in the brain of ALS patients (Douville et al. 2011). Intriguingly, mutant TDP-43, 
but not WT TDP-43, is shown to promote the accumulation and aggregation of 
HERV-K viral protein (Manghera et al. 2016), and expression of HERV-K 
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protein in human neurons or in the murine CNS caused neurotoxicity and 
selective motor neuron loss (Li et al. 2015).
I speculate that viral infections (or reactivation of HERV by various 
environmental stimuli) and subsequent immune response could trigger the 
disease onset by further dysregulating cellular pathways that are already 
perturbed by ALS-causing mutations. My study is the first to demonstrate the 
mechanism by which antiviral response may initiate and exacerbate the 
disease in the cells bearing a FUS gene mutation.
7.4.2. Stress granules during antiviral response
In Chapter 5, I have demonstrated that poly(I:C)-induced SGs persist in the 
cells, which may contribute to the insoluble cytoplasmic inclusion formation in 
ALS by holding together proteins harbouring prion-like domains. Here I will 
discuss other features of virus-induced SGs that might shed light on the link 
between viral infection and ALS pathology.  
Piotrowska et al. reported long-lasting presence of SGs over the course of 
infection in poliovirus-infected cells, where the SGs were composed of TIA-1 
and mRNA, but lacked G3BP1 (Piotrowska et al. 2010). Later, a follow-up 
study demonstrated that these TIA-1-containing SGs became devoid of 
mRNAs and other SG marker proteins, transforming to protein aggregates at 
the later stage of infection (White and Lloyd 2011). These studies 
demonstrated that cytoplasmic RNP assemblies induced by viruses can 
transform into protein aggregates, through the depletion of protein and RNA 
components, over the prolonged infection. Interestingly, recruitment of mutant 
FUS into SGs has been demonstrated to be protective against irreversible 
aggregate formation (Shelkovnikova et al. 2013b), and RNA depletion has 
been proposed to be the critical step triggering the transition of reversible FUS 
assemblies into pathological aggregates (Shelkovnikova et al. 2014a). 
Therefore, the transformable feature of virus-induced SGs into protein 
aggregates reinforces the link between viral infection and the onset of 
FUSopathy.
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Another intriguing finding regarding the effect of viral infection on SGs is that 
virus-infected cells show impaired SG assembly when exposed to additional 
stressful conditions. For example, cells infected with herpes simplex virus 2 
(HSV-2) failed to assemble SGs in response to SA-induced oxidative stress 
(Finnen et al. 2012, Finnen et al. 2014), and such impairment is ascribed to 
the virion host shutoff protein (VHS), which acts downstream of eIF2α 
phosphorylation (Finnen et al. 2014). SGs are central hubs for stress 
response and innate immunity, and cells with impaired SG assembly show 
decreased survival in stressful conditions (Anderson and Kedersha 2009b). 
These findings suggest that viral infection can render neurons incapable of 
managing cellular stresses, which will be extremely detrimental to neurons 
already expressing ALS-causative mutant proteins such as FUS. 
Of note, during a genuine viral infection (as opposed to poly(I:C) stimulation), 
the intracellular environment is much more complicated due to the expression 
of viral genes. Moreover, each virus affects SGs and related cellular signalling 
very differently in distinct cell types. Therefore, it will be very interesting to 
study SG dynamics in motor neurons of mice infected with certain neurotropic 
viruses that are associated with ALS.
7.4.3. Virus-induced pathological changes associated with 
ALS
In addition to persistent SGs, I have also found that nucleocytoplasmic 
transport and autophagy changes occur in mutant FUS-expressing cells 
subjected to a viral trigger. Other ALS-associated cellular abnormalities have 
also been reported in virus-infected cells by other groups. 
Many ALS mutations affect RBPs, as has been discussed earlier. Viruses rely 
heavily on host cell proteins for their replication, and many nuclear RBPs are 
found hijacked and detained in the cytoplasm by viruses. In cells infected with 
Enterovirus A71, the ALS-associated protein hnRNPA1 is found to be 
mislocalised to the cytoplasm, where it facilitates translation of viral proteins 
(Tolbert et al. 2017). Most interestingly, cytoplasmic translocation and 
cleavage of TDP-43, which is mediated by viral proteases, was reported in the 
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CVB3-infected cells (Fung et al. 2015). The cleaved TDP-43 N-terminal 
fragment compromised the function of WT TDP-43 resulting in abnormal 
alternative splicing of cystic fibrosis transmembrane conductance (CFTC) 
regulator gene. A similar finding was also reported very recently in the CNS of 
mice infected with Theiler’s murine encephalomyelitis virus (TMEV). In these 
mice, TDP-43 was found mislocalised and aggregated in the affected neurons 
and glia, and in vitro study revealed abnormal splicing events in infected cells 
(Masaki et al. 2019). Not only viral components, but host antiviral immune 
reaction itself is known to trigger RBP translocation. For instance, TNF-α and 
IFN-γ cause the mislocalisation of TDP-43 and hnRNPA1, respectively 
(Correia et al. 2015, Salapa et al. 2018). Therefore, altered localisation and 
function of RBPs, coupled with viral modification of SGs, collectively contribute 
to the dysregulation of RNA homeostasis.  
Attenuated clearance of misfolded proteins is one of the well-known 
mechanisms causing proteinaceous inclusion formation and neuronal death in 
ALS. In Chapter 5, I have demonstrated that the autophagy receptor 
optineurin was sequestered into dsRNA-induced cytoplasmic FUS 
assemblies, which could potentially subvert efficient clearance of misfolded 
proteins. In addition, many viruses exploit and/or modify the components of 
the protein quality control system for their own benefit. The autophagy adapter 
protein Sequestosome-1/p62, encoded by an ALS-associated gene SQSTM1, 
is also found cleaved by a viral protease of CVB3, leading to the functional 
loss of p62 and disruption of selective autophagy (Shi et al. 2013). 
Furthermore, the C-terminal cleavage product of p62 can compete with the 
uncleaved, functional form of the protein, further jeopardising autophagy (Shi
et al. 2014). This is consistent with earlier studies that reported abnormal 
accumulation and aggregation of misfolded proteins in the cells infected with 
the CVB3 virus (Gao et al. 2008, Si et al. 2008). Although limited evidence is 
available to directly support the link between virus-induced disruption of the 
protein degradation process and ALS, UPS and autophagy are among the 
most affected cellular machineries hijacked by viruses, supported by hundreds 
of reports (reviewed in (Luo 2016)).  Likewise, many viruses are known to 
cause ER stress by utilizing ER membrane for viral replication (Jheng et al.
2014), or by overwhelming host cell protein translation and folding machinery 
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(Zhang and Wang 2012). Hence, viral infection can be particularly detrimental 
to the neurons with perturbed proteostasis due to ALS-associated mutations.    
Chronic neuroinflammation is a common histopathological feature of ALS, and 
activation of microglia and astrocytes has been suggested to be the 
underlying cause (Robertson et al. 2001). Apart from direct damage to 
neurons, viruses could also cause immune-mediated injury by stimulating pro-
inflammatory cytokine release and activating glial cells. For example, in the 
CNS of mice infected with CVB3, a rapid release of chemokines, cytokines, 
and type I IFNs was observed, which remained upregulated for weeks post-
infection (Feuer et al. 2009). Consistently, the levels of IL-6 and IL-1beta are 
found upregulated in the CSF and serum of patients infected with enterovirus 
71 in CNS (Lin et al. 2003). Moreover, positron emission tomography imaging 
of HIV-1 infected patients revealed microglia activation even in the absence of 
neurological symptoms (Garvey et al. 2014). Activation of immune response is 
undoubtedly beneficial for the nervous system to fight against viral infection. 
However, dysregulation of the complicated network or persistent inflammation 
and glial cell activation can be deleterious for neuronal survival, which is 
particularly true in individuals with mutations in the genes encoding proteins 
participating in immune signalling, such as TBK1 and optineurin (Oakes et al.
2017, Slowicka and van Loo 2018).
In conclusion, an increasing number of studies suggest that viral infection, 
enteroviruses and retroviruses in particular, may act as a potential trigger for 
ALS onset and progression. Future studies should focus on finding direct 
evidence of viral infection in patients-derived samples. Histopathological 
analysis of infection-related proteins in the CNS of ALS patients might provide 
important clues. Meta-analysis of existing epidemiological data can also 
highlight previously unknown links between viral infections and ALS.
7.5. Frameshift mutations in ALS
In Chapter 7, I attempted to address possible effects of C-terminal peptide 
“tails” introduced by frameshift FUS mutations. Although these “tails” did not 
visibly change the distribution and aggregation patterns of truncated FUS, it is 
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still possible that they could confer toxicity by altering other features of FUS 
protein, for example the pattern of its post-translational modifications. 
Post-translation modifications, such as phosphorylation and methylation, are 
known to affect FUS protein subcellular localisation and functions. For 
example, phosphorylation of FUS protein on the N-terminus triggered its 
cytoplasmic translocation (Deng et al. 2014b), and phosphorylation of C-
terminal tyrosine residue inhibited its nuclear import (Darovic et al. 2015). 
Additionally, methylation of FUS protein is required for the toxic function of 
ALS-associated mutant FUS protein (Tradewell et al. 2012). Certain amino 
acids are the target of post-translational modifications - serines (S), threonines 
(T) and tyrosines (Y) are often targeted by phosphorylation, while arginines 
(R) are usually subject to methylation (Brautigan 1995, Bedford and Clarke 
2009). Intriguingly, C-terminal “tails” caused by frameshift mutations are 
enriched in such modification target sites, such as SMSRSGR (caused by 
G515SfsX8 mutation), VSTDRIAGRGRIN (caused by G466VfsX14 and some 
other mutations). As an important regulatory mechanism, post-translational 
modifications not only alter protein conformation and localisation but also 
change the nature and strength of protein-protein interaction, thereby affecting 
various cellular pathways (Fronz et al. 2011, Nishi et al. 2011). Therefore, 
investigating whether the C-terminal “tails” are post-translationally modified 
will provide us with clues about the properties conferred by these “tails”.
Apart from post-translational modifications, the presence of an extra chain of 
amino acids itself could result in changes in protein behaviours through 
changing protein conformation, which might in turn promote promiscuous 
protein interactions or interfere with normal FUS protein functions, which  
include transcription, splicing, DNA damage repair, miRNA biogenesis, mRNA 
transport, among others (Deng et al. 2014a). In addition, C-terminal “tails” can 
also affect protein turnover, as protein stability is in part determined by protein 
sequence and structure (Martin-Perez and Villen 2017). Environmental 
stresses, such as oxidative stress and heat shock, are known to trigger protein 
aggregation by causing unfolding of bulk cellular proteins or by irreversible 
protein modifications (Parsell et al. 1994, Stadtman and Levine 2000). Hence, 
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it is would be helpful to compare the aggregation of mutant FUS proteins with 
or without “tails” under various stress conditions.  
7.6. Concluding remarks
In the past decade, we have begun to appreciate the extraordinarily 
complicated mechanisms that underlie ALS. The global incidence of ALS is on 
the rise, especially in developing nations, due to the improved diagnosis and 
prolonged lifespan. It is estimated that the global number of ALS patients will 
increase globally by 69% by the year 2040 (Arthur et al. 2016). ALS greatly 
limits autonomy of patients and severely affects their quality of life. 
Furthermore, it causes substantial economic burden to their families and 
societies due to their early retirement, absolute dependence on caregiving and 
increased demand of orthopaedic devices (Lopez-Bastida et al. 2009). Since 
the FDA approval of the first ALS drug Riluzole in 1995, over 60 molecules 
have been tested as potential ALS drugs in more than 50 clinical trials 
worldwide (Petrov et al. 2017). These chemical compounds represent a wide 
range of broadly defined mechanisms of action including anti-glutamatergic, 
anti-oxidative, anti-inflammatory and neuroprotective, among others. Among 
them, only one drug, a potent free radical scavenger Edaravone, has 
demonstrated clinical efficacy and has been approved by FDA as the second 
drug for ALS treatment (Bhandari et al. 2018). Even though Riluzole and 
Edaravone can moderately improve some clinical manifestations of the 
disease and patients’ quality of life for a limited period of time, they cannot 
prevent or stop the disease progression. Therefore, therapeutic developments 
in the ALS field are still very limited, and more relevant disease model 
systems and further mechanistic studies are desperately needed.
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